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Haemophilia A and von Willebrand Disease (VWD) are disorders which can 
cause mild to severe bleeding in an individual.  In many cases, knowledge of 
the molecular basis of these disorders is required to enable appropriate genetic 
counselling within families, carrier diagnosis and, in some cases, prenatal 
diagnosis.  The current ‘gold standard’ for diagnosing patients with Haemophilia 
A and VWD disorders is by direct sequencing of genomic DNA to identify 
mutations.  However this method may not reveal the presence of larger 
heterozygous deletions or duplications of F8 and VWF due to masking by an 
unaffected allele.  Therefore the genetic basis of disease in a proportion of 
cases may remain unresolved.  Multiplex ligation-dependent probe amplification 
(MLPA) is a method based on gene dosage that can be applied to the detection 
of large gene deletions or duplications in Haemophilia and VWD, aiding 
effective genetic diagnosis. 
 
This project developed and applied MLPA to investigate the molecular basis of 
disease in a selected cohort of patients diagnosed with Haemophilia A, type 1 
and type 3 VWD, where standard direct sequencing protocols of F8 and VWF 
had failed to reveal causative mutations, and to assess its application in the 
genetic diagnosis of these disorders.  This extended previous work on the 
molecular basis of Haemophilia A and VWD carried out in the Molecular 
Diagnostics Centre (MDC) at Central Manchester NHS Foundation Trust.   
 
MLPA confirmed the presence of large deletions in seven Haemophilia A index 
patients, two type 1 VWD patients, seven type 3 VWD patients and one 
possible duplication in a female haemophiliac.   The presence of a masked 
gene abnormality was also confirmed in two carrier females.  
 
This demonstrates that MLPA is a useful diagnostic tool for detecting or 
confirming larger scale mutations not suited to DNA sequence analysis.  MLPA 
is an important addition to the range of molecular diagnostic tools for the 
investigation of these haemostatic disorders and may be utilised when 
conventional mutation screening has failed to identify a causative mutation. 
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1.1 NORMAL HAEMOSTASIS  
Normal haemostasis is responsible for ensuring the free flow of blood within the 
circulatory system.   The efficient flow of blood and prevention and control of 
bleeding from damaged blood vessels is maintained by haemostatic 
mechanisms which depend on a series of complex interactions involving the 
vascular endothelium, circulating platelets and activation of coagulation 
pathways. The balance of normal haemostasis maintains the equilibrium 
between keeping the blood fluid and preventing excessive activation of the 
procoagulatory components leading to intravascular thrombosis.   
 
1.1.1 The Haemostatic Response to Injury 
The initial haemostatic response to vascular damage is an immediate 
vasoconstriction of the injured vessel and constriction of adjacent small arteries 
and arterioles to reduce the flow of blood to the area of injury.  The reduced 
blood flow allows contact activation of platelets and coagulation factors.  The 
lumen of blood vessels is lined with endothelial cells (ECs) which form an 
impermeable layer preventing passive transfer of blood cells, except in the case 
of inflammation.  Within the sub endothelial layer are a number of components 
which have specific functions in both primary and secondary haemostasis.   
 
Following damage to the endothelial layer, the sub endothelial layer is exposed.  
This leads to activated platelets which adhere to exposed subendothelial fibrils, 
potentiated by von Willebrand factor (VWF).  Collagen fibers are the most 
thrombogenic components of the extracellular matrix.    Glycoprotein VI (GpVI) 
expressed on the surface of platelets binds to exposed collagen inducing 
platelet adhesion, degranulation and aggregation.  The platelets release 
chemical messengers such as adenosine diphosphate (ADP), serotonin and 
thromboxane A2 which cause them to aggregate to form a platelet plug 
covering the exposed connective tissue and providing temporary control of 
bleeding.   
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1.1.2 Coagulation Pathway 
The complete response is achieved by the process of secondary haemostasis. 
This involves the activation of the coagulation system leading to the generation 
of fibrin strands which are laid down between platelets and reinforce the platelet 
plug.  The classical model of blood coagulation was represented by a 
coagulation cascade mediated via two pathways - the contact activation 
pathway (intrinsic) and the tissue factor pathway (extrinsic) which were initiated 
by separate mechanisms and converged on a common pathway leading to clot 
formation (Davie and Ratnoff 1964; Macfarlane 1964).  The intrinsic system 
explained the reaction of enzymes intravascular to the blood, involving Factor 
XII, high-molecular-weight kininogen (HMWK), prekallikrein and Factor XI (FXI), 
Factor IX (FIX) and Factor VIII (FVIII) whilst the extrinsic system was named 
because it was activated by factors external to the blood system, i.e. tissue 
factor (TF).  The pathways merged with the binding of Factor X (FXa) to Factor 
V (FVa) to form prothrombinase leading to the subsequent conversion of 
prothrombin into thrombin and the thrombin mediated formation of fibrin from 
fibrinogen.  The fibrin clot was subsequently stabilised by the action of the 
activated Factor XIII (FXIIIa). 
 
More recently, a cell based model has been described which explains the 
pathophysiology of the mechanisms leading to clot formation, highlighting the 
roles of different cells and phospholipid surfaces for the localisation of the 
coagulation network to the site of vascular injury.  According to the cell based 
model, coagulation occurs in three different overlapping stages of initiation, 
amplification and propagation on tissue factor bearing cells and platelets 
(Hoffman 2003) (see Figure 1.1). 
 
1.1.2.1 Initiation 
In response to vascular damage, the coagulation process is initiated by the 
release of tissue factor (TF) by the endothelial cells.  The circulating zymogen 
Factor VII (FVII) is exposed to cells expressing TF on their surface and is 
activated to become the protease Factor VIIa (FVIIa).  FVIIa forms a high 
affinity complex with TF (TF/FVIIa) which leads to the activation of Factors IX 
(FIXa) and X (FXa).  FXa then activate FV and forms a prothrombinase 
 3 
complex (FXa/FVa) which generates trace amounts of thrombin from pro-
thrombin. 
 
1.1.2.2 Amplification 
Under normal conditions, haemostatic components in the vascular tissue are 
not able to leave the endothelial layer due to their size.  However, upon vessel 
wall injury, platelets, FVIII and VWF are able to leave the vascular tissue and 
come into close contact with thrombin generated in the initiation stage.  
Platelets become activated by the small amount of thrombin leading to 
exposure of binding sites and receptors on their surfaces for activated clotting 
factors.  The activated platelets release increased quantities of FV which 
becomes activated by thrombin.  Thrombin also cleaves FVIII from its stabiliser 
molecule VWF activating it on the platelet surface and activates Factor XI 
(FXIa) which binds to the surface of activated platelets. 
 
1.1.2.3 Propagation 
The propagation stage occurs on the phospholipid surface of activated platelets 
that have joined the site of vascular injury.  FXIa activates increased amounts 
of Factor IX (FIXa) which forms a complex with its cofactor FVIIIa on the 
surface of platelets known as the ‘tenase’ complex.  This complex activates 
sufficient FXa which in turn forms the ‘prothrombinase’ complex with FVa 
resulting in the explosive generation of thrombin from prothrombin.  This 
ultimately leads to generation of a fibrin clot by cleaving fibrinogen to fibrin 
monomers which polymerise to form a platelet plug.  The clot is stabilised by 
Factor XIII (FXIIIa) which is also activated by the large burst of thrombin. 
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Figure 1.1: The three stage cell-based model of coagulation (figure 
adapted from Jurlander, Thim et al. 2001). The initiation phase results in an 
initial burst of thrombin generation followed by amplification of the procoagulant signal, 
which leads to propagation of the procoagulant response causing increased thrombin 
generation and the formation of a stable fibrin plug. 
 
 
 
 
1.1.3 Regulation of Coagulation 
Normal haemostasis is maintained by surface expression of molecules on 
endothelial cells, circulating inhibitors of plasma proteins and negative feedback 
mechanisms.  Tissue factor pathway inhibitor (TFPI) and antithrombin (AT) are 
both key regulators of coagulation.  TFPI is regulated by binding to 
glycosaminoglycans on the surfaces of ECs while AT is bound to heparin 
sulphate proteoglycans on the surface of ECs.  Together they are able to inhibit 
any FXa that dissociates from the TF-bearing cell (on which it should form the 
prothrombinase complex with FVa).   
 
Thrombin plays a key role in the coagulation system because as well as its 
procoagulant role, it also has anticoagulant properties since it activates factors 
involved in fibrinolysis to dissolve the fibrin clot.  Thrombin dispersing from the 
site of vascular injury forms a complex with thrombomodulin (expressed on 
AMPLIFICATION 
Platelet 
Activated Platelet 
TF- expressing cell 
TF 
TF VIIa 
X 
Xa Va 
VIIa 
Prothrombin 
Thrombin 
VIII/vWF VIIIa 
V Va 
XI XIa 
Thrombin 
Prothrombin 
IX 
XaVa 
X 
VIIIa IXa 
IXa 
IX 
XIa 
INITIATION 
PROPAGATION 
 5 
ECs) to activate protein C which when bound to protein S inactivates FVIIIa and 
FVa, thus restricting clotting factors to the site of injury.   
 
1.1.4 Hypercoagulable States and Bleeding Disorders 
Abnormal bleeding is the result of defective vascular function or disturbed 
haemostasis after injury.  The great variety of congenital bleeding disorders 
provides clear evidence of the key role played by single components of normal 
haemostasis.  The bleeding tendency in patients with disorders such as von 
Willebrand disease (VWD) and the haemophilias demonstrates that all of the 
components are required for normal haemostasis, as a severe deficiency of 
one cannot be compensated for by normal activity/concentration of the others 
(Rasche 2001). 
 
1.2 FACTOR VIII 
FVIII is a complex plasma glycoprotein of 2351 amino acids that has an 
essential role in the haemostatic system. It is involved in the intrinsic pathway 
of the coagulation cascade where it functions as a cofactor for the factor X-
activating complex, which consists of FVIIIa, the serine protease FIXa, calcium 
ions and phospholipid membranes (Mann 1999).    
 
1.2.1 The role of Factor VIII in haemostasis 
The bleeding associated with haemophilia patients is due to failure of the 
secondary phase of haemostasis.  The formation of the platelet plug occurs 
normally but there is defective stabilisation by fibrin due to inadequate thrombin 
generation.  This is because FVIII and FIX are now known to be central to the 
blood coagulation process and for generation of adequate amounts of thrombin.  
Following blood vessel injury, TF activates FVII which mediates generation of 
FXa, and FVIII and FIX are required for amplification of this production to 
enable completion of the coagulation process.  If either FVIII or FIX are absent, 
bleeding will arise due to the insufficient amplification and generation of FXa to 
maintain haemostasis (Bolton-Maggs and Pasi 2003). 
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1.2.2 Physiology of FVIII 
The major source for plasma FVIII is the hepatocytes although the kidney, 
sinusoidal endothelial cells and lymphatic tissues can also synthesise small 
amounts of FVIII (Hollestelle, Thinnes et al. 2001).  It is produced as an inactive 
single-chain protein but following endoproteolytic processing, it is released into 
the circulation as a set of heterodimeric proteins.  FVIII freely interacts with 
VWF, circulating in a non-covalent complex which protects it from premature 
proteolytic degradation and concentrates it at sites of vascular injury (Lenting, 
van Mourik et al. 1998) (see Figure 1.2).  It is one of the largest and least stable 
coagulation factors and has a half life of about 12 hours in adults (shorter in 
children) (Bolton-Maggs and Pasi 2003). 
 
Figure 1.2: The lifespan of FVIII (figure adapted from Lenting, van Mourik 
et al. 1998) 
 
 
 
1.2.3. Molecular Biology of FVIII 
The molecular characterisation of the human FVIII gene (F8) was first carried 
out in 1984, where it was found to be the largest gene that had been 
characterised by that time, spanning nearly 0.1% (186 kb) of the X-
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chromosome.  It has been mapped to the long arm of X-chromosome at Xq28, 
and consists of 26 exons which range in size from 69 to 3,106 base pairs (bp) 
(Gitschier, Wood et al. 1984) and encode a polypeptide chain of 2351 amino 
acids (aa) (see Figure 1.3a&b).  This includes a signal peptide of 19 and a 
mature protein of 2332 aa.  The primary structure of FVIII has been shown to 
consist of a number of domains (see Figure 1.3c).  The A domains show 
approximately 30% homology to one another and display a comparable level of 
homology to the copper-binding protein ceruloplasmin and to FV, the cofactor in 
the prothrombinase complex.  These domains are surrounded by short spacers 
(a1, a2 and a3) that contain clusters of aspartic acid and glutamic acid 
residues, known as acidic regions.  The C domains are structurally associated 
with the C domains of FV.  The large B domain does not exhibit any major 
homology with any other known protein, its function is unknown and is not 
required for coagulant activity (Lenting, van Mourik et al. 1998). 
 
Figure 1.3: Schematic representation of the chromosomal localisation (a), 
exonic structure of F8 (b) and protein domains (c). 
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1.3 VON WILLEBRAND FACTOR  
VWF is a multimeric adhesive glycoprotein that is found in plasma, platelet α-
granules and subendothelial connective tissue.  Plasma VWF plays two 
essential roles in primary haemostasis as a carrier protein for FVIII, and a 
promoter of platelet adhesion to the damaged vessel wall (Hoffbrand 2005).   
 
1.3.1 VWF function in haemostasis and coagulation 
The main purpose of VWF is to promote thrombus formation by aiding adhesion 
of platelets to each other and the damaged vessel wall.  The circulating pool of 
VWF is essential for initiating platelet adhesion as it is not found in many 
vessels where platelet function is required for haemostasis (Bahnak, Wu et al. 
1989).  VWF is especially important in small blood vessels where there is high 
shear stress due to rapid blood flow and platelet adhesion and normal primary 
haemostasis rely on its adhesive properties (Savage, Saldivar et al. 1996).   
 
The initial step in platelet interaction to exposed subendothelium is the binding 
of the VWF A1 domain to glycoprotein Ib (GpIb) which tethers the platelets to 
the vessel wall whilst they roll on the surface.  The platelets then become 
activated and VWF binds to the glycoprotein IIb/IIIa (GpIIb/IIIa) complex in an 
irreversible manner to consolidate the platelet plug.  Fibrinogen and thrombin 
formation are required but not crucial to the process (Ruggeri 1997).  The 
stable adhesion is reinforced by GpVI which is exposed on the platelet surface 
and binds to collagen which is exposed by the subendothelium at the site of 
endothelial cell injury. 
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Figure 1.4: Mechanism of Platelet Adhesion to VWF (figure adapted from 
Robertson, Lillicrap et al. 2008) In high shear stress conditions, platelets roll 
along the endothelial cell surface and are tethered to the site of injury through the 
binding of subendothelial VWF to the GpIb protein of the Ib/IX receptor. Subsequently 
platelets are activated and the GpIIb/IIIa and GpVI are exposed on the platelet surface.  
GpIIb/IIIa binds to VWF to permanently tether the platelet to the vessel wall and GpVI 
binds to collagen as an additional anchor.  Interaction of fibrinogen and VWF with 
GpIIb/IIIa then consolidates the platelet adhesive events and initiates platelet 
aggregation.  
 
 
 
 
VWF also plays a key role in the stabilisation of FVIII in the blood as it forms a 
non-covalently bound complex with FVIII (VWF-FVIII) (see Figure 1.4).  This 
complex protects FVIII from activated protein C degradation and carries it to 
sites of platelet plug and subsequent clot formation (Koppelman, van Hoeij et 
al. 1996).  As a result reduced levels of VWF are associated with reduced 
levels of circulating FVIII, which are often seen in patients with VWD.   
 
1.3.2 Synthesis of VWF 
VWF is synthesised within EC’s as a polypeptide of 2813 aa (Jaffe, Hoyer et al. 
1973) which undergoes initial dimerization and then multimerization up to a 
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multimer with a molecular weight (MW) of 20 million Daltons. The higher 
molecular weight multimers are functionally more effective in promoting platelet 
adhesion and aggregation. The endothelial cells either directly release VWF 
into the plasma through a constitutive secretory pathway or store it in 
endothelial Weibel-Palade bodies where it also drives their formation (Michaux, 
Abbitt et al. 2006).  The VWF stored within these Weibel-Palade bodies is 
thought to be made up of the largest multimeric species which is not usually 
seen in the blood of normal individuals.  When released at sites of injury they 
present the most thrombogenic forms of VWF exactly where needed. 
Circulating high molecular weight (HMW) multimers are cleaved by the 
metalloproteinase, known as ADAMTS-13 (a disintegrin and metalloproteinase 
with thrombospondin type 1 motif), which regulates VWF platelet dependent 
activity by reducing the size of VWF multimers. 
 
VWF is also synthesised in the megakaryocytes (Nachman, Levine et al. 1977) 
and stored in the platelet α-granules (which may contain as much as 20 % of 
the total VWF present in blood) and on activation, secreted by the platelet 
release reaction.  The VWF stored within the platelet α-granules consists of the 
ultra-large VWF multimers and can be released upon stimulation by a number 
of agonists including ADP, collagen and thrombin.  This allows accumulation of 
VWF at the site of vascular injury where it can promote further platelet adhesion 
and thus haemostasis.  The VWF that is released from storage sites does not 
have FVIII bound to it, unlike circulating VWF/FVIII complex which enables 
FVIII to be concentrated at the site of vascular damage prior to subsequent 
detachment from VWF to serve as a clotting factor (Nesheim, Pittman et al. 
1991).  
 
1.3.3. Molecular Biology of VWF 
The VWF gene (VWF) was first cloned in 1985 and is located on the short arm 
of chromosome 12 at the locus 12p13.2.  It is a large gene spanning 178 kb 
and is composed of 52 exons (Ginsburg, Handin et al. 1985).  VWF transcribes 
a messenger ribonucleic acid (mRNA) product of 8.7 kb.  This is translated to 
produce a 2813 aa product which consists of a signal peptide of 22 aa, a large 
propeptide of 741 aa and a mature VWF molecule containing 2050 aa 
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(Bonthron, Orr et al. 1986; Verweij, Diergaarde et al. 1986).  A non-processed 
VWF partial pseudogene (VWFP) is located on chromosome 22 which 
duplicates the region spanning exons 23 through 34.  The pseudogene has 
97% homology with the genuine VWF which may complicate VWF analyses 
upon examination of genomic deoxyribonucleic acid (DNA) (Mancuso, Tuley et 
al. 1991).  The partial pseudogene does not produce a functional transcript due 
to the presence of splice site and nonsense mutations. 
 
The mature VWF protein of 2050 aa is composed of a sequence of four classes 
of homologous domains (D, A, B and C) which have specific functions (see 
Figure 1.5). The domains D1, D2, D’ and D3 are involved in multimerisation of 
the VWF dimers, which altogether span exons 3-28 of VWF (Verweij, Hart et al. 
1988; Wise, Pittman et al. 1988; Voorberg, Fontijn et al. 1990; Journet, 
Saffaripour et al. 1993). These domains are rich in cysteine residues which are 
vital for the multimerisation process.  The D’ domain displays a binding site for 
FVIII and heparin as well as possible binding sites for P-selectin which is 
capable of anchoring ultra-large VWF to the surface of EC’s, thus introducing 
VWF cleavage sites to ADAMTS-13 (Padilla, Moake et al. 2004).  The A1 
domain exhibits binding sites for the platelet receptor GPIbα, and contains 
supplementary sites for heparin, sulphated glycolipids, the snake venom 
botrocetin and collagen type VI (Ruggeri 2003).  Mutations present in this 
region will cause the molecule to be either more reactive (gain of function 
mutation, type 2B) or less reactive (type 2A or 2M).  The A3 domain is the 
binding region for collagens type I and III.  The C1 domain with its Arginine-
Glycine-Aspartate (RGD) sequence is the binding site for integrin αIIbβ3 
(GPIIbIIIa).  The A2 domain contains the cleavage site for ADAMTS-13.  The 
cysteine knot (CK) domain spanning exons 49 to 52, is rich in cysteine residues 
which are essential for the dimerisation of VWF monomers (Voorberg, Fontijn 
et al. 1991).  The domains D4, B1, B2 and B3 which cover exons 33-44 do not 
yet have a known role, however they may play an important part in the structure 
of the VWF protein. 
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Figure 1.5: Schematic representation of the functional domains and 
binding sites of the VWF Protein. 
 
 
 
 
 
1.4 HAEMOPHILIA A 
Haemophilia A is the most common X-linked inherited bleeding disorder 
affecting about 1 in 5000 males worldwide.  The disorder is caused by low 
concentrations of FVIII and can be diagnosed by measuring plasma levels of 
FVIII (FVIII:C).  The clinical severity is closely related to the level of activity of 
FVIII in the plasma and can be classified as mild, moderate or severe, 
depending on the level.  Severely affected haemophiliacs have plasma levels 
below 1 IU/dL (<1% of normal) and most frequently suffer from serious muscle 
and joint bleeds. Individuals who are moderately affected have plasma levels of 
between 1 and 5 IU/dL (1-5% of normal) and those with mild disease have 
levels of between 5 and 40 IU/dL (>5 to <40% of normal) (White, Rosendaal et 
al. 2001). 
 
Most cases are referred for investigation due to family history of the disease, 
however approximately one third of cases occur sporadically.  Severe 
haemophiliacs usually present at about 1 year of age when they become active 
with unexplained bruising and bleeding.  Earlier presentation may be seen in 
those who have received an intramuscular injection or experienced surgery or 
trauma.  Spontaneous bleeding is also common, occurring once or twice 
weekly.  A diagnosis is usually made following measurement of their FVIII:C.  In 
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males where there is a family history of haemophilia, the cord blood can be 
tested at birth for FVIII:C.  Those with mild or moderate disease may not 
present until they are adults when they are likely to be exposed to greater 
trauma (Keeney, Mitchell et al. 2005).   
 
The most common sites for bleeds are the main load-bearing joints i.e. knees, 
elbows, ankles, hips and shoulders.  The bleeding from the synovium into the 
joint cavity causes severe swelling, stiffness, pain and inflammation.  As blood 
is highly irritating to synovium, this initiates a strong inflammatory reaction 
which leads to synovial overgrowth and friable vascular tissue, which 
predisposes it to further haemorrhage.  If left untreated, the joint will be 
considerably weakened by the repeated bleeds and secondary osteoarthritis 
can occur, leading to physical disability.  The large weight bearing muscles 
such as the iliopsoas, calf, gluteal and forearm muscles can also be affected by 
bleeding leading to impairment of the blood supply, tissue ischemia, necrosis 
and subsequent fibrosis and muscle shortening (Hoffbrand 2005). 
 
1.4.1 Laboratory diagnosis of Haemophilia A 
In the phenotypic diagnosis of haemophilia A, an initial screening test may 
show a prolonged activated partial thromboplastin time (APTT), normal 
prothrombin time (PT), thrombin clotting time (TCT) and bleeding time (BT) with 
a normal platelet count.  Specific assays using factor deficient plasma can be 
used to detect and quantitate a deficiency.  Once it has been established that 
FVIII is involved the FVIII:C assay is performed.   This consists of measuring 
the intrinsic and common pathways of the coagulation cascade, with FVIII 
deficient plasma and varying dilutions of the patient plasma.  Correction of the 
clotting time of the deficient plasma by the patient plasma indicates there is no 
deficiency, however if the times are not corrected then the patient has a FVIII 
deficiency.  The results are compared to reference plasma containing known 
factor levels and the deficient FVIII level in the patient plasma can be 
quantitated (showing FVIII clotting activity below 50 IU/dL).  Assays for VWF 
antigen (VWF:Ag) and ristocetin cofactor activity (VWF:RCo) display  normal 
results and it is important that these are carried out in order to distinguish FVIII 
deficiency due to haemophilia A from VWD (see section 1.13).   
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Prior to the advent of routine genetic analysis, attempts were made to diagnose 
the carrier status of haemophilia A in females by phenotypic tests.  The routine 
clotting assay FVIII:C can be used to measure FVIII activity together with FVIII 
antigen (FVIII:Ag) as the defective gene is the one responsible for FVIII 
production.  VWF antigen levels can also be estimated by immunoassay 
although these should be normal as VWF production is autosomally controlled 
and is unaffected in haemophilia.  In the normal population the range of values 
for these factors is between 50 and 200 IU/dL.  The FVIII:C level in carriers with 
the haemophilia defect will be lower and average levels of about 50 IU/dL are 
found.  The ratio of FVIII:C/VWF:Ag can be a useful indicator, averaging at 1.0 
in normal individuals and 0.5 in carriers.  However the effect of lyonisation 
(skewed inactivation of the X-chromosome) can result in carriers with markedly 
decreased FVIII:C levels and some with normal FVIII:C, making carrier 
detection in the latter group extremely difficult.  There are approximately 10% of 
carriers who will appear phenotypically normal (Lillicrap, White et al. 1987).  
Therefore, a diagnosis should not be based on these results alone as there are 
a number of factors affecting FVIII:C and VWF:Ag levels which can hinder the 
ability to distinguish a minority of carriers from normal females which include 
ABO blood group, age and pregnancy (Graham, Rizza et al. 1986).  To improve 
the accuracy of phenotypic carrier diagnosis, discriminant function analysis can 
be used which takes these factors into account as well as FVIII:C and VWF:Ag 
levels.  Phenotypic tests for carrier diagnosis have now been effectively 
superseded by genetic analysis although they may still be used in developing 
countries. 
 
1.4.2 Treatment of Haemophilia A 
As there is no cure for haemophilia, treatment is based upon raising the 
concentration of FVIII to arrest haemorrhage or to cover surgery.  In some mild 
haemophiliacs, the level of FVIII can be raised transiently by the use of 
desmopressin (DDAVP) which is an analogue of antidiuretic hormone.  In all 
other cases, a concentrate of FVIII should be administered.  Plasma-derived 
and recombinant FVIII concentrates are available.   Recombinant products are 
the preferred treatment if available and affordable as they remove the risk of 
transmission of human and animal infectious agents (Bolton-Maggs and Pasi 
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2003).  Prophylactic treatment with FVIII concentrates can be given regularly to 
prevent spontaneous joint bleeds from occurring.  Prophylaxis is the 
recommended strategy for children with severe haemophilia and should begin 
by the age of 4 years, as by this time most affected children will have 
experienced their first joint bleed.  The initial cost of prophylaxis is expensive 
due to the products, however over the lifetime of an adult with normal joints and 
good quality of life it proves to be cost effective (Bolton-Maggs and Pasi 2003). 
 
1.4.3 Differential Diagnosis of Haemophilia A 
1.4.3.1 Type 2N VWD 
Specific variants of coagulation proteins that directly interact with FVIII such as 
VWF, FII, FIX and FX may affect the amount and function of FVIII.  In some 
cases mutations in VWF associated with the VWD variant type 2N, have an 
impact on the level of FVIII in the circulation and are responsible for the 
bleeding phenotype seen in these patients, indistinguishable from the one 
dependent upon mutations in F8 itself.  Both disorders display reduced levels of 
FVIII:C (~5-40 IU/dL) and normal-to-borderline-low levels of VWF.  The 
symptoms of type 2N VWD are similar to those of mild haemophilia A and 
include excessive bleeding during surgery or other invasive procedures.  The 
best way to distinguish between the two disorders is to use the VWF:FVIII 
binding test (VWF:FVIIIB), which determines the ability of VWF to bind FVIII 
(Casonato, Pontara et al. 2007).  Type 2N VWD should be suspected in 
patients diagnosed with mild haemophilia A who either do not respond well to 
FVIII infusions or belong to families in which males and females are equally 
affected.  Missense mutations in VWF reduce the ability of VWF to bind and 
protect FVIII, therefore VWF and FVIII levels can look identical to those in 
males with mild haemophilia A or in symptomatic haemophilia A carrier 
females.   
 
1.4.3.2 Combined Deficiency OF FV and FVIII (F5F8D) 
The combined deficiency of coagulation FV and FVIII (F5F8D) is an autosomal 
recessive bleeding disorder.  F5F8D is distinguished by coexisting low levels 
(usually between 5 and 30 IU/dL) of both FV and FVIII and exhibits a mild to 
moderate bleeding tendency (Zhang and Ginsburg 2004).  However F5F8D is 
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completely independent of FV deficiency and FVIII deficiency and is unusual 
because it arises because of mutations in two genes (LMAN-1 and MCFD2) 
which encode proteins involved in the FV and FVIII intracellular transport rather 
than DNA defects in the genes which encode the corresponding coagulation 
factors.  Null mutations in the LMAN-1 gene (Lectin Mannose Binding Protein) 
have been found in approximately 70% of affected patients, while null and 
missense mutations in MCFD2 (Multiple Coagulation Factor Deficiency 2) 
account for the remaining 30% (Zhang, McGee et al. 2006).  Bleeding episodes 
are treated by replacing FV through fresh frozen plasma and FVIII by DDAVP 
or specific FVIII concentrates.  While F5F8D is extremely rare (1:1,000,000 in 
the general population), it has an increased frequency in populations where 
there is a high incidence of consanguineous marriages and therefore should be 
considered in some cases of mild haemophilia A where no mutation is 
detectable. 
 
1.5 MOLECULAR PATHOLOGY OF HAEMOPHILIA A 
The molecular basis of haemophilia A is extremely diverse and there are 
approximately 2100 individual mutations which have been found in F8 which 
have been attributed to the clinical phenotype.  The most common gene defects 
seen in approximately 90% of patients are point mutations (single nucleotide 
substitutions), followed by deletions which are found in approximately 5-10% of 
patients.  Insertions and rearrangements/inversions are rarely seen in 
haemophilia patients, with the exception of two common inversions involving 
intron 1 and 22 the intron found in patients with severe haemophilia A (Bowen 
2002).   The Haemophilia A Mutation Database and FVIII Resource Site 
(HAMSTeRS) is a locus specific database which lists mutations that have been 
characterised in haemophilia A and can be readily accessed 
(www.hadb.org.uk). 
 
This molecular characterisation has also led to developments in the production 
of recombinant therapeutic clotting-factor concentrates, the generation of 
animal disease models and the production of wild-type and mutant proteins for 
structure-function analysis (Bolton-Maggs and Pasi 2003). 
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1.5.1 Gross DNA Rearrangements 
1.5.1.1 Common Partial Inversions of FVIII 
The intron 22 inversion mutation is responsible for disease in 20% of all 
patients and always results in severe disease.  It is the causative mutation in 
nearly 45% of severe haemophilia A cases (Lakich, Kazazian et al. 1993; 
Naylor, Brinke et al. 1993).  The intron 22 inversion occurs because of 
homologous recombination between copies of a repeated DNA sequence, the 
intron 22 homologous region (int22h), one copy located in intron 22 of FVIII, the 
other two copies distal and telomeric to FVIII.  It is primarily an error of DNA 
replication during spermatogenesis and completely disrupts F8 leading to 
severe disease.  Until relatively recently the intron 22 inversion was detected by 
Southern blot analysis, however this has been replaced by long polymerase 
chain reaction (PCR) protocols which are able to detect normal and inverted 
genes (Liu, Nozari et al. 1998) and more recently still by inverse PCR protocols 
(Rossetti, Radic et al. 2005; Rossetti, Radic et al. 2008). 
 
The intron 1 inversion is the second most common mutation in severe 
haemophilia A and has been reported to have a frequency of 1.8% in the UK 
population (Cumming 2004).  The mutation can be detected by a robust dual 
PCR assay which has been designed to amplify sequence flanking the intron 1 
homologous (int1h) regions independently (Bagnall, Waseem et al. 2002). 
 
1.5.1.2 Large Deletions 
Deletions affecting F8 include whole gene deletions, partial gene deletions at 
the 5’ end, 3’ end, or within the gene, and microdeletions of one to several base 
pairs.  They do not seem to be confined to a specific region of the gene but 
appear to be randomly distributed throughout.  Deletions have the capability of 
damaging genetic function, removing amino acids, or introducing a frameshift 
which is why they are generally associated with severe disease. 
 
Large deletions (more than 100 nucleotides) are found in approximately 5% of 
patients with haemophilia A (Antonarakis 1998).  As of November 2012, the 
HAMSTeRS database contains 255 large deletion mutations which range from 
less than 1 kb up to more than 210 kb deleting the entire gene, which is 
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probably the result of non-homologous recombination (Woods-Samuels, 
Kazazian et al. 1991).  Large deletions in F8 are normally associated with 
clinically severe disease with no measurable FVIII activity in plasma samples 
and undetectable antigen as any truncated proteins produced are either poorly 
expressed, inactive or cleared from the circulation.  There are known reports of 
a deletion of exon 22 and also of exons 23-24 that are associated with 
moderate disease.  This may result from in-frame splicing of mRNA leading to 
the production of hypoactive FVIII which lacks short stretches of amino acids 
(Youssoufian, Antonarakis et al. 1987; Lavergne, Bahnak et al. 1992).  Exon-
spanning deletions are easily detected in affected males due to lack of PCR 
amplification of missing exons of F8.  However, in carrier females, these 
mutations are masked by amplification of the normal allele.  For methods used 
to identify female carrier status see section 1.9.   
 
1.5.1.3 Insertions of Retrotransposons 
A very small number of patients have an insertion of a repetitive element 
(LINE1 or Alu) which causes severe haemophilia by disrupting the coding 
sequence of the gene.  The de novo insertion of long interspersed nuclear 
elements (LINEs) in the human genome was first reported in F8 in two severe 
haemophilia A patients (Kazazian, Wong et al. 1988). The first case was a 3.8 
kb portion of a LINE element inserted in exon 14 of FVIII.  The inserted DNA 
had a poly(A) tail, produced a target site duplication, and was inserted in a 
relatively adenine-rich sequence of exon 14.  The second case involved the 
insertion of a 2.1 kb portion of a LINE element in a different section of exon 14 
and had all the features of a retrotransposition.  LINE insertions or other 
retrotransposons are relatively uncommon as there has only been two 
examples in >1000 patients studied. 
 
1.5.1.4 Duplications 
There have been several cases reported involving duplications in F8.  The first 
report described a duplication of 23 kb of intron 22 inserted between exons 23 
and 25 (Gitschier 1988).  This rearrangement found in two female siblings was 
apparently unstable and led to deletion of exons 23-25 in the male offspring of 
one of the females.  A second exon duplication of F8 was identified in 1990 and 
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was characterised as an in-frame tandem duplication of exon 13 that produces 
an unstable FVIII protein with a short half-life (Murru, Casula et al. 1990).  This 
has since been shown to be present in up to one third of cases in the northern 
Italian mild haemophilia population (Acquila, Pasino et al. 2004).   
 
As standard PCR-based techniques do not indicate relative template dosage, 
further F8 duplications have not been reported until recently following the 
introduction of Multiplex Ligation-dependent Probe Amplification (MLPA) (see 
section 1.9.1).  A study carried out by Rost, Loffler et al. (2008) reanalysed 80 
mutation-negative haemophilia A patients from a cohort of about 2000 using 
MLPA and identified exon duplications in nine cases, a frequency of ~0.5% 
(see section 1.10). 
 
1.5.2 Point Mutations 
The point mutations that arise in haemophilia are made up of missense 
mutations (where a codon is changed so that a different amino acid is 
encoded), nonsense point mutations (where an amino acid codon is changed 
into a premature translation stop codon) and mRNA splice site point mutations 
(which corrupt a true mRNA splice site, or create a novel one).  The 
HAMSTeRS database last updated in November 2012 reported a total of 1349 
unique single base (point) mutations, of which 983 were missense, 208 were 
nonsense and 158 were splice site related. 
 
1.5.2.1 Missense Mutations 
Missense point mutations can give rise to varying severity of haemophilia 
depending on the nature and location of the amino acid substitution.  Less 
severe disease is associated with semi-conservative amino acid substitutions 
where the new amino acid has very similar properties to the normal one, unless 
they occur in regions of structural and functional importance.  Whereas 
moderate to severe disease tends to arise because of non-conservative amino 
acid substitutions, no matter where they occur in the protein.  With non-
conservative amino acid substitutions there is a higher chance of them having 
an overall more damaging effect as they have the capacity for structural 
perturbation/destabilisation (Bowen 2002). 
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1.5.2.2 Nonsense Mutations 
Severe haemophilia is associated with nonsense mutations and this is because 
the resulting transcripts may undergo nonsense mediated ribonucleic acid 
(RNA) decay or, if translated, result in a truncated protein molecule which is 
highly likely to lack function.  Another negative effect which can arise from 
nonsense mutations is exon skipping which can cause either an in frame skip 
leading to a protein lacking the amino acids encoded by the skipped exon, or  
an out of frame skip which results in a frame shift (Bowen 2002). 
 
1.5.2.3 mRNA Splice Site Mutations 
Mutations that destroy or create mRNA splice sites are associated with variable 
severity of haemophilia, depending on whether some correct transcripts can be 
processed (mild to moderate disease) or whether there is a complete loss of 
correct mRNA processing (severe disease).  Splice site mutations can also 
cause exon skipping with the overall severity depending on whether the skip is 
in frame or results in a frame shift. 
 
1.5.2.4 Small Deletions/Insertions 
Small deletions in the coding region of F8 are generally associated with severe 
haemophilia A.  They vary in size from 1 bp to 86 bp and most result in frame 
shifts which consequently eliminate FVIII expression.  More than one-third of 
small deletions are found in the largest exon, exon 14 and the majority occur in 
DNA regions of short direct repeats (Antonarakis 1998). 
 
Insertions have also been characterised in F8 and like deletions can be gross 
or as small as one or several nucleotides.  They range in size from 1 bp up to 
2.1 kb and 3.8 kb LINE elements.  Most insertions are of 1 bp, often an A in a 
stretch of A residues.  They are usually associated with severe disease as gene 
function or the gene product can be adversely affected. However an exception 
to this is small deletion/insertion mutations within poly-A runs of F8 which have 
been shown to be associated with a less severe haemophilia A phenotype.  
Small deletions/insertions resulting in uninterrupted stretches of adenines are 
likely to be sensitive to DNA replication/RNA transcription and translation errors 
thereby promoting the mechanism of partial correction of the reading frame.  
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Subsequently, affected individuals have a milder than expected form of 
haemophilia A (Young, Inaba et al. 1997). 
 
1.6 FACTOR VIII INHIBITORS 
Approximately 30-50% of patients with severe haemophilia A develop 
antibodies (known as inhibitors) to FVIII following treatment with exogenous 
FVIII which is due to insufficient synthesis of endogenous FVIII protein by the 
individual to induce immune tolerance.  These inhibitors may be either low titre 
antibodies, managed by increased or continuing treatment with FVIII 
concentrates, or high titre antibodies which prevent treatment with factor 
concentrates (Bolton-Maggs and Pasi 2003). 
 
The risk of developing an inhibitor is related to the nature of the molecular 
defect in F8.  Nonsense mutations, deletions and inversions in F8 are most 
commonly found in the majority of reported inhibitor cases.  Patients with these 
types of mutation have a 35% higher incidence of developing an inhibitor 
compared to those carrying missense mutations or small deletions because 
they can either severely truncate or stop production of the protein.  Gross 
deletions of F8 have also been found to cause a two- to three-fold increased 
incidence of inhibitors than for patients without detectable deletions (Millar, 
Steinbrecher et al. 1990). 
 
1.7 INHERITANCE OF HAEMOPHILIA A 
A female carrier of the defective X-linked gene has a 50% chance of passing it 
on to her children, resulting in affected males or carrier females (see Figure 
1.6a).  The daughters of a haemophiliac father will be obligatory carriers of the 
defective gene (see Figure 1.6b).  Sporadic haemophilia is caused by de novo 
mutations and represents approximately one third of cases.  Females at risk of 
being a carrier can be identified by validating the pattern of inheritance by 
genetic analysis which is the definitive diagnostic tool for carriership analysis.  
In families with sporadic cases, the risk of somatic mosaicism must be 
considered as it causes uncertainty about the recurrence risk in parents who 
appear to be non-carriers (Peyvandi, Jayandharan et al. 2006).  Severe 
haemophilia in females is rare, however it can arise from genetic mechanisms 
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such as extreme lyonisation, Turner’s syndrome or transmission of a mutation 
by both parents (father with haemophilia and mother a carrier).  Following 
haemophilia diagnosis, an accurate family history must be taken in order to 
create a pedigree by which other family members at risk of passing it on to their 
offspring can be counselled.  
 
Figure 1.6: Inheritance in haemophilia (figure adapted from Peyvandi, 
Jayandharan et al. 2006). The X indicates the defective gene that is inherited. 
 
 
 
 
1.8 GENETIC DIAGNOSIS OF HAEMOPHILIA A 
The practice guidelines for the molecular diagnosis of haemophilia A 
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establish the causative F8 mutation (UKHCDO 2010).  Genetic analysis is also 
necessary for the reliable identification of female carriers following phenotypic 
testing, therefore allowing them to make informed choices should they wish to 
start a family or in the early stages of pregnancy.  Genetic counselling should 
always be carried out by suitably qualified health professionals who have a 
detailed knowledge of haemophilia.  All testing should be performed in a 
member laboratory of the UK Haemophilia Centre Doctors’ Organisation 
Haemophilia Genetics Laboratory Network (UKHCDO-GLN) working to agreed 
peer-reviewed standards of quality (Keeney, Mitchell et al. 2005). 
 
The genetic diagnostic strategy is influenced by the severity of the disorder 
within a family therefore this should be determined before any screening is 
undertaken.  Severe haemophiliacs should be screened for the F8 intron 22 
inversion mutation followed by the F8 intron 1 inversion mutation, which will 
identify the underlying mutation in 45-50% of cases.  For the remaining 
pedigrees, full mutational analysis of F8 should be performed.  Mild/moderate 
haemophiliacs require full mutation analysis as they are not associated with a 
common mutational mechanism (UKHCDO 2010).  
 
Historically, the most common method for resolving female carrier status was 
linkage analysis; however this has now been overtaken by direct mutation 
detection, including DNA sequencing, which is considered the gold standard for 
mutation detection.  Linkage analysis may also fail in a number of families due 
to either lack of prior family history, key pedigree members not being available, 
polymorphisms which are uninformative in key females or non-paternity.  In the 
UK, mutations are usually identified by direct DNA sequencing of F8 in affected 
males and then confirmed or excluded in female relatives.  Intragenic linked 
markers may still be useful in circumstances where a family has previously 
been investigated by linked markers and the mutation has not been identified, 
or where a mutation has not been verified or found, although where a mutation 
has not been identified in an index male after full mutation analysis has been 
performed then linkage of the FVIII deficiency to F8 cannot be assumed.   
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1.8 MOSAICISM 
Genetic diagnosis in haemophilia A can be complicated by germ line and 
somatic mosaicism which has been reported in 13% of families with sporadic 
severe haemophilia associated with point mutations (Leuer, Oldenburg et al. 
2001).  Therefore the prospect of mosaicism should be considered in sporadic 
haemophilia where the mother of an affected male does not seem to carry the 
mutation in her leucocyte DNA, especially when the de novo mutation appears 
to be a point mutation. 
 
1.9 DETECTION OF LARGE SCALE DELETIONS IN HETEROZYGOUS 
CARRIERS 
Large scale mutations are easily detected in affected males as the missing 
regions of F8 fail to amplify.  However heterozygous carriers with these 
mutations may not be identified due to amplification of one normal allele.  
Methods that can be applied to the F8 locus to establish female carrier status in 
these families include; linkage analysis, gene dosage analysis, gap-PCR 
(where deletion boundaries are already known) and other indirect methods 
such as Multiplex Ligation-dependent Probe Amplification (MLPA) (Keeney, 
Mitchell et al. 2005). 
 
1.9.1. MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION 
(MLPA) 
MLPA is a fairly new multiplex PCR method which is used to quantify the 
relative copy number of up to 50 different genomic DNA or RNA sequences of a 
gene in one single reaction (Schouten, McElgunn et al. 2002).  The MLPA 
reaction consists of denatured genomic DNA which is hybridised with region or 
exon-specific probes.  Each probe is made up of 2 oligonucleotides, one 
synthetic and one M13-derived which hybridise to adjacent target sequences 
and are then ligated.  The probe ligation products are subsequently amplified 
by PCR using only one primer pair.  The quantity of amplification product is a 
measure for the number of total target sequences in the sample.  The 
amplification products are separated by capillary electrophoresis and compared 
to a control DNA sample, to determine the relative copy number of the target. 
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The use of MLPA for detecting copy numbers offers many advantages 
compared to other techniques.  Methods such as sequencing fail to detect copy 
number changes, while Southern Blot analysis which is capable of detecting 
many aberrations is not ideal as a routine technique due to its laborious, 
technically demanding nature which has been largely superseded by PCR 
based methods where possible.  When compared to florescent in situ 
hybridisation (FISH), MLPA is more sensitive at detecting some single gene 
aberrations.  It can be used on purified DNA and is a relatively simple and fairly 
robust method.  Probe sets are now commercially available from MRC Holland 
(P178-B1 F8) for the F8 locus capable of detecting deletions/duplications of 
one or more exons.  In the case of F8, the deletion of probe recognition 
sequences in affected males will be obvious by the absence of the probe 
amplification product.  In female carriers, you would expect to see a 35-50% 
reduced relative peak area of the amplification product of a probe.  For full 
explanation of the MLPA technique see Materials and methods section 2.4. 
 
1.10 MOLECULAR STUDIES OF LARGE SCALE DELETIONS / 
DUPLICATIONS IN HAEMOPHILIA 
Various studies have been recently carried out to determine the underlying 
genetic defect in patients where it was not clear.  It is still true that the intron 22 
and intron 1 inversion mutations are the most common causative mutation in 
severe haemophilia and in the remainder of cases, the molecular defects are 
predominantly single base-pair substitutions, but large deletions or insertions 
are found in approximately 5% of patients (Becker, Schwaab et al. 1996). 
 
Pavlova, Forster et al. (2008) reported an assay based on multiplex 
amplification of a number of exons of F8 of differing lengths which they 
consequently quantitated by liquid chromatography (LC).  Using this method 
they investigated 19 families with severe haemophilia A where an index patient 
exhibited a large deletion of one or more exons.  Of 24 possible carriers they 
were able to accurately classify 16 female carriers and eight non-carriers for the 
presence of a large deletion.  One mother and one grandmother were 
determined to be non-carriers. This study high-lighted the high de novo 
mutation rate of large deletions in female germ cells.  They concluded that the 
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multiplex PCR-LC technique has been shown to be a rapid, simple and reliable 
method for detection of heterozygous large deletions in carrier females. 
 
A study by Rost, Loffler et al. (2008) investigated 80 mutation negative cases 
comprising severe, moderate and mild haemophiliacs from a cohort of 2000 
haemophilia A patients.  The 80 patients were screened using MLPA analysis 
and among these patients they detected nine large duplications.  Two cases 
showed duplications of single exons 13 and 14, while the other duplications 
affected more than one exon.  In the patients studied they discovered seven 
novel large deletions and one recently described single-exon duplication within 
F8.  Only one patient with mild haemophilia A was found to have an exon 13 
duplication which leads to an internal in frame duplication within the FVIII 
protein.  This mutation has been shown to be present in 32% of northern Italian 
patients with mild haemophilia A, likely due to a founder effect.  The mother of 
this single patient was also found to have an exon 13 peak with a ratio of 1.5 by 
MLPA which identified her as carrier for the duplication and hence haemophilia 
A.  The remaining eight patients all had severe haemophilia A with less than 
1% FVIII activity.  All the novel duplications found were expected to produce 
frame shifts of the F8 mRNA and protein sequence if they were re-arranged in 
a head-to-tail mode (tandem duplication) which is in concurrence with the 
severe phenotype of these patients.  The development of inhibitors did not 
occur in seven of the severe haemophiliacs. 
 
Not all large duplications occur in tandem and may result in transposition to a 
genomic position outside of the affected gene locus.  However the haemophilia 
phenotype is unlikely to be caused by this type of mechanism as it should not 
influence the transcription and translation of the intact F8.  In conclusion from 
the cohort studied, approximately 0.5% of 2000 haemophilia A patients showed 
large duplications of one or more exons which add to the recurrent low-
frequency mutation types like the inversion of intron 1.  
 
Another study by Zimmermann, Oldenburg et al. (2010) was the first to carry 
out a broad analysis of sequences that produced exon-spanning duplications 
affecting F8 using MLPA.  They identified breakpoints in 10 out of 16 unrelated 
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cases with large duplications, including those identified by Rost, Loffler et al. 
(2008).  These involved nine tandem duplications plus one mixed duplication 
(exons 1-22) and triplication (exons 23-25), affecting regions throughout F8 and 
ranging from the duplication of exon 6 alone to duplication of exons 2-25.  
Characterisation of these duplications showed that LINEs and SINEs are often 
found in proximity to F8 duplication breakpoints.  Three mutations with Alu 
SINEs at each breakpoint shared significant sequence homology (>78%) while 
two mutations with LINEs at each breakpoint illustrated only slight flanking-
sequence homology.  These events could originate from mechanisms such as 
homologous and illegitimate recombination.  Other more complex 
rearrangements could also be responsible as six mutations were unable to be 
characterised due to unsuccessful amplification.  Most introns involved in 
breakpoints are the same as those already associated with large F8 deletions, 
for example introns 13, 22 and 25.  This is due to the fact that some of these 
regions have an abundance of repetitive sequence elements which present 
sequences that are prone to recombination. 
 
Theophilus, Baugh et al. (2011) investigated 11 families among a cohort of 
about 400 in whom a mutation could not be identified by traditional screening 
methods, using MLPA analysis.  They identified whole exon deletions or 
duplications in seven families affected with severe haemophilia, but not in one 
family with moderate or the three families with mild haemophilia A.  In four of 
the severe patients, they suspected that deletions of 1 to 6 exons of F8 were 
responsible due to repeated failure to amplify the corresponding exons by PCR.  
Using MLPA they were able to confirm deletions of exons 1, 1-6, 6 and 25 in 
these severe families which have all been previously associated with a severe 
phenotype.  In two cases, they were also able to confirm the gene abnormality 
in the affected male’s carrier mother.  In the remaining three families with 
severe haemophilia A, they identified novel duplications of exons 2-12 and 
exon 15 and a previously reported duplication of exons 14-22.  These 
duplications would result in a frame shift if located in tandem orientation.  Rost, 
Loffler et al. (2008) have previously reported duplications of exons 14, 1-5, 5-
25, 23-25, 2-25, 14-21 and 7-11 and one recently described duplication of exon 
13 within F8. 
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In the remaining families with mild and moderate haemophilia, MLPA analysis 
demonstrated normal gene dosage results for all 26 F8 exons.  They had been 
fully analysed by DNA sequencing and combined F5F8D and type 2N VWD 
had been ruled out.  Therefore they speculated that the underlying mutations 
responsible for their disease may be located deep within introns or comprise 
undiscovered mutation types in F8 that are undetectable by current methods.  
On the other hand the reduced FVIII:C levels may be due to mutations in other 
genes which affect F8 expression. 
 
Theophilus, Baugh et al. (2011) also looked into the inhibitor status for each 
index case and they found that only one index case with a deletion 
encompassing the promoter region to exon 6) had high titre non-transient 
inhibitors.  Interestingly, in comparison, a study carried out in 100 Korean 
patients with severe haemophilia A found that when inhibitor status was 
correlated with the genotype, the highest risk (100%) was observed in large 
deletion mutations (4/4).  This is consistent with the opinion that large deletions 
are the single most significant inhibitor risk factor in severe haemophilia A (Kim, 
Chung et al. 2012). 
 
Another recent study by Rafati, Ravanbod et al. (2011) found ten large 
deletions and one duplication in F8 of eleven unrelated Iranian severe 
haemophilia A families using MLPA.  Their results illustrated that 3.2% (11/347) 
of their severe haemophilia A patients have large deletions or duplications in 
their F8 among whom 8 patients developed high-titre antibodies to FVIII. 
 
A report by Lannoy, Abinet et al. (2009) illustrated the importance of genetic 
analysis of F8 in female patients presenting with FVIII deficiency in the absence 
of a family history of haemophilia or VWD.  They identified two F8 de novo 
deletions which had not been previously reported, using MLPA, in two girls with 
isolated factor VIII deficiency.  Both deletions were predicted to result in a 
severe form of haemophilia.  The slight reduction in FVIII levels seen in the two 
girls is attributed to the preferential inactivation of the X chromosome, which 
carries no deletion.  As the patients had no family history of haemophilia and no 
mutations were identified in both mothers, they concluded that the deletions 
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were caused by de novo mutations occurring in the male germ cells.  Therefore 
both patients were deemed to be carriers of a severe form of haemophilia A 
and the risk of having an affected son 1:2.  The risk of an affected male 
offspring developing inhibitors to FVIII was estimated at 40%.  They also 
concluded that in cases such as these, MLPA should be employed to exclude 
F8 deletions in the absence of the common inversions involving intron 22 or 1 
or point mutations. 
 
These studies have shown that the introduction of copy number variation (CNV) 
analysis, in particular MLPA, are essential for determining haemophilia A 
carrier-status in female relatives of males with large F8 deletions.  It can also 
be used to confirm previously suspected exon deletions in males with 
haemophilia A.  MLPA can also be used to successfully detect F8 duplications 
following DNA sequence analysis due to the fairly low frequency of duplication 
mutations.  MLPA is an important addition to the repertoire of tests used to 
detect F8 mutations and can be implemented after traditional methods or where 
the latter has failed to identify a causative mutation. 
 
1.11 VON WILLEBRAND DISEASE (VWD) 
VWD is the most commonly inherited bleeding disorder in humans with a 
prevalence of 1:100-1:1000 (Rodeghiero, Castaman et al. 1987; Holmberg and 
Nilsson 1992).  It was first described in 1926 by Erik von Willebrand who 
discovered a novel bleeding disorder in a large family from Foglo, an island in 
the Åland archipelago of Finland.  He reported a serious haemorraghic 
condition which he called ‘pseudohaemophilia’ because of the autosomal 
dominant inheritance and attributed to a platelet or vessel wall defect (von 
Willebrand 1926; von Willebrand 1931).   
 
VWD is now defined as a deficiency of VWF function leading to impaired 
haemostasis, caused by either a decrease in VWF levels (quantitative 
deficiency) or a decrease in VWF function (qualitative deficiency).  The pattern 
of inheritance is autosomal dominant or recessive, however women with milder 
VWD forms appear more symptomatic than men.   
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1.11.1 Clinical Manifestations 
As described in section 1.3, VWF is essential for primary haemostasis, 
therefore individuals with VWD present with bleeding symptoms such as 
bruising, epistaxis, oral cavity bleeding, menorrhagia, gastrointestinal bleeding 
and bleeding after trauma or surgery (Federici 2004).  The severity of clinical 
symptoms varies in individuals as they are dependent upon a number of 
molecular and genetic factors. Most patients with severe forms of VWD present 
in childhood whilst milder forms may not present until adulthood when an 
individual may experience a significant haemostatic challenge.  As VWD is 
such a heterogeneous disorder some patients with milder forms of the disease 
remain asymptomatic and therefore remain under- or mis-diagnosed (Laffan, 
Brown et al. 2004).  This had led to the classification of VWD based on distinct 
types and treatment decisions are made according this.  Multiple tests are used 
to diagnose and classify VWD accurately as no single clinical or laboratory 
assessment can give a definitive diagnosis. 
 
1.11.2 Bleeding history 
The three key components needed to make a diagnosis of VWD are: a positive 
bleeding history since childhood, a family history of bleeding with an autosomal 
dominant or recessive pattern of inheritance, and reduced VWF activity in the 
plasma (Federici 2009).  The bleeding severity score (BSS) is a summary score 
which can be used to quantify the bleeding symptoms in patients suspected of 
having VWD and is essential in the diagnosis of VWD.   
 
1.12 CLASSIFICATION OF VWD 
In 1994 the Subcommittee on VWF published recommendations for the 
classification of VWD based upon available laboratory tests and clinical 
characteristics (Sadler 1994).  Further research into understanding the 
pathophysiology of VWD has led to re-evaluation of this classification.  The 
classification now identifies three main categories (see Table 1.1).  Type 1 
refers to a partial quantitative deficiency of VWF, type 2 represents qualitative 
abnormalities and type 3 includes a complete deficiency of VWF.  Type 2 is 
further subdivided into four categories based on their phenotype (2A, 2B, 2M, 
2N) (Sadler, Budde et al. 2006).  These six variants manifest due to different 
 31 
pathophysiologic mechanisms and are associated with individual clinical 
features and therapeutic requirements.  Although mixed VWF phenotypes can 
arise due to complex VWF mutations which work alone or in combination.   
 
1.12.1 Type 1 VWD  
The most common form of VWD is type 1 which results from a partial, 
quantitative deficiency of VWF and accounts for 50-75% of all VWD cases 
seen.  A number of factors including reduced secretion, accelerated clearance 
or enhanced sensitivity to proteolysis can lead to reduced VWF levels.  Type 1 
VWD diagnosis can often be difficult and the main criterion used is low VWF 
levels, however this can be influenced by age, sex, exercise and stress and 
blood group.  The significant laboratory findings for type 1 disease include a 
normal ratio of VWF activity to VWF level in plasma (VWF:RCo/VWF:Ag >0.6), 
normal multimer size distribution but with a reduced concentration (Ruggeri, 
Mannucci et al. 1982).  
 
The bleeding diathesis seen in type 1 VWD patients is mild to moderate.  Mild 
type 1 VWD can be harder to diagnose as it is difficult to identify them from 
individuals with low normal VWF levels due to the broad normal range of 
plasma VWF (Laffan, Brown et al. 2004).   
 
A definitive diagnosis can be made by autosomal dominant inheritance, 
abnormal bleeding symptoms and decreased levels of qualitatively normal VWF 
(Federici 1998; Laffan, Brown et al. 2004).    A diagnosis of type 1 VWD can be 
made difficult by incomplete penetrance and variable expression of the disease 
(Sadler and Rodeghiero 2005).  Several subgroups of VWD type 1 have been 
identified based on the relative levels of plasma and platelet VWF which 
indicates that different molecular mechanisms may be responsible.  In many 
affected families it has been seen that a spectrum of mutations rather than one 
single mutant allele is responsible for disease symptoms.  These consist of 
mainly deletions, frameshifts and nonsense mutations and are similar to that in 
type 3 VWD (Sadler, Mannucci et al. 2000).  Type 1 VWD can also be inherited 
infrequently as a dominant trait with extremely high penetrance and very low 
VWF levels.  This has been attributed to dominant negative missense 
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mutations that impair the intracellular transport and secretion of normal VWF 
subunits (Eikenboom, Matsushita et al. 1996).   
 
1.12.2 Type 2 VWD  
Type 2 VWD is due to a qualitative defect of VWF function and is subdivided 
into four variants (2A, 2B, 2M and 2N) which contribute to 25% of all VWD 
cases diagnosed (Holmberg and Nilsson 1985).   
 
1.12.2.1 Type 2A VWD 
Type 2A VWD is associated with reduced VWF-dependant platelet adhesion 
and a deficiency of HMW VWF multimers resulting in disproportionate 
reductions in platelet interaction and collagen binding relative to VWF levels 
(VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag, respectively).  The deficiency of 
HMW multimers may result from impaired multimer assembly or greater 
sensitivity to cleavage by ADAMTS-13.  The loss of large multimers is 
associated with unequal reductions in platelet interaction and collagen binding 
in relation to VWF levels (Favaloro, Lillicrap et al. 2004).  The minimum criteria 
for diagnosis include a personal or family history of bleeding, VWF:RCo below 
50 IU/dL and a VWF:Ag level of <0.7 in the absence of HMW multimers.  
Patients present with a history of mucosal or trauma-related bleeding and 
inheritance is generally autosomal dominant although some cases may be 
autosomal recessive (Holmberg and Nilsson 1992).   
 
1.12.2.2 Type 2B VWD 
Type 2B VWD is defined as a qualitative gain of function variant of VWF with 
increased affinity for platelet GpIb.  This VWD variant is quite uncommon and 
accounts for less than 5% of all cases.  Patients are diagnosed by a personal or 
family history of mucosal bleeding, increased sensitivity to RIPA at low-dose 
ristocetin (≤0.75 mg/mL) and exclusion of pseudo (platelet type) VWD.  Patients 
present with a history of mucosal or trauma-related bleeding and inheritance is 
normally autosomal dominant although recessive cases have been described 
(Laffan, Brown et al. 2004).   
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1.12.2.3 Type 2M VWD 
Type 2M VWD is a qualitative variant characterised by decreased platelet-
dependant function that is not caused by the absence of HMW multimers.  
Patients present with a history of mucosal or trauma-related bleeding and 
inheritance is autosomal dominant.  A diagnosis can be made by a VWF:RCo 
below 50 IU/dL and <0.7 of the VWF:Ag level and the presence of HMW 
multimers (Laffan, Brown et al. 2004).  Type 2M is caused by mutations that 
inactivate specific binding sites for ligands in connective tissue or on the 
platelet surface without affecting multimer assembly or stability.   
 
1.12.2.4 Type 2N VWD 
Type 2N VWD is a recessively inherited disorder with decreased affinity for 
FVIII.  FVIII/VWF binding is essential for normal FVIII survival in the circulation 
therefore the reduced binding results in accelerated clearance of FVIII.  
Therefore a diagnosis can be made by decreased FVIII:C level and decreased 
binding of control FVIII to patient VWF. However this can also cause confusion 
between a diagnosis of haemophilia A and type 2N VWD and it has been 
reported that a small number of patients with apparent haemophilia A actually 
have type 2N VWD (Schneppenheim, Budde et al. 1996).  It is important to 
distinguish VWD type 2N from haemophilia A so that bleeding episodes can be 
treated appropriately, valid genetic counselling can be given and accurate 
carrier or pre-natal diagnosis provided (Laffan, Brown et al. 2004). 
 
1.12.3 Type 3 VWD 
Type 3 VWD is a severe autosomal recessive disorder which arises because of 
a quantitative deficiency of the VWF protein.  It is characterised by an absence 
or virtual absence of VWF (<5% of normal) and FVIII activity is notably reduced 
due to the requirement for VWF to stabilise FVIII in the plasma (Budde and 
Schneppenheim 2001; Federici 2003).  In the general population the incidence 
of type 3 VWD is reported to be 0.55 to 3.2 per million (Mannucci, Bloom et al. 
1984) in Western countries, however a higher prevalence may be seen in 
populations where consanguinity is widespread (Berliner, Seligsohn et al. 1986; 
Sadler, Mannucci et al. 2000).  Type 3 VWD patients usually present in 
childhood with symptoms such as severe mucocutaneous haemorrhage and 
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bleeding following minor trauma (Laffan, Brown et al. 2004).  Heterozygous 
relatives can be seen to have normal or mildly reduced levels of VWF, and are 
generally asymptomatic although a minority may suffer from mild bleeding 
symptoms (Schneppenheim, Krey et al. 1994).  Both type 3 and type 1 VWD 
arise from quantitative defects and have a similar pathophysiology, however 
they have been classified separately as type 3 symptoms are more severe and 
require a different treatment regime.   
 
Table 1.1: Classification of VWD (adapted from Sadler, Budde et al. 2006). 
Type Description 
1 Partial quantitative deficiency of VWF. 
2 Qualitative VWF defects. 
2A 
 
Decreased VWF-dependant platelet adhesion and a selective  
deficiency of HMW VWF multimers. 
2B Increased affinity for platelet glycoprotein Ib. 
2M Decreased VWF-dependant platelet adhesion without a selective 
deficiency of HMW VWF multimers. 
2N Markedly decreased binding affinity for FVIII. 
3 Virtually complete deficiency of VWF. 
 
1.13 LABORATORY DIAGNOSIS OF VWD 
Laboratory investigations for VWD are only carried out if a diagnosis will be of 
benefit to advise or treat a patient with bleeding symptoms.  The VWF protein 
can be characterised by a number of different techniques and relies upon these 
to identify the correct classification of VWD.  Primary screening tests are used 
to initially evaluate a bleeding patient, specific tests are required to confirm a 
diagnosis of VWD and discriminating tests are essential in distinguishing the 
subtypes from one another (Sadler, Mannucci et al. 2000). 
 
1.13.1 SCREENING TESTS 
1.13.1.1 Bleeding Time (BT) 
The BT is the length of time that it takes for a standardised skin wound to stop 
bleeding.  The BT is always prolonged in severe VWD (types 3 and some forms 
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of type 2).  In milder forms of VWD the BT is usually found to be normal or 
minimally prolonged but can vary in a particular patient.  Limitations of this test 
include insensitivity, lack of specificity and poor reproducibility (Sadler, 
Mannucci et al. 2000) and should not form part of a standard diagnostic workup 
for the disorder. 
 
1.13.1.2 Closure time (CT) 
CT is the determination of VWF dependant platelet function using the PFA-
100TM (Platelet Function Analyser).  This involves a high sheer stress system 
and can produce sensitive and reproducible results to screen for VWD, 
however the CT is normal in type 2N VWD (Sadler, Mannucci et al. 2000). 
Studies have shown that the PFA-100 has a higher sensitivity than the BT for 
detecting moderately severe VWD, however has reduced sensitivity for 
identifying cases of mild type 1 VWD (Cattaneo, Federici et al. 1999; Nitu-
Whalley, Lee et al. 2003; Posan, McBane et al. 2003). 
 
1.13.1.3 Platelet count 
The platelet count, which is part of a full blood count, is usually included in the 
initial screening tests for VWD.  It is not directly affected by other types of VWD 
but may be decreased in VWD type 2B, especially in relation to surgery or 
pregnancy (Sadler, Mannucci et al. 2000). 
 
1.13.1.4 Activated Partial Thromboplastin Time (APTT) 
The APTT may be found to be prolonged in patients with VWD as plasma 
levels of FVIII commonly depend on the VWF levels, therefore it is useful in 
identifying type 3 and type 2N where FVIII is always reduced.  However, it is 
not sensitive for screening milder forms of VWD where FVIII levels are normal 
or near-normal (Sadler, Mannucci et al. 2000). 
 
1.13.2 Specific Tests 
Plasma VWF and FVIII levels can be influenced by many physiological 
parameters such as age, ethnic group and hormonal status.  The observed 
normal values show a wide range from 40 to 240 IU/dL and diagnosis may not 
always be clear-cut as one or more of the activities of FVIII/VWF may be 
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borderline normal or even normal.  It is often necessary to repeat testing on at 
least three occasions, as the concentration of both proteins can be affected by 
a number of endogenous factors (e.g. intercurrent illness).  The ABO blood 
group is also related to both FVIII and VWF levels.  Those with blood group O 
have FVIII/VWF levels that are 15-20% lower than those with blood group A; 
this should be taken into account when investigating people with borderline 
results (Gill, Endres-Brooks et al. 1987).  In some patients with normal or 
borderline VWF levels, a primary platelet disorder should also be taken into 
account, as the clinical presentation of bleeding can be identical.   
 
1.13.2.1 Factor VIII Activity (FVIII:C) 
Factor VIII secretion and plasma half-life are dependant on VWF because of its 
function as a carrier and stabiliser of FVIII in the plasma.  Therefore FVIII:C 
levels usually mirror those of VWF:Ag.  Low FVIII levels relative to VWF levels 
(FVIII/VWG:Ag <1) suggests type 2N disease, which is characterised by poor 
interaction between VWF and FVIII.   
 
FVIII:C is measured by either a one-stage or two-stage clotting assay based on 
the APTT method or by a chromogenic assay based on the generation of 
activated FX (Sadler, Mannucci et al. 2000). 
 
1.13.2.2 von Willebrand Factor Antigen (VWF:AG) 
Plasma VWF antigen (VWF:Ag) measures the level of VWF in circulation using 
immunological methods.  Previous electrophoretic immunoassays have been 
replaced with more sensitive enzyme immunoassays.  Decreased levels of 
plasma VWF:Ag are seen in patients with quantitative VWF defects but may be 
normal in type 2 variants (Sadler, Mannucci et al. 2000). Type 3 VWD is 
characterised by very low levels of VWF:Ag (<1 IU/dL) as this indicates an 
almost total absence of VWF in the plasma. 
 
1.13.2.3 Ristocetin CoFactor Activity (VWF:RCo) 
The VWF:RCo assay is used to determine VWF activity by measuring the 
interaction between VWF and platelet GPIb in the presence of the antibiotic 
ristocetin.  Aggregometry is used to assess platelet agglutination following 
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addition of ristocetin to a suspension of normal platelets and patient plasma 
(Macfarlane, Stibbe et al. 1975).  The rate and extent of platelet agglutination is 
dependant upon the concentration of VWF.  This is a useful VWD screening 
test; however it is limited by poor reproducibility. 
 
Quantitative type 1 and type 3 VWD and VWF variants with conserved platelet-
dependant function (type 2N) show a normal ratio of VWF:RCo/VWF:Ag.  
Although type 1 disease can also be identified by an equal reduction in both the 
activity and amount of VWF (VWF:RCo/VWF:Ag ratio of >0.6).  Some type 2 
forms of VWD are indicated by a disproportionate reduction in VWF activity 
compared to VWF levels (VWF:RCo/VWF:Ag ratio of <0.6) as normal ristocetin-
mediated platelet agglutination is dependant upon the largest multimeric forms 
of VWF.   
 
1.13.3 Discriminating Tests 
Following a diagnosis of VWD, these tests are required to identify a specific 
subtype. 
 
1.13.3.1 Ristocetin-Induced Platelet Aggregation (RIPA) Assay  
The primary haemostatic function of VWF is best assessed by it ability to 
support ristocetin-induced platelet aggregation in vitro.  This involves 
measuring the ability of a patient’s VWF to bind to platelets in vitro in platelet-
rich plasma at varying concentrations of ristocetin.  RIPA is undetectable with 
any ristocetin concentration in VWD type 3, but may be normal in patients with 
VWD type 1.  Type 2B disease can be characterised by RIPA as they have 
VWF that has a higher affinity for GpIbα receptor binding and so can stimulate 
platelet aggregation at lower concentrations of ristocetin (<0.8 mg/ml) 
compared to other patients with VWD (>1.2 mg/ml).   
 
1.13.3.2 VWF Collagen Binding (VWF:CB) 
The VWF:CB assay measures the binding of VWF to collagen and measures 
preferentially the HMW multimers of VWF and complements the results of the 
VWF:RCo.  VWF:CB activity is measured using ELISA plates coated with 
collagen and the amount of patient VWF that binds is quantified and compared 
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to a plasma standard.  This assay is helpful in distinguishing certain subtypes of 
type 2 VWD from type 1 as it has the ability to preferentially bind HMW 
multimers which are lacking in type 2A and type 2B VWD (Favaloro 2000). 
 
1.13.3.3 VWF Multimer Analysis 
VWF multimeric analysis is used to visualise the pattern of VWF multimers in 
plasma in order to distinguish VWD subtypes.  VWF multimer analysis can be 
performed by sodium dodecyl sulphate-agarose discontinuous gel 
electrophoresis with enzyme-labelled antibodies.  The VWF multimers are 
visualised using enhanced chemiluminescence kits followed by 
autoradiography (Cumming and Wensley 1993).  Normal plasma VWF is visible 
as a series of bands separated in size by the mass of two VWF subunits and 
range in size from 500 to >10,000 kDa. 
 
Type 1 patients exhibit the full range of VWF multimers but they may be 
reduced in intensity whereas they are absent in patients with type 3.  Type 2A 
and 2M both have low VWF activity compared to the amount of VWF present 
therefore they can be distinguished from one another by assessing the size 
distribution of multimers, as type 2A VWD patients lack HMW VWF multimers 
whereas type 2M do not.   
 
1.13.3.4 VWF-FVIII Binding Assay 
This assay measures the affinity of FVIII-VWF binding (VWF:FVIIIB) by 
isolating patient VWF by immunoadsorption, with subsequent binding of 
purified, exogenous, FVIII.  The bound FVIII is then measured either by a 
chromogenic assay or an ELISA method.  This test can be used to confirm a 
diagnosis of VWD type 2N in those with a low FVIII/VWF:Ag from mild or 
moderate forms of haemophilia A.   
 
1.13.4 Treatment of VWD 
Treatment for VWD patients is targeted at correcting the functional deficiency of 
VWF and increasing low FVIII levels (Favaloro, Lillicrap et al. 2004).  The two 
main treatment options are DDAVP and transfusion with blood products that 
contain the FVIII-VWF complex (replacement therapy).  DDAVP is most useful 
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in treating patients with type 1 VWD however patients with type 3 VWD are 
usually unresponsive.  Unresponsive patients are generally treated with 
replacement therapy. 
 
Other non-transfusional treatments include antifibrinolytic drugs such as 
tranexamic acid and hormonal therapy (i.e. oral contraceptive).  Antifibrinolytic 
drugs can either be given alone or in combination with other therapies and are 
effective in the treatment of nasopharyngeal, oral or gastrointestinal bleeding 
(Mannucci 1998).   
 
1.14 MOLECULAR PATHOLOGY OF VWD 
Mutations identified in VWF are generally thought to be the main cause of VWD 
as they have been found in coding regions which alter the expression, 
processing, structure and function of VWF and mature VWF (Sadler 1994).  
However, it is now understood that VWD is not only associated with mutations 
in VWF.  The underlying genetic defects associated with types 2 and 3 VWD 
are well defined but the molecular pathogenesis behind type 1 VWD still 
remains inconclusive, particularly in milder cases.  There have been many 
mutations reported to be associated with the various subtypes of VWD and a 
database of known VWF mutations and polymorphisms is maintained by The 
International Society on Thrombosis and Haemostasis Scientific and 
Standardisation Committee (ISTH SSC) (Ginsburg and Sadler 1993).  The 
database is maintained by the School of Medicine and Biological Sciences at 
the University of Sheffield and can be accessed at 
http://www.vwf.group.shef.ac.uk.   
 
1.14.1 Type 1 VWD 
As mentioned earlier the underlying molecular mechanisms of type 1 VWD 
have only been identified in a small proportion of patients and lacking a 
common mechanism causing the disease state.  Three large population studies 
in the UK, Canada and Europe have been carried out to investigate the genetic 
defects causing type 1 VWD and reported inconclusive results (Cumming, 
Grundy et al. 2006; Goodeve 2007; James, Notley et al. 2007).  Therefore 
supporting the hypothesis that the type 1 VWD phenotype does not always 
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correlate with the genotype rendering the genetic diagnosis of type 1 as limited 
(Collins, Cumming et al. 2008).  According to the ISTH VWF mutation database 
the majority of mutations or candidate mutations associated with type 1 VWD 
are missense mutations.  The rest are made up of small deletions, splice site 
mutations, promoter region mutation, insertions, duplications and nonsense 
mutations.  These reported mutations are spread throughout the entire length of 
the gene and not restricted to a specific region of VWF (see Figure 1.7). 
 
Figure 1.7: Diagram representing the distribution of type 1 VWD 
mutations in VWF (Cumming et al. 2010), used with the authors’ 
permission. N = nonsense, F = frameshift, D = small deletion, S = splice site, M = 
missense 
 
 
 
The three recent population studies have highlighted the need for further 
studies to be carried out to examine the cause of type 1 VWD which include the 
possibility of small or large deletions (see section 1.17), or splicing variants not 
caused by changes at the invariant splice sites.  Although it was also made 
clear that there may be no apparent mutational mechanism responsible for a 
large proportion of type 1 VWD. 
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1.14.2 Type 2 VWD 
The majority of the mutations are found within the VWF domain A2 which is 
located in exon 28 of VWF, with fewer in VWF domain A1 (Schneppenheim, 
Budde et al. 2001) (see Figure 1.8).  The majority of mutations reported on the 
ISTH VWF database are missense, with a smaller percentage caused by frame 
shifts, insertions and deletions.  The most commonly reported missense 
mutations are c.Arg1597Trp and c.Ser1506Leu within the A2 domain which 
account for up to a third of type 2A cases (Meyer, Fressinaud et al. 1997; 
Nichols and Ginsburg 1997). 
 
1.14.2.1 Type 2A VWD 
Two classes of mutations are known to produce type 2A VWD, referred to as 
group 1 and group 2 mutations (Lyons, Bruck et al. 1992; O'Brien, Sutherland 
et al. 2005).  Group 1 mutations cause defective intracellular transport of VWF 
and damages the assembly, storage and secretion of large VWF multimers in 
both the plasma and platelet compartments.  Group 2 mutations do not affect 
VWF assembly or secretion but make the multimers more sensitive to 
proteolysis in plasma (Dent, Berkowitz et al. 1990).  In both cases of type 2A 
VWD mutations, the mutant subunit results in the characteristic loss of large 
VWF multimers. 
 
1.14.2.2 Type 2B VWD 
All of the mutations associated with type 2B VWD are located in the A1 domain 
of VWF which contains the GpIb binding site.  Nearly all of these are missense 
mutations with the most frequently reported mutations being p.Arg1306Trp, 
p.Arg1308Cys, p.Val1316Met and p.Arg1341Gln accounting for 70% of type 2B 
VWD (Cooney, Nichols et al. 1991; Lillicrap, Murray et al. 1991; Eikenboom, 
Reitsma et al. 1994; Casana, Martinez et al. 1998).   
 
1.14.2.3 Type 2M VWD 
The majority of mutations associated with type 2M are located in the A1 domain 
which mediates VWF interaction with platelet GpIb.  Therefore these mutations, 
which are primarily missense, result in impaired binding of VWF to platelet GpIb 
(Meyer, Fressinaud et al. 1997; Casana, Martinez et al. 1998; Casonato, 
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Pontara et al. 2006).  Another variant known as VWD type 2M (Vicenza) 
displays extra large VWF multimers in plasma and low VWF antigen and 
activity, caused by candidate mutations in exon 28 of VWF (Casonato, Pontara 
et al. 2006). 
 
1.14.2.4 Type 2N VWD 
Individuals with type 2N VWD are expected to be homozygous, compound 
heterozygous or pseudo-homozygous (i.e. inheritance of one allele containing a 
type 2N VWD mutation and one allele with a VWF null mutation).  According to 
the ISTH database the majority of mutations associated with type 2N are 
missense and are located in exons 18-20 of VWF.  The most commonly 
reported mutation is p.Arg854Gln and has been shown to interfere with VWF 
binding to FVIII which causes low level FVIII levels (Hilbert, Jorieux et al. 2004).  
There have been reports of mutations associated with type 2N which lie outside 
the FVIII binding domain, however these may cause key structural changes to 
VWF which result in loss of ability to bind to FVIII effectively (Gu, Jorieux et al. 
1997; Casonato, Sartorello et al. 2003).  Co-inheritance of a type 2N VWD 
mutation with a type 1 VWD allele has also been reported which may contribute 
to the variable expressivity of type 1 VWD (Eikenboom, Reitsma et al. 1993; 
Casonato, Gaucher et al. 1998). 
 
Figure 1.8: Diagram representing the distribution of type 2 VWD 
mutations in VWF (Cumming et al. 2010) used with the authors 
permission. 
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1.14.3 Type 3 VWD  
Type 3 VWD arises because of homozygous or compound heterozygous 
recessive mutations at the VWF locus that produce null alleles.  A wide 
spectrum of mutations are associated with type 3 VWD and can be found 
throughout the 178 kb length of VWF, including the promoter region, coding 
and non-coding regions, and the 5’ and 3’ untranslated regions (see Figure 1.9) 
 
Initially type 3 VWD was presumed to arise from large deletions of the gene 
encoding VWF, however according to the ISTH VWF database only 12 of 109 
type 3 VWD mutations are large gene deletions.  Large deletions are generally 
defined as ranging from the deletion of one or more exons of VWF and have 
been shown to be a relatively infrequent cause of type 3 VWD (Baronciani, 
Cozzi et al. 2000; Baronciani, Cozzi et al. 2003).  However a recent study by 
Sutherland, Cumming et al. (2009) identified a large deletion of VWF exons 4-5 
in a cohort of type 3 VWD patients from the north-west of England.  This 
mutation was seen in 7 of 12 Caucasian type 3 VWD patients from unrelated 
families but was absent in nine patients of Asian origin with haplotype analysis 
indicating a possible founder origin of the mutation in families originating from 
Britain.  This mutation was found to be Alu-mediated which has also been seen 
in a least two other deletions in type 3 VWD as Alu repeats are known to 
promote unequal homologous recombination which results in deletion 
mutations (Xie, Wang et al. 2006; Mohl, Marschalek et al. 2008).  Heterozygous 
carriers of VWF deletions are usually found to be clinically asymptomatic and 
have normal levels of VWF which proves that the presence of a single VWF 
locus can supply sufficient functional VWF.  Although it has been reported that 
some carriers do have reduced levels of VWF:Ag and VWF:RCo and that some 
heterozygous carriers of type 3 VWD demonstrate a mild type 1 VWD 
phenotype (Peake, Liddell et al. 1990; Anvret, Blomback et al. 1992). 
 
The exon 4-5 deletion discussed above has also been found in a number of 
type 1 VWD families segregating with VWD in an autosomal dominant fashion 
and exerting a dominant-negative effect to produce a type 1 VWD phenotype. 
The most common mutations are total or partial VWF deletions, nonsense, 
splicing and frame shift mutations.  Deletion mutations result in the elimination 
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of vital sequences of VWF and range from the deletion of one or more exons of 
VWF to the deletion of the entire gene (see section 1.17).  The presence of 
large or complete VWF deletions or other gene deletions which lead to the 
production of a truncated or absent protein, can cause the development of 
alloantibodies to VWF following the transfusion of VWF replacement therapy 
products.  These anti-VWF alloantibodies can produce severe anaphylactic 
reactions in patients who are receiving replacement treatment at the time 
(Mannucci, Tamaro et al. 1987).  Therefore it is important to identify the 
underlying VWF defect in type 3 VWD patients to aid the assessment of risk for 
inhibitor development. 
 
Figure 1.9: The distribution of type 3 VWD mutations in VWF (Cumming et 
al. 2010) used with the authors permission.  N = nonsense, F = frameshift, D = 
deletion (small or whole exon), S = splice site, M = missense, GC = gene conversion 
event.   
 
 
Nonsense mutations or small deletions or insertions associated with a null 
allele make up approximately 80% of reported VWF mutations in type 3 VWD.  
These types of mutations produce mutant alleles which fail to generate any 
mature VWF protein leading to a complete quantitative deficiency.  A few 
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studies have identified splice-site mutations associated with type 3 VWD which 
result in exon skipping in affected VWF mRNA transcripts (Eikenboom, 
Castaman et al. 1998; Baronciani, Cozzi et al. 2000; Hollestelle, Thinnes et al. 
2001; Baronciani, Cozzi et al. 2003).  Homozygous or compound heterozygous 
missense mutations are responsible for 15-20% of type 3 sequence variants 
(Cumming et al. 2010).  Missense mutations specifically located at a cysteine 
amino acids are expected to have a detrimental effect on mature VWF because 
cysteine residues aid the formation of disulphide bonds, which are required for 
the proper function and tertiary structure of the mature VWF protein.  Unpaired 
cysteine residues are recognised to inhibit the intracellular transport of many 
proteins. It has been shown in expression studies of normal and mutant VWF 
that these mutations can interfere with dimerisation of VWF monomers 
(Schneppenheim, Krey et al. 1994; Eikenboom, Castaman et al. 1998; 
Castaman, Eikenboom et al. 2000; Schneppenheim, Budde et al. 2001; 
Tjernberg, Vos et al. 2004) and impair VWF multimerisation and secretion 
through a dominant-negative mechanism (Zhang, Blomback et al. 1994; Allen, 
Abuzenadah et al. 2000; Baronciani, Cozzi et al. 2000; Baronciani, Cozzi et al. 
2003; Baronciani, Federici et al. 2008).  It is also thought that mutations which 
cause frame shifts result in defective protein folding hence interfering with 
normal propeptide processing (Mohlke, Nichols et al. 1996). 
 
Gene conversions between VWF and VWFP have been identified as making a 
significant contribution to the molecular mechanism behind type 3 VWD.  The 
conversion event occurs due to the high degree of sequence homology 
between VWF and VWFP (97%) and is generally constrained to the region of 
the 3’ part of intron 27 and 5’ part of exon 28 of the gene and pseudogene.  
This is a result of chi sequences (CCTGGTGG) or chi-like sequences 
(GCTGGTGG) present in the region which encourage DNA recombination 
(Kenter and Birshtein 1981).  The identification of multiple base substitutions 
within the region of VWF corresponding to the VWFP sequence signifies that a 
gene conversion has taken place.  A common mutation that has often been 
seen in association with a gene conversion event in type 3 VWD is the 
nonsense mutation p.Gln1311X in exon 28 of VWF (Casana, Martinez et al. 
2000; Surdhar, Enayat et al. 2001; Baronciani, Cozzi et al. 2003; Gupta, 
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Adamtziki et al. 2005; Gupta, Saxena et al. 2008).  The phenotypic expression 
can differ depending on the length of the gene conversion or whether it is 
homozygous, heterozygous or compound heterozygous. 
 
1.15 GENETIC TESTING IN VWD 
Section 1.13 describes the phenotypic diagnosis of VWD based on the patient’s 
clinical and familial features.  The practice guidelines for the molecular analysis 
of VWD describe how molecular analysis of VWF can help to identify the 
underlying genetic defect responsible for the phenotypic characteristics and 
help to confirm a diagnosis (Keeney, Bowen et al. 2008).  Now that gene 
sequencing technology is more straightforward and is more widely available it is 
possible to screen the whole or relevant parts of VWF for specific mutations to 
aid VWD classification.  This may be significant when confirming a diagnosis of 
type 2A, 2B, 2M or 2N, however in cases where the subtype is clear from the 
phenotype, its clinical use is limited.  In type 3 VWD, genetic investigation is 
particularly beneficial for family studies and prenatal diagnosis.  It can also 
provide important information for clinicians involved in the management of the 
birth of an affected child and post natal care of the neonate.  Genetic 
counselling is an essential requirement for patients and families with VWD, 
before and after genetic investigations are undertaken.  This is so that 
individuals understand the inheritance of VWD in their families and the results 
of subsequent genetic tests (Keeney, Bowen et al. 2008). 
 
In the UK, genetic testing for VWD should be performed in a member laboratory 
of the UKHCDO-GLN which is a consortium of laboratories who work to peer-
defined, peer reviewed standards (Laffan, Brown et al. 2004) to provide a 
comparable quality of testing nationally. 
 
1.15.1 Diagnostic Strategy 
Mutation analysis is carried out by DNA sequencing of the essential regions of 
VWF which is considered to be the gold standard.  The essential regions of 
VWF are characterised by the promoter region, exons 1 to 52 together with the 
splice junctions and flanking sequences, and the 3’ UTR region.   
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Genetic testing and family studies in type 3 VWD are important because of the 
severity of the bleeding tendency and the autosomal recessive pattern of 
inheritance.  It is particularly valuable for the identification of asymptomatic 
carriers of type 3 VWD as this cannot be diagnosed phenotypically or by 
pedigree analysis.  If no causative mutations are found in a type 3 VWD patient, 
or if a patient appears to be homozygous for a given mutation, the presence of 
an insertion, rearrangement or whole or partial gene deletion on the other VWF 
allele should be taken into account.  Southern blot analysis can be used to 
investigate this, however this is no longer a mainstream routine diagnostic 
technique (see section 1.9 for other described methods). 
 
For the majority of type 2 VWD cases a diagnosis is made following phenotypic 
testing, however, now that the molecular basis for type 2 is more clearly 
understood, genetic testing may help to confirm a phenotypic diagnosis.    
 
1.16 DETECTION OF LARGE SCALE HETEROZYGOUS DELETIONS   
CNV’s involving large deletions within VWF have been reported, although in the 
past only homozygous deletions have been found in type 3 VWD, as 
heterozygous deletions (or duplications) are not easily detected during PCR 
amplification due to the presence of one normal VWF allele.  The presence of a 
large homozygous VWF deletion is generally predicted to disrupt protein 
translation and prevent VWF expression.  A few reports have identified large 
heterozygous deletions in types 1 and 2 VWD using linkage analysis which has 
highlighted unusual polymorphic marker inheritance (Bernardi, Marchetti et al. 
1990; Johansson, Hallden et al. 2011) or by using a mutation specific PCR 
assay for a previously characterised type 3 VWD deletion (Sutherland, 
Cumming et al. 2009).  These mutations tend to be in-frame and function in a 
dominant-negative manner. 
 
Since standard diagnostic methods, including DNA sequencing, are unable to 
detect large heterozygous deletions, various techniques can be used to identify 
mutation status in heterozygous carriers. These include linkage analysis (which 
may reveal loss of heterozygosity for markers in the deleted region), analysis of 
platelet derived VWF mRNA (which may reveal an aberrantly sized RT-PCR 
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product), gene dosage analysis, such as MLPA and Gap or Long PCR 
protocols (to partially or fully map deletion boundaries) (Keeney, Bowen et al. 
2008).  MLPA can be used to detect homozygous and heterozygous CNV’s and 
recently has been used to identify additional deletions contributing to VWD in 
both heterozygous type 2 and in compound heterozygous type 3 patients 
(Yadegari, Driesen et al. 2011). 
 
1.17 MOLECULAR STUDIES OF LARGE DELETIONS IN VWD USING MLPA 
Large deletions are regarded as a rarity for being the underlying genetic defect 
in VWD, which generally result in a complete absence of VWF protein 
(Schneppenheim, Castaman et al. 2007).  In type 3 VWD, 12 large deletions 
have so far been reported, ranging in size from a single exon to the entire gene.  
It is also worth noting that a large deletion spanning all VWF A domains has 
been identified in type 2A VWD (www.vwf.group.shef.ac.uk). 
 
As discussed above, the identification of large deletions is harder in autosomal 
conditions, where the presence of a normal allele masks the failure to amplify 
the mutant one.  Therefore false-negative results are often found in carriers of 
heterozygous large deletions.  MLPA as described in section 1.9.1 can be used 
to successfully identify heterozygous deletions.  To date there have been two 
reports of large deletions identified in patients without a causative mutation 
using MLPA. 
 
The first report was from Cabrera, Casana et al. (2011) who were investigating 
the underlying genetic defects of two severe type 3 VWD patients.  In the two 
patients with VWD they identified a large homozygous deletion after the PCR 
technique failed to amplify from exon 15 to exon 43.  However in the parents, 
sister and a non carrier relative of the patients, all exons successfully amplified.  
Further analysis using MLPA showed that the patients had an almost total 
reduction in peaks corresponding to exons 16-43 whereas the area of these 
same peaks was around 50% in their relatives indicating their heterozygous 
state.  The fact that exon 15 had failed to amplify using PCR indicated that the 
breakpoint of the deletion was located behind the exon 15 reverse primer used 
for PCR.  Therefore long and accurate (LA) PCR was used to determine the 
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deletion breakpoints and this showed that the deletion covered from the 5’ end 
of intron 15-3266 bp within intron 43.  This gave an explanation for the 
discordant results between PCR and MLPA as the intron 15 breakpoint was 
located within the nucleotide sequence annealing to the reverse primer.  In 
conclusion they reported a type 3 VWD family whose patients are homozygous 
for a large 84 kb deletion and all carriers share the same deletion in the 
heterozygous state.  This has allowed them to offer tailored genetic counselling 
to all members of the family. 
 
Yadegari, Driesen et al. (2011) performed a study on a cohort of patients in 
Germany using MLPA analysis to look for large deletions in patients where 
analysis had failed to identify the causative mutations for their VWD.  MLPA 
analysis was carried out using a kit supplied by MRC-Holland.  In total they 
detected 6 large deletions (5 novel) in their cohort of 23 VWD patients.  They 
found five large gene alterations in patients with type 3 VWD and one in a 
patient with type 2 VWD, however they did not detect any large deletions in 11 
index patients with type 1 VWD in whom the VWF antigen level was more than 
33 IU/dL.  Therefore they concluded that the presence of large deletions should 
be taken into account for the diagnosis of type 3 VWD, especially in patients 
who do not have two clear causative mutations.  If sequencing results reveal 
the presence of homozygous polymorphisms or a homozygous mutation then 
the possibility of a large deletion should always be taken into consideration.  
Also, patients diagnosed with type 2 VWD without a VWF mutation should also 
be analysed for large gene deletions and although no large deletions were 
detected in type 1 VWD, they should be investigated for the presence of 
possible heterozygous large deletions where no causative mutation has been 
identified. 
 
These studies show that MLPA can be successfully used to determine the 
dosage of the 52 exons of VWF and can aid the identification of possible 
carriers with heterozygous deletions/insertions.   
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1.18 PROJECT AIMS AND OBJECTIVES 
Knowledge of the molecular basis of inherited bleeding disorders is required in 
many cases to enable genetic counselling within families, carrier diagnosis and, 
in some cases, prenatal diagnosis.  Genetic information may also be useful for 
differential diagnosis, and the nature of the genetic defect can inform clinical 
management in certain circumstances. The current gold standard for genetic 
diagnosis in patients with VWD and haemophilia A is direct sequencing of 
genomic DNA to identify gene mutations. However there are cases where large 
heterozygous gene deletions or duplications in patients with VWD and in 
haemophilia A carriers are undetectable by DNA sequencing (Sutherland, 
Cumming et al. 2009).  Therefore the genetic basis of disease in a proportion of 
cases remains unresolved.  Recent studies have shown that the MLPA 
technique which is based on gene dosage can be applied to detect large gene 
deletions in haemophilia and VWD and therefore establish carrier status (Rost, 
Loffler et al. 2008; Lannoy, Abinet et al. 2009; Zimmermann, Oldenburg et al. 
2010; Cabrera, Casana et al. 2011; Rafati, Ravanbod et al. 2011; Theophilus, 
Baugh et al. 2011; Yadegari, Driesen et al. 2011). 
 
The aim of this study was to determine the molecular basis of disease in 
patients with haemophilia A and VWD using MLPA, where direct sequencing of 
F8 and VWF failed to reveal causative mutations, and to assess its application 
in the genetic diagnosis of these disorders. 
 
Objectives: 
1. To develop, optimise and validate MLPA assays for the detection of large 
deletions/duplications in F8 and VWF. 
2. To apply these methods to investigate the genetic basis of disease in 
selected patients with Haemophilia A and VWD. 
3. To introduce MLPA as part of the routine diagnostic strategy for Haemophilia 
A and VWD cases analysed within the Haematology Molecular Diagnostics 
Centre (MDC) at Manchester Royal Infirmary (MRI). 
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1.19 PREVIOUS STUDIES RELATED TO THIS PROJECT 
1.19.1 General Mutation Detection Strategies for Haemophilia A 
The diagnostic strategy used for mutation detection is determined by the 
severity of the haemophilia in the index case.  The initial approach for severe 
haemophiliacs is to screen them for the intron 22 inversion mutation, followed 
by the intron 1 inversion mutation, which would identify the underlying genetic 
defect in 45-50% of severe haemophilia A patients.  Following this, full 
mutation analysis of the essential regions of F8 is carried out on the remainder 
of severe haemophilia A cases.  The strategy for mild and moderate 
haemophilia cases is that full sequence analysis is performed as there is no 
common mutational mechanism linked to these forms.  This general diagnostic 
strategy had been applied previously to the patients included in this study and 
the methods used are outlined below. 
 
1.19.1.1 Intron 22 inversion detection by Long PCR 
A Long range PCR method was used for the detection of the F8 intron 22 
inversion.  The method has been modified from standard long range PCR 
methods to include the addition of DMSO (Dimethyl sulfoxide) to enable read 
through of a high GC content upstream of F8.  The ABgene Extensor PCR kit is 
also used to simplify the reaction set-up procedure from the original 
publications of the method.  The multiplex PCR protocol relies on overlapping 
PCR to generate a constant 10 kb PCR product which appears with all 
templates, and acts as a control to show that the reaction has worked 
efficiently.  The large fragments produced by long-range PCR are analysed on 
conventional agarose gels (0.7% w/v for the intron 22 PCR).  The largest 
amplification product seen using this method is 12 kb.  Full method details, 
including full primer sequences, are available in the paper by (Liu, Nozari et al. 
1998). 
 
1.19.1.2 PCR Amplification of the F8 Intron 1 Inversion 
A dual PCR assay was used to detect the intron 1 inversion.  Both are 
standard PCR assays designed to amplify independently sequence flanking 
the int1h regions (from intron 1 homologous sites).  Int1h-1 specifies the assay 
for the copy in F8 and Int1h-2 the homologous region 140 kb more telomeric.  
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Full details for this method are available in the paper by Bagnall, Waseem et 
al. (2002). 
 
1.19.1.3 Direct DNA Sequencing 
Full DNA sequence analysis of the coding regions of F8 was used to identify 
unknown Haemophilia A mutations in index cases and their relatives.  The 
protocol utilised custom-designed PCR primers that allows rapid DNA 
identification and sequencing of F8.  Thirty-seven sets of primers have been 
designed to amplify the essential regions of F8 under the same thermal cycling 
conditions.  Both forward and reverse primers for each PCR have a common 
tail (N13F and N13R respectively) to facilitate the use of one complementary 
sequencing primer in all forward and reverse strand sequencing reactions. 
This was an in-house protocol developed within the MDC. 
 
1.19.1.4 Detection of Partial Gene Deletions 
Large deletion mutations are easily identified in affected males due to failure of 
amplification of the missing regions of F8.  However, in carrier females it is 
especially difficult to identify these mutations as the failure to amplify part of F8 
will be masked by the normal gene sequence on the corresponding allele. 
 
Previous diagnostic approaches developed in the MDC could be applied to 
this problem.  Large deletions were identified in affected males by the absence 
of amplification products for one or more exons using the standard set of 37 
PCR primer pairs.  The presence of a partial gene deletion was confirmed by 
combining the forward and reverse primers from the exons either side of the 
expected breakpoint in a PCR reaction or long PCR reaction (for method 
details see Keeney et al. 2007).  This enables fragments over 2.5 kb long to 
amplify across the breakpoint.  The ABgene Extensor Hi-Fidelity PCR Master 
Mix was used for long PCR protocols, however if this method failed to amplify 
any fragments, the TaKaRa Ex Taq 10x PCR Buffer, dNTP 
(deoxyribonucleoside triphosphates) mixture for PCR (TAKARA BIO INC) was 
used under the same PCR and thermal cycling conditions. 
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The size of the fragments produced were analysed on an agarose gel.  In 
affected males with the deletion, a smaller than expected amplified fragment 
was seen.  Long PCR amplification was performed for carrier females and the 
presence of a deletion was revealed by a larger band representing the normal 
allele and a second smaller band representing the deleted allele.  Normal 
control samples only produced the larger band representing the normal allele, 
or it failed to amplify since the product would be too large. In these cases a 
gap PCR approach was used to confirm the presence of the normal allele.  
 
DNA sequencing was used where possible to confirm the identity of the 
fragments produced, and to investigate the position of the partial gene deletion 
breakpoint.  Sequence traces from patients with partial gene deletions were 
compared with the normal F8 sequence to identify the position of the deletion 
breakpoint. 
 
1.19.2 General Mutation Detection Strategies for VWD 
There are a number of mutations that are recurrent in certain VWD subtypes 
(in particular in type 2 VWD), therefore patients can be directly screened for 
relevant characterised mutations or for previously identified familial mutations 
in VWF. The following diagnostic strategies had been applied previously to the 
type 1 and type 3 VWD patients included in this study and the methods used 
are outlined below. 
 
1.19.2.1 Type 1 VWD 
As part of a UK national type 1 VWD study, all index cases entered were 
initially screened for mutations in exon 27 and exon 28 of the VWF.  This was 
performed to screen for any type 2 VWD or qualitative variant mutations.  Exon 
28 is the largest exon in VWF and has the most described mutations identified 
in type 1 and type 2 VWD (http://www.vwf.group.shef.ac.uk/).  The remaining 
index cases with no mutation identified within these regions were screened for 
mutations in all 52 exons and the promoter region of VWF by DNA 
sequencing. 
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1.19.2.2 Type 3 VWD 
As part of the UK type 3 VWD study, patients had been screened for 
mutations in VWF by direct DNA sequencing.  In patients where 
heterozygosity for a single VWF change or no detectable VWF mutation was 
present, platelet-derived VWF mRNA was studied to search for large 
heterozygous deletions or cryptic splice site mutations that could not be 
detected using conventional PCR techniques.  Platelet-derived VWF mRNA 
studies had also been previously carried out on patients from the UK national 
type 1 VWD study where no mutation had been identified to account for the 
bleeding phenotype. 
 
1.19.2.3 Screening of VWF 
Fifty one previously designed in-house primer pairs, each consisting of a 
forward and reverse primer, were used in order to amplify the essential regions 
of VWF including the 5’ promoter region, 52 exons, flanking intronic regions 
and 3’ untranslated region.  Amplification of genomic DNA was performed by 
PCR (Saiki, Scharf et al. 1985; Saiki, Gelfand et al. 1988) using standard 
thermal cycling conditions followed by direct DNA sequencing utilising 
automated capillary electrophoresis.  The DNA sequence data generated were 
analysed using comparative sequence analysis software and any sequence 
variants were compared with the published VWF sequence 
(http://www.vwf.group.shef.ac.uk/).  
 
Exon 15 of VWF had previously shown to be difficult to amplify using 
conventional PCR techniques as it is extremely GC rich in content, which 
leads to the formation of secondary structures, such as hairpin loops.  
Therefore this causes problems when trying to amplify genes using standard 
PCR approaches.  Previous work by Cumming, Grundy et al. (2006) had been 
carried out to optimise the PCR reaction using the TripleMaster® PCR System 
(QIAGEN® LongRange PCR System, supplied by Qiagen UK) and the 
annealing temperature of the primers at 57 °C.  The cycling conditions for the 
PCR reaction were also modified from the standard PCR conditions according 
to the manufacturer’s instructions. 
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Exon 28 of VWF had also been shown to be difficult to amplify due to its large, 
highly polymorphic nature.  It proved difficult to design primers that would 
successfully amplify appropriate segments of the exon without the primers 
lying over a polymorphism, which would mean that pathogenic mutations 
would potentially be missed due to allele dropout.  Therefore primers were 
designed to amplify the whole of exon 28 producing a product that is 1556 bp 
in size.  Consequently, sequence analysis of this product had to be performed 
in two segments using overlapping internal primer pairs which allowed forward 
and reverse sequence analysis of the full length of exon 28. 
 
1.19.2.4 Identification of the VWF exon 4 and 5 deletion  
Previous work by Sutherland et al. (2009) had led to the identification of a 
large deletion mutation encompassing exons 4 and 5 of VWF at the genomic 
level in the homozygous state in type 3 VWD patients of Caucasian origin.  
The exact locations of the deletion breakpoints were determined by primer 
walking.  Amplification of the genomic region from exon 3 to exon 6 (26 kb) 
was performed using 18 primer sets which produced ~1.5 kb overlapping 
fragments.  The truncated product produced using combinations of these 
primers was analysed by direct sequencing.  This led to the design of further 
primers to amplify a smaller product (1084 kb) so that sequencing could be 
performed to determine the precise deletion breakpoints.  Development of a 
multiplex PCR enabled the homozygous/heterozygous status of the deletion to 
be confirmed, as described in Sutherland et al. (2009).  For those patients in 
whom the exon 4 and 5 deletion mutation was identified, haplotype analysis 
was performed to investigate the possibility of a founder effect for this 
mutation.   
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All analyses were performed at the MDC in MRI which is a Clinical Pathology 
Accreditation (CPA) laboratory.  The MDC is a participant in the UK national 
external quality assurance scheme (NEQAS) for haemophilia and VWD 
diagnostic screening through direct DNA sequencing.  The appropriate 
guidance on ethics had been obtained.  No specific ethical approval was 
required for the project as the research carried out was an extension of the 
patients’ diagnostic analysis and all patients whose specimens were used had 
given appropriate consent at the time of collection.  Statistical analysis was not 
used in this project as the cohort of patients being studied have had the 
conventional mutation mechanisms eliminated, and therefore pre-selected on 
this basis for the investigation of the presence of partial gene deletions.  For 
previous work in support of this study, see Introduction section 1.19. 
 
2.1 SELECTION OF PATIENTS 
2.1.1 Haemophilia A 
Patients were selected from those who had given informed consent for the 
genetic diagnosis of haemophilia A referred to the MDC for investigation.  Full 
F8 sequence analysis has been carried out at the MDC since 2003 on all 
referred patients.  All index cases with suspected partial gene deletions 
detected by absence of amplification of one or more exons were chosen for 
further study by MLPA.  The patient cohort also included index cases where 
no causative mutation had been identified by DNA sequence analysis.  Carrier 
female relatives of index patients selected were also included (where samples 
were available).  The selected patient group included those with mild, 
moderate and severe types of haemophilia A.  Nineteen patients were 
investigated in the study which included hemizygous males who could not be 
detected by conventional techniques and carrier diagnosis of their relatives 
(see Results Table 3.3). 
 
2.1.2 Type 1 VWD 
Patients were selected individuals who had previously been recruited through 
the UKHCDO clinical network into a UK national study of type 1 VWD.  Each 
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patient had a historical diagnosis of type 1 VWD made by the referring centre 
and had previously sent blood samples to the MDC for mutation analysis of 
VWF.  In total, sixteen patients were investigated by MLPA which included 
those with suspected partial gene deletions and those where no causative 
mutation had been previously identified (see Results Table 3.5).  Ethics 
approval, including permissible extension of the work into which the current 
study fitted, had previously been obtained for the UK national study from the 
Multi-centre Research Ethics Committee (MREC) for Wales (reference 
number: MREC 01/9/32). 
 
2.1.3 Type 3 VWD 
Patients were selected individuals who had either previously been invited to 
participate in a study of type 3 VWD in Manchester or had been referred to the 
MDC for genetic diagnosis.  Each patient had been previously diagnosed with 
type 3 VWD at MRI and had sent blood samples to the MDC for mutation 
analysis of VWF.  All patients with the novel exon 4-5 deletion (c.221-
977_532+7059del mutation) discovered in this study were included for 
additional study by MLPA.  In total, ten patients were investigated by MLPA 
including those previously found to have the exon 4-5 deletion and those with 
a small deletion, duplication or point mutation (see Results Table 3.4).  Ethics 
approval, including permissible extension of the work into which the current 
study fitted, had previously been obtained for the study of type 3 VWD patients 
in Manchester from the Central Manchester Local Research Ethics Committee 
(LREC) (reference number: 05/Q1407/191). 
 
2.2 PHENOTYPIC DATA 
Phenotypic data were obtained for all patients included in the study.  For the 
haemophilia A patients, phenotypic laboratory results were acquired from 
individual patient records which included FVIII:C levels and inhibitor status.  
Phenotypic data for the type 1 VWD and type 3 VWD index cases were 
attained from the previous respective studies. 
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2.3 SAMPLE COLLECTION AND PROCESSING 
Previously extracted genomic DNA was obtained for patients from an archived 
bank of DNA samples at the MDC which are stored at -80 °C indefinitely.  For 
each patient, DNA had been extracted from 10-20 ml of EDTA 
(Ethylenediaminetetraacetic acid 7.2 mg in a 4 ml tube) anticoagulated fresh 
whole blood.  DNA extraction was performed by an ammonium acetate 
method (the procedure is a modification of the method described by SA Miller 
of the Analytic Genetic Centre Inc, Denver).  Additional patient samples in the 
form of extracted DNA were analysed from external referral centres where 
deletions had been detected by other means.  
 
2.4 MLPA® TECHNOLOGY 
MLPA is a high-throughput method that can be performed to detect 
quantitative genomic changes such as deletions or insertions.  It allows the 
copy number of up to 50 different genomic DNA sequences to be determined 
in one multiplex PCR-based reaction.  The MLPA reaction produces a mixture 
of amplification fragments ranging between 100 to 500 nt in length, which can 
be separated and quantified by capillary electrophoresis.  SALSA® MLPA® 
kits are sold by MRC-Holland (The Netherlands). 
 
The principle of the MLPA technique is based upon amplification of the MLPA 
probes themselves, not the sample DNA.  Each probe is made up of two 
adjacent oligonucleotides which hybridise to their target sequence in genomic 
DNA and are then ligated.  Amplification only occurs following successful 
ligation of the probes, which then produce exon-specific PCR products of 
differing lengths.  In comparison to conventional multiplex PCR which requires 
one pair of primers for each fragment to be amplified, only one pair of PCR 
primers is used in the MLPA PCR reaction, making it a more robust system. 
This is because in standard multiplex PCR, primers are present in large 
amounts in the reaction mixture which can lead to various technical 
complications.  Firstly since the efficiency of different primers usually varies, it 
is difficult to determine the relative quantitation of target sequences. In 
addition, small differences in reaction conditions often result in large 
differences in the results obtained.  Following the resulting amplification, 
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products ranging between 130 and 480 nt in length are separated by capillary 
electrophoresis.  The peak patterns obtained can be compared to reference 
samples (see 2.6.3.1) to see which sequences show aberrant copy numbers. 
 
2.4.1. MLPA Probe Chemistry 
MLPA probes consist of two oligonucleotides, each containing a PCR primer 
sequence and a sequence complimentary to the target, known as the 
hybridisation sequence (see Figure 2.1). 
 
The two probes hybridise immediately adjacent to each other.  When the 
probes correctly hybridise to the target sequence they are ligated by a thermo 
stable ligase enzyme.  The PCR primers exponentially amplify the ligated 
probes.  One of the primers is labelled with a fluorescent dye to visualise the 
amplification product of the probe.  Probe oligonucleotides that are not ligated 
only contain one primer sequence therefore they cannot be amplified 
exponentially and will not generate a signal.  The non-ligated probes do not 
need to be removed therefore the MLPA assay can be analysed in a single 
tube.  Sequencing electrophoresis is used to separate the resulting PCR 
products.  Each MLPA probe set is designed so that the length of each 
product is unique and can be easily identified when electrophoresed through a 
gel.  The difference in size is achieved with the help of a stuffer sequence. 
 
Figure 2.1: MLPA® probe set 
 
 
 
 
 
 
PCR primer sequence Y  
PCR primer sequence X  
Hybridisation sequence  Hybridisation sequence  
Stuffer sequence  
(different for each probe)  
Synthetic oligonucleotide 50-60bp  M13-derived oligonucleotide 60-450bp 
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2.4.2 MLPA Reaction 
The MLPA reaction can be separated in five major steps: 1) DNA denaturation 
and hybridisation of MLPA probes; 2) Ligation; 3) PCR reaction; 4) Fragment 
analysis by electrophoresis; and 5) data analysis (see Figure 2.2).  During step 
1 the DNA sample is denatured to single strands and incubated overnight with 
the MLPA probe mix.  Each MLPA probe consists of two sequence specific 
oligonucleotides which hybridise to immediately adjacent target sequences.  In 
step 2, the oligonucletides are ligated with a thermostable ligase but only if 
they have successfully hybridised to their target sequence.  In step 3, a 
universal primer pair is added to the reaction.  The successfully ligated probes 
are amplified to generate exon-specific products of differing lengths which can 
be used to determine gene dosage.  In step 4, the amplification products are 
separated using capillary electrophoresis. 
 
Figure 2.2: MLPA reaction overview 
 
 
 
2. Ligation 
                       1. Denaturation and hybridisation 
4. Fragment Analysis 
        3. PCR with universal primers X and Y 
        X                                               Y 
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2.4.3 Experimental set up 
2.4.3.1 Reference samples 
Identification of deletions and duplications by MLPA is achieved by analysis of 
relative changes in probe amplification signals, therefore slight differences 
between experiments and samples used may affect the MLPA peak pattern.  
Therefore it was necessary to include reference (control) samples in each 
MLPA experiment.  The reference samples used were DNA samples that had 
been obtained from healthy individuals.  The DNA samples were all derived 
from peripheral blood and had been extracted using the same method as the 
test samples, as recommended by MRC-Holland.  
 
At least 5 reference samples from individuals with normal copy numbers of the 
gene to be analysed were included in each run, together with a ‘no DNA 
control’ reaction.  The ‘no DNA control’ reaction was carried out on TE (10 mM 
Tris-HCl pH 8.2 + 0.1 mM EDTA) and was used to show any possible 
contamination of dH2O, TE, MLPA reagents, electrophoresis reagents or 
capillaries.   
 
Positive controls were not included in the MLPA experiments; it is 
recommended but not essential. 
 
2.4.3.2 Sample treatment 
It is recommended that a total quantity of between 50-250 ng of human 
genomic DNA in a 5 µL volume is used for each MLPA reaction.  MLPA results 
can be affected by extraction methods, handling and storage of DNA.  
Although MLPA does not require a unique DNA extraction method, it is 
essential that the extraction method does not leave a high concentration of 
contaminants such as salt as it is known to interfere with the technique.  Also 
heparinised samples are not recommended for use as traces of heparin are 
difficult to remove from DNA preparations and can alter the MLPA reaction. 
 
All DNA samples (including reference samples) used were extracted from 
peripheral blood in EDTA by the ammonium acetate method.  The overall DNA 
concentration of each sample was measured using a NanoDrop ND-1000 
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spectrophotometer (supplied by LabTech, UK).  Each sample was diluted in 
TE (10 mM Tris-HCl pH 8.2 + 0.1 mM EDTA) to make a working stock of 40 
ng/µL concentration at least 24 hours (h) before use.  Some DNA samples 
which were considered to be of poor quality were diluted in TE to a working 
stock of 10-20 ng/µL.  This was due to the premise that reducing the amount 
of sample DNA also reduces the amount of impurities and often has a 
favourable effect on the MLPA result, although too little DNA in the reaction 
may lead to failure of ligation and amplification. An RNase treatment was used 
for some samples which consistently failed (see section 2.6.1 for details).  This 
can be used for every sample however it is only essential when screening for 
a gene that is very highly expressed in the sample tissue under investigation. 
 
2.5 SALSA® MLPA® KITS 
 The SALSA® MLPA® kits are sold by MRC-Holland.  The following kits were 
used in this study: 
 
1. Haemophilia A – SALSA® MLPA® KIT P178-B1 F8 
2. von Willebrand disease (2 part kit) – SALSA® MLPA® KIT P011-B1 / 
P012-B1 VWF 
 
The SALSA® MLPA® kits consisted of reagents shown in Table 2.1.  They 
were stored at -20 °C and were shielded from light.  Prior to use all buffers and 
probe mix reagent tubes were thawed on ice, briefly vortexed and spun down 
for a few seconds to dislodge drops that may have adhered to the lid.  Enzyme 
solutions were never vortexed to avoid inactivation.  To reduce viscosity, it was 
recommended to hold the enzyme solution in your hand for 10 seconds (s) 
and then mix by pipetting up and down.  Mastermix containing the enzyme 
was also mixed by pipetting gently before use.  For details of SALSA® MLPA® 
probemixes for F8 and VWF see Appendices 1, 2a and 2b. 
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Table 2.1: Components of SALSA® MLPA® kit  
SALSA® MLPA® kit component INGREDIENTS 
SALSA MLPA Buffer (yellow cap)  KCl, Tris-HCl, EDTA and PEG-6000.  
pH 8.5 
Probemix (black cap) Synthetic oligonucleotides,  
oligonucleotides purified from bacteria, 
Tris-HCl, EDTA. pH 8.0 
Ligase Buffer A (transparent cap) NAD (bacterial origin). pH 3.5 
Ligase Buffer B (white cap) Tris-HCl, non-ionic detergents,  
MgCl2. pH 8.5 
SALSA Ligase-65 (green cap) Glycerol, BRIJ (0.05%), EDTA,  
β-Mercaptoethanol (0.1%), KCl,  
Tris-HCl. pH 7.5, Ligase-65 enzyme 
SALSA PCR Buffer (red cap)* Tris-HCl, EDTA, KCL,  
non-ionic detergents. pH 8.5 
SALSA PCR Primer Mix (brown cap)** Synthetic oligonucleotide, one of which  
is fluorescently labelled with FAM,  
dNTP’s, TRIS-HCl, KCl, EDTA, BRIJ  
(0.04%). pH 8.0 
SALSA Polymerase (orange cap) Glycerol, BRIJ (0.5%), EDTA, DTT  
(0.1%), KCl, Tris-HCl, Polymerase  
enzyme (bacterial origin). pH 7.5 
SALSA Enzyme Dilution Buffer (blue cap)* Tris-HCl, KCl, EDTA,  
non-ionic detergent. pH 8.5 
* Not required for one-tube protocol, introduced in June 2011 
**New MLPA PCR primer mix introduced for one-tube protocol 
 
2.6 MLPA REACTION METHOD 
The MLPA reaction method is a two day method with the first day requiring an 
18 h overnight incubation. 
 
The use of a thermocycler with a heated lid (99-105 °C) was essential (2720 
Thermocycler, Applied Biosystems, UK).  Before any initial MLPA experiments 
were set up, a test was performed on the thermocycler for excessive 
evaporation, which could be due to problems with the heated lid or brand of 
tubes (the plastic of the tubes is weak at high temperatures and so can 
deform).  This was carried out by incubating 8 µL water overnight at 60 °C in 
two different brands of tubes.  The next day at least 5 µL water was required to 
still present at the bottom of the tube.  The 0.2 ml 8-strip PCR tubes with 
individually attached dome caps from Starlab (Cat no. I1402-2900) had the 
least amount of evaporation had and so were used in all MLPA experiments.   
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2.6.1. DNA Denaturation (Day 1) 
On day 1, 5 µL of DNA sample (50-250 ng) was aliquoted into each tube of 0.2 
ml strips (or TE for the ‘no DNA control reaction’) and spun down in a strip 
microcentrifuge (PeqLab, Perfect Spin Mini).  The tubes were placed in the 
thermocycler and the MLPA thermocycler program started (see Table 2.2).  
The sample DNA was denatured for 5 min at 98 °C and cooled to 25 °C before 
being removed from the thermocycler (see Table 2.2). 
 
2.6.1.1 RNase treatment 
If using an RNase treatment, 4 µL of DNA sample was aliquoted into each 
tube of 0.2 ml strips together with 1 µL of RNase treatment.  The tubes were 
placed in the thermocycler and the MLPA thermocycler program started with 
an extra RNase treatment step for 30 min at 37 °C prior to denaturation (see 
Table 2.2). 
 
A working stock of the RNase treatment was made by making a 1 in 8 dilution 
of the stock RNase A Solution (Promega, code A7973; 4 mg/mL solution) in 
TE buffer to obtain a concentration of 0.5 mg/mL.  This was then kept at -20 
°C for future use. 
 
2.6.2. Hybridisation reaction (Day 1) 
Prior to the hybridisation reaction, a PCR mastermix was prepared containing 
MLPA buffer and probemix: 
 
 Per reaction:  
1.5 µL MLPA buffer (yellow cap) 
1.5 µL probemix (black cap) 
 
Following DNA denaturation, the samples were removed from the 
thermocycler and spun down.  Using a multi-channel pipette, 3 µL of the 
hybridisation master mix was added to each sample tube (the thermocycler 
program is held at 25 °C for 15 min to allow enough time for the hybridisation 
master mix to be added).  The strips were returned to the thermocycler and the 
program continued with incubation for 1 min at 95 °C and then for 18 h at 60 
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°C overnight (see Table 2.2).  As part of optimisation, different thermal cycler 
parameters were assessed to determine which would produce the best results 
(see Results section 3.2.4). 
 
2.6.3. Ligation reaction (Day 2) 
On day two, a ligase mastermix was prepared shortly before the end of the 18 
h hybridisation reaction using the following reagents: 
 
Per reaction:  
25 µL dH2O 
3 µL Ligase Buffer A (transparent cap) 
3 µL Ligase Buffer B (white cap) 
1 µL Ligase-65 enzyme (green cap) 
 
Following the 18 h at 60 °C, the thermal cycling reaction was cooled to 54 °C 
and paused (the pause button on the thermocycler allows a 10 min pause, in 
which time the ligase master mix should be added while the samples are still 
on the block).  Using a multi-channel pipette, 32 µL of ligase master mix was 
added to the tubes and mixed gently by pipetting up and down, making sure 
not to introduce any bubbles.  The thermocycler program was continued with 
15 min incubation at 54 °C (for ligation) followed by 5 min at 98 °C for heat 
inactivation of the Ligase-65 enzyme.  The samples were then held at 4 °C 
until removed from the thermocycler. 
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Table 2.2: Thermocycler Program for the MLPA Denaturation, 
Hybridisation and Ligation Reactions 
 
Step Temperature Time No. of cycles 
RNase treatment* 37 °C 30 min  
DNA Denaturation 98 °C 
25 °C 
5 min 
Pause  
 
 
Held for 15 min 
Hybridisation reaction 95 °C 
60 °C 
1 min 
pause 
 
Held for 18 h 
Ligation reaction 54 °C 
54 °C 
98 °C 
4 °C 
pause 
15 min 
5 min 
pause 
 
* Only required if using an RNase treatment 
 
2.6.4. PCR reaction (Day 2) 
2.6.4.1 One tube protocol 
The following instructions are for the one-tube protocol introduced by MRC-
Holland in June 2011.  This also required the use of a new MLPA PCR primer 
mix (FAM: lot number F44 onwards).  The complete ligation reaction is now 
used for the PCR and the PCR should be started at room temperature.  For 
the PCR reaction a polymerase master mix was prepared and stored on ice 
prior to use: 
 
Per reaction: 
7.5 µL dH2O 
2 µL SALSA PCR primer mix (brown cap) 
0.5 µL SALSA polymerase (orange cap). 
 
At room temperature using a multi-channel pipette, 10 µL of polymerase mix 
was added to each tube, mixed gently by pipetting up and down and spun 
down in a strip micro centrifuge.  The strips were then placed back onto the 
thermocycler and the PCR reaction program started (see Table 2.3).  Once the 
PCR reaction had completed, samples were stored at 4 °C for up to one week 
in a dark box wrapped in aluminium foil to protect the light sensitive 
fluorescent dyes, until fragment separation by capillary electrophoresis. 
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Table 2.3: Thermocycler Program for the MLPA PCR Reaction 
Step Temperature Time No. of cycles 
PCR reaction 60 °C** 
95 °C 
60 °C 
72 °C 
72 °C 
8 °C 
pause 
30 s 
30 s 
60 s 
20 min 
pause 
 
 
35 cycles 
 
**Not required for one-tube protocol, introduced in June 2011 
 
2.6.4.2 Two-tube protocol 
Prior to June 2011, the two-tube protocol was used which required an extra 
PCR buffer and Enzyme dilution buffer (see Table 2.1).  A new set of strip 
tubes were required for the PCR reaction. A PCR buffer mix was prepared: 
 
Per reaction:  
26 µL dH2O 
4 µL SALSA PCR buffer (red cap) 
 
Then 30 µL of the buffer mix was added to each tube with a multi-channel 
pipette.  At room temperature, 10 µL of the ligation product was transferred to 
the corresponding PCR tube.   
 
A separate polymerase master mix was then prepared and stored until 
required: 
 
Per reaction:  
5.5 µL dH2O 
2 µL SALSA PCR primers (brown cap) 
2 µL SALSA Enzyme dilution buffer (blue cap) 
0.5 µL SALSA polymerase (orange cap) 
 
The thermocycler was preheated to 60 °C and paused whilst the PCR tubes 
were placed in the thermocycler.  At this stage, 10 µL of the polymerase mix 
was added to each tube using a multi-channel pipette and mixed gently by 
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pipetting up and down.  The thermocycler program was continued immediately 
(see Table 2.3). 
 
2.6.5 Fragment Separation by Capillary Electrophoresis (CE) 
For fragment separation the amount of MLPA PCR reaction, run conditions 
and fluorescent label required for analysis all depend on the type of capillary 
electrophoresis instrument used. 
 
The following equipment and reagents were used supplied by Applied 
Biosystems, UK: 
1. Capillary electrophoresis instrument with fragment analysis software:  
     ABI-3130xl with Standard Foundation Data Collection Software  
2. High quality formamide: Hi-Di Formamide 
3. Labelled size standard: GeneScan™ 500 ROX™  
4. Electrophoresis polymer: POP-7  
 
Immediately prior to fragment analysis, a master mix was prepared with the 
following reagents: 
 
Per reaction: 
9 µL Hi-Di Formamide 
0.3 µL ROX size standard 
 
A 96 well plate was used for set-up and 9.3 µL of the mastermix was added to 
each sample well for the required number of samples.  Using a multi-channel 
pipette, 1 µL of the PCR reaction was added to each well containing the 
mastermix.  The plate was then sealed with a silicone mat and centrifuged at 
170 x g for 30 s to spin down the contents.  The plate was placed onto the 
thermal cycler for denaturation at 94 °C for 5 min.  Immediately after 
denaturation, the plate was placed on ice to prevent the subsequent re-
formation of secondary structures in the product. 
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The plate was then loaded onto the ABI-3130xl sequencer and the data 
analysis parameters selected: 
1. Application – Genemapper DF3HOXLI 
2. Results group – MLPA_RESULTS.DF3HOXLI 
3. Instrument protocol – FragmentAnalysis_POP7 
 
A 16 channel 50 cm capillary was used to analyse 16 samples per automatic 
loading.   
 
2.6.6 Overview of fragment analysis 
The fluorescently labelled fragments are detected using the ABI-3130xl 
analyser and then interpreted using GeneMapper v.4.0 (Applied Biosystems, 
UK) analysis software.   
 
During capillary electrophoresis, molecules from the samples are 
electrophorectically injected into thin, fused-silica capillaries filled with liquid 
polymer (POP-7, Applied Biosystems, UK).  Electrophoresis of all samples 
begins at the same time when a voltage is applied across all capillaries.  The 
DNA fragments migrate toward the other end of the capillaries through the 
electrophoresis medium with the shorter moving faster than the longer 
fragments.  As the fragments enter the detection cell, they pass through the 
path of a laser beam, which causes the dyes attached to the fragments to 
fluoresce.  The dye signals are separated by a diffraction system and a 
charge-coupled device (CCD) camera detects the fluorescence.  Five different 
coloured fluorescent dyes can be detected in the one sample.  One of the dye 
colours is used for a labelled size standard (ROX 500, Applied Biosystems, 
UK) that is added to each lane to allow comparison of samples from lane to 
lane or gel to gel.  The analysis software uses the size standard to create a 
standard curve for each lane and the length of each dye-labelled fragment can 
then be determined by comparing it with the standard curve for that specific 
lane.  Data were collected and stored as electropherograms prior to analysis. 
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2.7 ANALYSIS OF DATA 
Initial analysis of the fragment analysis data were performed using the 
GeneMapper analysis software version 4.0 (Applied Biosystems, UK).  This 
was prior to probe ratio calculation to evaluate the quality of the MLPA 
experiments by inspecting the MLPA peak patterns (electropherograms).   
 
2.7.1 Evaluating data  
Raw peak patterns were first analysed using the GeneMapper software.    The 
MRC-Holland probemixes contain MLPA probes for each exon of the gene 
(some exons may have more one probe), reference probes and internal quality 
control fragments.  The various control fragments (see Table 2. 4) are included 
to identify common errors in the MLPA reaction.  Once the raw data had been 
size-called and visualised to obtain the genotypes, it was essential to evaluate 
the MLPA internal quality control fragments.   
 
Table 2.4: Internal Quality Control Fragments 
Name Length (nt) PURPOSE 
92 nt control 92 Ligation-dependant probe, works in  
same way to other MLPA probes.   
Acts as a standard for comparison of  
other control fragments. 
Q-fragments  64, 70, 76, 82 Indicators of when the amount of DNA  
is too low.  Signals which are higher 
than ⅓ of the 92 nt control  
fragment = DNA quantity insufficient. 
D-fragments 88, 96 Identify denaturation problems.  Signals 
which are lower than 40% of the 92 nt  
control fragment = DNA denaturation 
problems 
X and Y fragments 100, 105 Controls for male and female samples 
 
The Q-fragments are four oligonucleotides which are present in all SALSA 
MLPA probemixes.  As they contain both MLPA PCR primer sequences in a 
single molecule, they are able to amplify in the PCR reaction without the need 
for hybridisation to the target DNA or ligation.  When there is enough sample 
DNA in the extraction, the Q-fragments are outcompeted by the amplicons of 
the MLPA probes as they are present in such small quantities.  Therefore if the 
Q-fragment peaks are low or invisible, this indicates that adequate sample 
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DNA was present and the ligase reaction was successful.  However if the 
peaks of all four Q-fragments are higher than ⅓ of the height of the 92 nt 
ligation-dependant control fragment and the MLPA probes, this is an alert that 
the amount of sample DNA was insufficient or the ligation reaction failed. 
 
The two denaturation D-fragments are synthetic MLPA probes which detect a 
sequence within a strong CpG island.  CpG islands are chromosomal regions 
which are difficult to denature because of their very high CG content.    
Incomplete denaturation is signified if the two D-fragment peaks are much 
lower (<40%) than the 92 nt fragment and the other MLPA probes.  This 
means that results are unreliable for probes that are detecting sequences in or 
near (<5 kb) CpG islands.  This can be as a result of salt contamination of the 
DNA sample as the melting temperature of DNA is increased at higher salt 
concentrations.  Figure 2.3 illustrates a sample with peaks representing the D-
fragments at 88 nt and 96 nt (1st and 3rd peaks, circled in red) which are of 
equal height to the 92 nt fragment (2nd peak, circled in red) indicating 
successful denaturation.  Exon 1 probes are most often affected by incomplete 
DNA denaturation as CpG islands are usually located near mRNA 
transcription start locations.  When using the ABI POP-7 polymer for CE, a 
non-specific fragment of ~87 nt is usually present and may overlap with the 88 
nt D-fragment.  If this affected analysis of the 88 nt D-fragment then only the 
96 nt peak was used.   
 
The X and Y fragments at 100 nt and 105 nt respectively indicate whether the 
sample is from a male or female.  This can be helpful in the case of identifying 
that a sample swap has occurred if running only male or female samples. 
 
In the no DNA control reaction, only the Q-fragments generate a probe signal.  
However, MLPA PCR reactions are more prone to having non-specific peaks 
than a normal PCR reaction as they contain numerous long MLPA probe 
oligonucleotides, each of which contain a perfect copy of one of the PCR 
primers.  In the majority of cases, the non-specific peaks do not influence the 
MLPA results as they are outcompeted by the genuine MLPA probe 
amplification products in the same way as the Q-fragments. 
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Figure 2.3: Raw peak pattern for a sample tested with the P178-B1 F8 
MLPA kit visualised using GeneMapper Software.  The probe signals show 
successful amplification from male DNA indicated by the 4th and 5th peaks 
(circled in red) representing the X and Y fragments at 100 nt and 105 nt 
respectively. The 1st, 2nd and 3rd peaks (circled in red) show successful 
amplification of the fragments for the 88 nt D-fragment, 92 nt control and 96 nt 
D-fragment respectively. 
 
 
2.8 INTERPRETATION OF RESULTS 
Once the data had passed raw data and peak pattern evaluation, it was ready 
for data normalisation.  The data needs to be normalised as the absolute 
fluorescence intensities detected by the CE instrument depend on many 
factors (degradation of the fluorescent dye, variability between capillaries, 
pipetting accuracy).  MLPA normalisation happens in a two step model.  First 
the relative fluorescence intensity of each peak within a sample is determined 
(intra-normalisation) by dividing the peak area of each probe’s amplification 
product by the total area of only the reference probes in the probemix; in a 
second step, this relative peak is compared to that in other samples (inter-
normalisation) by dividing the intra-normalised probe ratio in a sample by the 
average intra-normalised probe ratio of all reference samples.  The final ratio 
for a given probe in a test sample compared to the same probe is called the 
Dosage Quotient of that probe. 
 
MLPA dosage quotients were calculated using spreadsheets designed by the 
National Genetics Reference Laboratory (Manchester) and were obtained from 
their website www.ngrl.org.uk/Manchester.  The spreadsheets have been 
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created in Microsoft Excel 2003 and are specific for the different MLPA kits 
used.  They analyse data to produce DQ’s in the standard way, however they 
also include two original features of analysis to help with interpretation. 
 
The first feature is that they are able to generate a likelihood probability of 
agreeing with one of three hypotheses, that a ligation product is present at 
either one, two or three copies within the test sample.  This figure is a result of 
comparing the test sample to five normal controls.  The amount of variability 
for each ligation product can be determined from the controls, therefore 
allowing the probability of deviation from expectation of the test sample to be 
estimated using the t-statistic. 
 
The second feature measures the standard deviation of the DQ’s obtained for 
all the control ligation products which can be used as a control for the overall 
quality of the test.  Each sample is deemed to be of good quality or poor 
quality (see Figure 2.4).  The samples that have a standard deviation of more 
than 0.1 are deemed to be poor quality.  Retrospective studies by Dr Ruth 
Charlton, Regional Genetics Service, Leeds (unpublished data) have shown 
that samples with control standard deviations less than 0.1 shows no overlap 
between normal, duplicated and deleted ranges.  Therefore those samples 
with higher degrees of variability are excluded which reduces the possibility of 
making an incorrect diagnosis. 
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Figure 2.4: Example of the NGRL spreadsheet.  This illustrates the 
appearance of a typical sample where the data quality has been judged to be 
good (highlighted in green).  If the sample quality has been judged to be poor, 
it will be highlighted in red. 
 
Test 1 Lab No   C1 Xp22.11 CXq27.3 
  F8 C1 Xp22.11 1.00 1.09 
  Operator C2 Xq27.3 0.92 1.00 
  Michelle C3 Xq13.1 1.03 1.12 
  Worksheet C4 Xq22.1 0.92 1.00 
  2 C5 Xq13.1 1.03 1.12 
  Int QC Stand Dev C6 Xp21.3 0.95 1.03 
  0.052054129 C7 Xq28 0.98 1.07 
   C8 Xq26.2 1.02 1.11 
   C9 Xq22.3 0.96 1.05 
   C10 Xp11.3 1.01 1.10 
   C11 Xq21.2 1.04 1.13 
   C12 Xp21.2 0.90 0.98 
   MEAN 0.98 1.07 
  FEMALE ODDS NORMAL :DEL 112464:1 64418:1 
  FEMALE ODDS NORMAL :DUP 2084:1 289:1 
  MALE ODDS NORMAL :DUP 9444:1 1920:1 
  PROB OF DEVIATION NORMAL ###### ###### 
  FEMALE PROB OF DEVIATION DELETED ###### ###### 
  FEMALE PROB OF DEVIATION DUP ###### ###### 
  MALE PROB OF DEVIATION DUP ###### ###### 
 
The peak height data generated from a GeneMapper output table is pasted 
directly into the cells of the raw data sheet.  The spreadsheets must have five 
normal controls in order to function properly and can accept up to 10 test 
samples.  Once the test samples have been added to the raw data sheet, the 
results may be visualised on the results spreadsheet.  This is estimated by 
measuring the standard deviation of all the test ligation products against each 
other.  The results are presented in a tabular format and the cells are 
conditionally formatted to highlight deleted/duplicated and aberrant results.  
The actual settings that have been given for the conditional formats are given 
in the spreadsheet, for typical ranges see Table 2.5. 
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Table 2.5: Typical ranges for Dosage Quotients 
copy number STATUS Dosage Quotient 
Normal 0.85 – 1.15 
Deleted  0.35 – 0.65 
Duplicated  1.35 – 1.65 
Equivocal 0.65 – 0.85 
 
The spreadsheets also incorporate a graphical representation of the results in 
the form of a histogram (see Figure 2.5).  The probes for each exon of the gene 
are represented by the green bars in the histogram.  The internal reference 
probes also included in the probemix are represented by the blue bars in the 
histogram.  The F8 exon numbering used by MRC-Holland adopts the NCBI 
Refseq exon numbering for F8.  There is no probe for exon 23 therefore exons 
24, 25, 26 and 27 in the MLPA kit relate to exons 23, 24, 25 and 26 of F8 
respectively. 
 
Figure 2.5: Example of a histogram from the P178-B1 F8 MLPA 
spreadsheet summarising the mean DQ data.  The green bars represent F8 
exons while the blue bars represent internal reference probes.  Ratios are 
calculated by intra-sample normalisation of peak areas to reference probes, 
and inter-sample normalisation of probe ratios to the corresponding ratios in 
the reference samples.  This particular sample showed normal odds ratios for 
all ligation products. 
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The output from the above process could then be interpreted as representing 
either failed data which required repeat MLPA analysis, or good quality data 
which could be analysed for evidence of the presence of deletions or 
duplications associated with the gene undergoing analysis. 
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At the MDC, a genetic diagnostic service for haemophilia A and VWD has been 
set-up in line with guidelines from the UKHCDO and is offered for Greater 
Manchester and the North West.  Recent publications have demonstrated the 
advantages of including MLPA analysis in the genetic diagnosis of haemophilia 
A and VWD to help identify those with large deletions/duplications and aid 
carrier diagnosis.  MLPA is a technique which was first described in Nucleic 
Acid Research by Schouten, McElgunn et al. (2002).  I have investigated 
patients with haemophilia A and VWD using this technique in order to identify 
any mutations which may have gone undetected using conventional analytical 
methods or confirm deletions detected by an independent method and to 
introduce it as part of the routine diagnostic service.   
 
3.1 CHOICE OF METHOD  
The MLPA kits used in this study were obtained from MRC-Holland who first 
established MLPA technology.  They are the primary producers of MLPA kits 
and currently offer probe kits for a large number of genes.  In this study MLPA 
probe kits for F8 and VWF were chosen to investigate haemophilia A and VWD 
respectively.   
 
3.2 MLPA EXPERIMENT OPTIMISATION  
As MLPA was a new method to be investigated, it was necessary to carry out a 
number of optimisation steps before patient samples could be tested.  Different 
parameters such as extraction methods, handling and storage of DNA and 
experimental set-up have an important role in the quality of MLPA results 
produced.  As part of my investigation into setting up this method, I visited the 
haematology laboratory at Edinburgh Royal Infirmary who already had this 
method established as part of their genetic diagnostic service for Haemophilia 
and VWD. 
 
3.2.1 Results of the Evaporation test 
As recommended by MRC-Holland, the use of a thermal cycler with a heated lid 
(99-105 °C) was essential in order to minimise evaporation losses.  A test for 
CHAPTER 3: RESULTS 
 
 78 
excessive evaporation was performed on the thermocycler to be used for the 
MLPA experiments.  Eight µL of water was incubated overnight at 60 °C in all 8 
tubes of two different brands of 0.2 ml 8-strip PCR dome capped tubes (see 
Table 3.1).  The following day, the volume of the water in each tube was 
compared to see which had the least amount of evaporation.  Each of the 8 
tubes of the StarLab brand had only ~1 µL of water evaporated compared to 
~3.5 µL in each of the 8 Alpha Labs tubes, therefore it was decided that the 
StarLab brand of tubes would be used in all experiments. 
 
Table 3.1: Results of the evaporation test comparing two brands of tubes. 
Tube brand Volume before O/N 
incubation 
Vol. after O/N 
incubation 
Vol. of evaporation 
Starlab (I1402-2900) 8 µL 7 µL 1 µL 
Alpha Labs (LW2510) 8 µL 4.5 µL 3.5 µL 
 
3.2.2 Evaluation of the MRC-Holland MLPA method using control samples 
The MRC-Holland MLPA kits for F8 and VWF were first tested using a fresh 
control sample obtained from a healthy patient.  DNA had previously been 
extracted from the control sample using standard protocols (see Materials and 
Methods section 2.3).  The amount of DNA was measured and diluted to a final 
concentration of 40 ng/ul as per the protocol.  The control samples were tested 
according to the standard MLPA procedure and thermal cycler parameters 
outlined by MRC-Holland (see Materials and Methods section 2.6).  Initial 
results for both kits are shown in Figure 3.1.  The histograms showed equal 
peak heights for all the exons in both kits with a standard deviation of less than 
0.1 which demonstrated good results.  From this preliminary experiment it was 
clear that the MLPA technique was a robust method and therefore patient 
samples could now be tested.  It was advised that at least 5 control samples 
should be included with each MLPA run, therefore it was decided that 7 control 
samples should be used to cover for any controls that might fail.   
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Figure 3.1: Initial test control sample histograms for MLPA kits.  The 
height of the columns represents the normalised data obtained in genomic 
DNA.  In a) F8 and b) VWF kit 1, the blue bars represent the internal reference 
probes and the green bars indicate the probes of each exon. In c) VWF kit 2 the 
first 10 blue bars represent the internal reference probes and the rest represent 
the probes for each exon.  In all the normal controls, the probes are at a height 
of around 1.0. 
a) 
 
b) 
 
c) 
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3.2.3 Assessment of sample quality 
The extraction methods, handling and storage of DNA have an important role in 
the quality of MLPA results produced.  The DNA used in this project was not 
from fresh samples and had been stored at -80 °C for a number of years.  For 
best results it is recommended that DNA should be extracted from fresh 
samples and that a concentration of between 50-250 ng of DNA in a 5 µL final 
volume is recommended for each MLPA reaction.  As the samples had been 
frozen for a long time, DNA degradation had occurred and so the concentration 
was often low which would contribute to consistently poor results found for 
some patients.  An example of this can be seen in the histogram below (figure 
3.2) for a patient tested with the F8 MLPA kit.  The reference probes in blue are 
not of a consistent height with the third reference probe, marked by an arrow, 
considerably lower than the others.  This leads to failure of internal 
normalisation and a standard deviation of more than 0.1 indicating a sample of 
poor quality where the results cannot be reliably reported. 
 
Figure 3.2: Example of a poor quality sample used for MLPA analysis of 
F8 with a standard deviation of >0.1. The third blue reference probe indicated 
by the arrow is significantly lower than the rest of the reference probes, which 
leads to failure of intra-normalisation. 
 
 
3.2.4 Optimisation of the MLPA thermal cycler programme 
On examination of the optimised MLPA protocol in use at Edinburgh Royal 
Infirmary it was apparent that there were slight differences in the conditions of 
the hybridisation, ligation and PCR reactions compared to the standard MLPA 
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protocol supplied by MRC-Holland (see Table 3.2 below and Table 2.2 in 
Materials and methods).  These differences may have allowed more consistent 
MLPA results, especially for samples which repeatedly failed quality control, so 
they were noted down with the intention of testing these conditions on the 
thermocycler in Manchester to see if they had an effect.   
 
Table 3.2: Thermocycler Program for the MLPA Denaturation, 
Hybridisation, Ligation and PCR Reactions as per Edinburgh laboratory.
  
Step Temperature Time No. of cycles 
DNA Denaturation 98 °C 
22 °C 
5 min 
Pause  
 
 
Held for 15 min 
Hybridisation reaction 95 °C 
60 °C 
1 min 
pause 
 
Held for 16 h 
Ligation reaction 54 °C 
54 °C 
98 °C 
22 °C 
pause 
15 min 
5 min 
pause 
 
PCR reaction 60 °C 
95 °C 
60 °C 
72 °C 
72 °C 
08 °C 
pause 
30 s 
30 s 
60 s 
20 min 
pause 
 
 
33 cycles 
 
 
To establish whether better quality MLPA results could be obtained using the 
conditions used in Edinburgh, two experiments were tested in parallel using the 
two different cycler programmes but with the same set of 6 samples for the F8 
MLPA kit.  The PCR products for both sets of experiments were tested together 
on the fragment analyser to ensure identical analysis conditions.  The results 
from this experiment showed a definite difference between the samples tested 
with different cycler parameters.  Five of the six samples tested showed better 
results using the standard MRC-Holland protocol compared to the optimised 
Edinburgh protocol.  This was demonstrated by better peak amplification and 
morphology.  An example of this can be seen in Figure 3.3 which shows the 
genotype plots generated by the GeneMapper® software for one of the 
samples using the two different parameters.  The top plot shows the sample 
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tested with MRC-Holland parameters and it can be seen that all the peaks to 
evaluate internal quality control showed good amplification together with peaks 
for each exon.  In comparison the genotype plot below for the same sample 
tested using Edinburgh parameters showed some non-specific peaks at the 
beginning of the trace and absence of  peaks where the probes had not bound 
which could potentially indicate the false presence of a deletion.  One of the six 
samples tested using both parameters showed identical results.  Following this, 
when the results were analysed using the NGRL spreadsheet, five out of six of 
the samples using the Edinburgh parameters showed a standard deviation of 
more than 0.1 and therefore did not pass quality control indicating that the 
results were not reliable.  From this experiment it was decided that better 
results were obtained using the standard MRC-Holland protocol and that this 
method would be used routinely.  
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Figure 3.3: Genotype plots for a sample tested in parallel to compare the 
MRC-Holland and Edinburgh parameters.  The top plot shows the sample 
tested with MRC-Holland parameters with good peak amplification of quality 
control fragments and exons.  The bottom plot shows the sample tested with 
the Edinburgh parameters illustrating non-specific peak amplification at the 
beginning of the trace and complete absence of peaks for certain exons. 
 
 
3.2.5 Internal quality controls and Non-specific peaks  
As outlined in section 2.7.1 of the Materials and methods, SALSA MLPA probe 
mixes contain a number of control fragments which identify common problems 
in the MLPA reaction.  The four Q-fragments at positions 64, 70, 76, and 82 nt 
should be low or invisible when there is sufficient sample DNA present and the 
successful ligation has occurred as they are present in low quantities and so 
are outcompeted by the amplicons of the MLPA probes.  If the peaks of all four 
Q-fragments are higher than 1/3 of the height of the 92 nt ligation-dependant 
control fragment and the MLPA probes this can indicate that the sample DNA 
was insufficient or failure of the ligation reaction.  However if there are only one 
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or two increased peaks visible in the 64-82 nt range, this is classed as a non-
specific peak rather than a Q-fragment.  The presence of non-specific peaks 
was commonly observed when reviewing the genotype plots for both controls 
and patient samples.  Figure 3.4 shows an example of a non-specific peak 
(circled in red) observed in the 64-82 nt range for a patient sample tested with 
the F8 MLPA kit.  This peak would not affect the reliability of the results 
produced. 
 
Figure 3.4: Example of a non-specific peak in the 64-82 nt range. The peak 
observed in the 64-82 nt range (circled in red) for a patient sample tested with 
the F8 MLPA kit is not considered to be a Q-fragment and therefore would not 
affect the reliability of the result. 
 
 
The MLPA probe mixes for F8 and VWD also contain two DNA denaturation 
fragments (D-fragments) at 88 and 96 nt which show low amplification 
compared to the 92 nt control fragment if there is incomplete DNA denaturation.  
A non-specific fragment of ~87 nt was often observed in samples which was 
close to the 88 nt D-fragment (see Figure 3.5).  According to the MRC-Holland 
MLPA protocol this non-specific fragment at ~87 nt is usually present when 
using the ABI POP7 polymer for capillary electrophoresis.  It can be ignored as 
it represents non-specific amplification of a long primer-dimer that has the same 
mobility as one of the quality fragments.  If the non-specific peak affected the 
analysis of the 88 nt D-fragment, only the 96 nt peak was used. 
 
 
 
 
 
 85 
Figure 3.5: Examples of non-specific peaks at ~87 nt observed in two 
different patient samples.  The non specific peaks at ~87 nt (circled in red) 
observed in two different patient samples tested with VWD MLPA kits 1 (top) 
and 2 (bottom) which can occur when using the ABI POP7 polymer for capillary 
electrophoresis.  
 
 
 
Non specific peaks were also commonly observed in the ‘no DNA’ control 
reaction of some experiments.  These were generally found to not have an 
impact on the overall MLPA results and could be distinguished from any form of 
contamination.  MLPA PCR is more prone to generation of unspecific long 
amplification products in the absence of sample than a normal PCR as the 
reaction contains numerous long MLPA probe oligonucleotides, each of which 
contain a perfect copy of one of the PCR primers. 
 
3.2.6 Bioinformatic analysis 
Following experimental set-up and method optimisation, it was necessary to 
evaluate the software programs that were available for fragment analysis and 
gene dosage.  Initial peaks generated by fragment analysis were evaluated 
using the ABI GeneMapper® software which was already available in the 
Molecular Diagnostics Centre.  Gene dosage was determined by MLPA 
spreadsheets devised by the NGRL in Manchester which were available for 
free download from their website.  The gene dosage spreadsheets were first 
reviewed in April 2011 and it was noted that the spreadsheets for both F8 and 
VWD did not contain the latest cross reference data for the MLPA probe mixes 
which had been updated by MRC-Holland in March 2011.  Therefore new 
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spreadsheets were obtained from Sheffield Regional Genetics Service who had 
updated them for use in their routine diagnostic service.    
 
In the Edinburgh laboratory, an alternative software programme was used 
called GeneMarker v1.8 (Softgenetics.com) which allowed both raw data to be 
viewed for evaluation of probe peaks and gene dosage analysis.  It was 
important to establish whether this software was more user friendly and if it was 
worth considering for future use instead of the combined ABI GeneMapper 
software and NGRL MLPA spreadsheets.  A free one month download version 
of GeneMarker v1.8 was obtained and previous results were analysed using 
the software.  The previous results analysed by GeneMapper and MLPA 
spreadsheets were validated using the GeneMarker software.  The software 
proved just as user friendly as the other methods and although it had the added 
benefit of being able to generate reports, this was not enough to account for the 
financial cost of the licence needed for use of the full version.  Therefore it was 
decided that the analysis methods that were already in place were sufficient 
enough for use in the routine service at the MDC. 
 
3.3. RESULTS OF MLPA ANALYSIS IN THE HAEMOPHILIA A PATIENT 
GROUP 
In total, nineteen patients were investigated for large deletion/duplications in F8 
(see Table 3.3).  These included haemophilia A patients where no causative 
mutation had been identified and those with suspected partial gene deletions 
detected by absence of amplification of one or more exons and relevant female 
carrier relatives.   
 
 
 
 
 
 
 
 
 87 
Table 3.3: Haemophilia A patients and query carrier relatives investigated 
by MLPA analysis following routine F8 screening. 
PATIENT CASE SEVERITY FVIII (IU/DL) INHIBITORS RESULT PRIOR TO  
MLPA ANALYSIS  
1 Index ?Mild 30 No None found 
2 Index Mild 11-16 No None found 
3 Index Mild 13 No None found 
4 Index Mild 13 No None found 
5 Index Severe unknown Yes Hemizygous for deletion  
removing exons 16-22 
6 Carrier 
(Sister of  
Patient 5) 
Severe Not done N/A None found, consistent  
with non-carriership 
7 Index Severe 1.1 Yes ?hemizygous deletion  
involving exon 7 
8 ?Carrier 
(Mother of  
Patient 7) 
Severe Not done N/A ?carrier diagnosis 
9 Index Severe <1 Yes Hemizygous for deletion  
removing exons 15-22 
10 ?Carrier 
(Niece of  
Patient  9) 
Severe Not done N/A None found, suggestive  
of non-carriership 
11 Index Severe <1 Yes Hemizygous for deletion  
removing exons 24-25 
12 Index Severe unknown Yes Hemizygous for deletion  
removing exon 24 
13 Carrier Severe 72 N/A Heterozygous for deletion  
of exon 5 
14 Index Severe unknown Yes Hemizygous for deletion  
removing exons 7-10 
15 Index Severe unknown Yes Hemizygous for deletion  
removing exons 7-9 
16 Index 
(Aunt of  
Patient 17) 
Severe 4 No None found 
17 Index Severe unknown       unknown None found 
18 Index Severe <1 Yes Hemizygous for  
c.5644_5657dup14 
19 Carrier  
(Sister of  
Patient 18) 
Severe 40 N/A Heterozygous for the 
c.5644_5657dup14 
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3.3.1 Mild haemophilia A patients with no causative mutation identified 
Four patients had been diagnosed with mild haemophilia A.  Routine 
sequencing of F8 had been previously performed and had failed to identify a 
candidate mutation, although it has been reported by (Bogdanova, Markoff et 
al. 2007) that 12% or more of cases classified as mild haemophilia A have no 
detectable mutation within F8. 
 
Patient 1 had a baseline FVIII:C level of 30 IU/dL.  As there was no family 
history of bleeding disorders, it was considered to be a case of sporadic 
haemophilia.  The possibility of type 2N VWD should have been investigated for 
by VWF-FVIII binding studies or type 2N VWD mutation screening, however no 
results were available.  It was unclear whether FV:C levels had been measured 
in order to exclude the rare possibility of combined FV/FVIII deficiency.   
 
Patient 2 had reduced FVIII:C levels of between 11-16 IU/dL.  Investigations for 
possible type 2N VWD showed borderline low/normal results for VWF:Ag and 
VWF:RCo and normal VWF multimers.  No FV:C level had been measured to 
exclude a combined FV/FVIII deficiency.  Sequencing of exons 18-20 and 23-
27 of VWF had also been carried out and had failed to identify any mutations 
associated with type 2N VWD. 
 
Patients 3 and 4 were brothers who both had baseline FVIII:C levels of 13 
IU/dL.  Their nephew had also been diagnosed with mild haemophilia A, 
however no candidate mutations in F8 had been found in him.  Sequencing of 
exons 18-20 of VWF in Patient 3 did not identify any candidate type 2N VWD 
mutations.  Patient 4 had FV:C levels measured at 193 IU/dL, excluding the 
possibility of a FV/FVIII deficiency. 
 
MLPA analysis carried out on this group of haemophilia patients gave normal 
results and did not identify any large deletions or duplications within F8. The 
analysis was performed at least twice on different occasions for each patient, 
thereby confirming the initial result.  The histograms show that the probes for 
each exon were amplified (see Figure 3.6), indicating that no large deletions 
were present.  The heights of the internal reference probes (blue bars) were 
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compared to the height of the each test probe (green bars) to measure for 
possible duplications.  No evidence for the presence of any duplications were 
identified.  The only sample to repeatedly fail quality control was for Patient 1 
(Figure 3.6a).  The best standard deviation obtained for this sample gave a 
value of 0.147 (>0.1 is deemed to be poor quality, see Materials and Methods 
section 2.8).  This increases the possibility of making an incorrect diagnosis, 
however it was clearly shown that no obvious major deletion was present in this 
sample. 
 
Figure 3.6: MLPA Histograms for Haemophilia A Patients 1, 2, 3 and 4. The 
histograms for a) Patient 1, b) Patient 2, c) Patient 3 and d) Patient 4 illustrated 
normal dosage quotients for all exons of F8 (green bars).  The histogram for 
Patient 1 illustrates why the sample gave a standard deviation of >0.1 due to 
the low peak height of one of the internal reference probes (blue bar indicated 
by an arrow). 
 
a) 
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b) 
 
 
c) 
 
d) 
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3.3.2 Severe haemophilia A patients with large deletions and carrier 
relatives 
Nine families were investigated for large deletion mutations.  Those with 
suspected gene deletions had been discovered through routine screening by 
failure of one or more exons to amplify by PCR.  Further mutation analysis had 
been performed for some of the families using primer pairs picked from the 
standard stock to amplify either side of the expected deletion breakpoint.  
These primer pairs were utilised in the ABgene Long PCR protocol to amplify 
across the breakpoint, with deletions being visible on gel electrophoresis as 
smaller than expected fragments.  The TaKaRa protocol for Long PCR was 
also utilised to amplify fragments which were too large for the ABgene protocol 
(see Introduction section 1.19.1.4).  MLPA analysis was performed on all nine 
families to confirm the presence or absence of a deletion or duplication.  All 
MLPA results obtained from these families were of good quality (standard 
deviation of <0.1) and therefore could be reported reliably (see Materials and 
methods section 2.8). 
 
3.3.2.1 Patients 5 and 6 
Patient 5 is a severe haemophilia A affected male with an unreported FVIII:C 
level and a high titre FVIII inhibitor. He had also been reported to be normal for 
the intron 1 and intron 22 inversions. Mutation analysis had been previously 
carried out with the aim of identifying the underlying candidate mutation 
associated with haemophilia A in this family.  Amplification of the essential 
regions of the gene from the genomic DNA had failed to amplify exons 16 to 21 
(Figure 3.7a).  Subsequent long PCR utilising a primer pair designed to amplify 
exons 15 through to 22 produced a ~3.25 kb fragment instead of the expected 
~11 kb fragment indicating the presence of a partial deletion of F8 between 
introns 15-21.  Limited DNA sequencing of the ~3.25 kb fragment across the 
breakpoint had confirmed the identity of this product and indicated that the 
deletion was likely to be a 7356bp fragment removing exons 16 to 21 (Figure 
3.7b).  This deletion was highly likely to account for the severe haemophilia A 
phenotype seen in the patient.  Long PCR encompassing exons 15 and 22 
could be applied to carrier diagnosis of female members of this family. 
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Figure 3.7: Results from previous mutation analysis of Patient 5. 
a) Image of the agarose gel where exons 16-21 failed to amplify following 
standard PCR amplification (underlined in red) b) Sequence trace for the partial 
gene deletion (g.116547_123812del7356) showing the exon 15 breakpoint 
(indicated by the blue arrow). 
a) 
 
b) 
 
 
Carrier diagnosis had also been carried out on the sister (Patient 6) of Patient 5 
to investigate for the presence of this deletion by long PCR.  Patient 6 was 
found to have only amplified the normal fragment (~11 kb compared to the 
~3.25 kb fragment representing the deletion) and partial DNA sequencing 
confirmed the identity of the ~11 kb normal fragment.  This genotype was 
consistent with a diagnosis of non-carriership. 
 
MLPA analysis for both patients confirmed the results that had been obtained 
using long PCR and sequencing.  For Patient 5 the large deletion of exons 16-
21 can be clearly seen in the MLPA histogram (Figure 3.8a) where the peaks 
are absent for exons 16-21.  The genotype is consistent with a diagnosis of 
severe haemophilia A.  Patient 6 (Figure 3.8b) shows normal dosage quotients 
for all exons in that sample confirming non-carriership of the partial gene 
deletion.   
 
intron 15 sequence    intron 21 sequence 
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Figure 3.8: MLPA Histograms for Patients 5 and 6.  The histogram for a) 
Patient 5 illustrates the hemizygous deletion of exons 16-21 (indicated by the 
bracket) where the green bars representing these exons are absent.  The 
histogram for b) Patient 6 shows normal dosage quotient data for all the exons 
of F8 indicating that the deletion is not present. 
a) 
 
b) 
 
 
3.3.2.2 Patients 7 and 8 
This family was initially investigated as the mother (Patient 8) of the index case 
(Patient 7) was pregnant.  Patient 7 is a severe haemophiliac with a baseline 
FVIII:C level of 1.1 IU/dL and a FVIII inhibitor.  Routine screening of F8 by 
sequencing had been normal apart from the inability to amplify exon 7.  Repeat 
analysis had still failed to amplify exon 7 which provided indirect evidence that 
a partial gene deletion involving this region may be present.  As attempts to 
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map this region failed a possible genotype of a suspected hemizygous deletion 
involving exon 7 was reported.  As the precise nature of the mutation had not 
been mapped it was not possible to provide a female carrier diagnosis for the 
mother as the deletion would have been masked by the normal allele on the 
other chromosome.  The mother later gave birth to a female. 
 
MLPA analysis of both of these patients confirmed the suspected deletion 
involving exon 7 as the underlying genetic cause of the haemophilia.  The 
histogram for Patient 7 (Figure 3.9a) shows that both peaks that should be 
amplified for exon 7 are completely missing indicating that this exon has been 
deleted.  The histogram for Patient 8 (Figure 3.9b) shows that both peaks for 
exon 7 are half the height of the control peaks indicating that this is a 
heterozygous deletion involving exon 7, which confirms the carrier status of his 
mother.   
 
Figure 3.9: MLPA Histograms for Patients 7 and 8.  The histogram for a) 
Patient 7 illustrates the hemizygous deletion of exon 7 (indicated by the arrows) 
where the probes representing exon 7 are absent.  The histogram for b) Patient 
8 shows the presence of a heterozygous deletion of exon 7 where the probes 
representing exon 7 (indicated by arrows) are half the height of the internal 
reference probes (blue bars). 
 
a) 
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b) 
 
 
3.3.2.3 Patients 9 and 10 
The index case for this family (Patient 9) had severe haemophilia A (FVIII:C 
level <1 IU/dL) and a FVIII inhibitor.  This patient was previously found to be 
hemizygous for a large deletion spanning exons 15-22 following DNA 
sequencing.  Long PCR had also been performed using primers for exons 14-
23 which produced a 10 kb truncated fragment indicating a partial deletion, 
however the precise deletion boundaries had not been mapped.  This exon 15-
22 deletion has been reported, as would be expected, to be associated with a 
severe phenotype.  It was suggested that further analysis should be performed 
in order to map the boundaries of this deletion breakpoint prior to developing a 
direct detection assay that could be used in female carrier studies within this 
family. 
 
Carrier diagnosis had also been carried out on the niece (Patient 10) of Patient 
9 to identify if she was heterozygous for the partial gene deletion.  Long PCR 
had been performed using the same primer pair but did not detect the truncated 
product.  This negative finding was suggestive of non-carriership, however the 
result needed to be corroborated by development of a direct screening assay 
for this test when the deletion was fully mapped. 
 
MLPA analysis of both patients confirmed the results that had been obtained 
through sequencing and long PCR.  The Haemophilia Centre in Sheffield had 
 96 
previously confirmed these results using MLPA, thereby this was an 
independent validation of their results.  It can be clearly seen in the histogram 
for Patient 9 (Figure 3.10a) that the peaks associated with exons 15-22 are 
completely absent indicating a partial gene deletion.  The histogram for Patient 
10 (Figure 3.10b) shows normal dosage quotients for all exons in that sample 
confirming non-carriership of the partial gene deletion.   
 
Figure 3.10:  MLPA Histograms for Patients 9 and 10.  The histogram for a) 
Patient 9 illustrates the hemizygous deletion of exons 15-22 (indicated by the 
bracket) where the green bars representing these exons are absent.  The 
histogram for b) Patient 10 shows normal dosage quotient data for all the exons 
of F8 indicating that the deletion is not present. 
 
a) 
 
b) 
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3.3.2.4 Patient 11 
Patient 11 was the proband for this family with severe haemophilia A (FVIII:C 
<1 IU/dL) and a high titre FVIII inhibitor.  Previous screening for the intron 1 and 
22 inversions had shown normal results and standard PCR amplification of the 
essential regions of F8 failed to amplify exons 24-25.  Therefore this patient 
was diagnosed to be hemizygous for a candidate deletion removing exons 24-
25 of F8 which is consistent with severe haemophilia A phenotype.  It was 
suggested that further analysis should be performed in order to map the 
boundaries of the deletion breakpoint to allow the development of direct 
detection assay for female carrier studies within this family. 
 
MLPA analysis carried out on the same DNA sample from this patient 
confirmed the presence of a deletion involving exons 24-25.  The MLPA 
histogram for this patient (Figure 3.11) shows the deletion encompassing exons 
24-25, which is consistent with a severe haemophilia A phenotype.   
 
Figure 3.11:  MLPA Histogram for Patient 11.  The histogram for Patient 11 
illustrates the hemizygous deletion of exons 24-25 (indicated by the arrows) 
where the probes representing these exons (MRC-Holland exon 25-26) are 
absent. 
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3.3.2.5 Patient 12 
Patient 12 was a severe haemophilia A affected male with a FVIII inhibitor.  
Routine screening for the intron 1 and intron 22 inversions showed normal 
results.  Sequence analysis identified a deletion mutation removing exon 24 of 
F8.  Subsequent deletion breakpoint analysis showed that the deletion 
encompassed 1328 bases of genomic DNA.  The 5’ breakpoint lies within intron 
23 of F8 and the 3’ breakpoint lies within intron 24 (c.6575-262_6724-192del).  
This deletion predicts a frame shift mutation affecting amino acid valine at 
position 2242 in the FVIII protein creating a downstream premature stop codon 
p.(Val2242Serfs*3).  There is one entry on the HAMSTERs database 
describing a similar mutation (Nakaya, Hsu et al. 2004) in association with 
inhibitor development in severe haemophilia A.  Therefore his genotype was 
reported as hemizygous for the c.6575-262_6724-192del mutation.  A multiplex 
PCR was developed specifically to identify this mutation allowing genetic carrier 
diagnosis to be offered to female family members if required. 
 
MLPA analysis confirmed the deletion of exon 24 (MRC-Holland exon 25) in 
this sample, which can be clearly seen in the MLPA histogram (Figure 3.12). 
 
Figure 3.12: MLPA Histogram for Patient 12.  The histogram for Patient 12 
illustrates the hemizygous deletion of exon 24 (indicated by the arrow) where 
the probe representing this exon (MRC-Holland exon 25) is absent. 
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3.3.2.6 Patient 13 
Patient 13 was a mother of a severe haemophiliac in whom a partial F8 deletion 
mutation has been identified.  The index case had a FVIII:C level of <1 IU/dL 
and was normal for the intron 1 and intron 22 inversions.  Mutation analysis had 
been previously carried out on the index case to identify the underlying 
candidate mutation associated with haemophilia A in the family.  Classic PCR 
of the essential regions of F8 from the genomic DNA failed to amplify exon 5.  
Subsequent long PCR using a primer pair to amplify from exon 4 to 6 produced 
a truncated fragment of approx 6.5 kb, rather than the expected 8.5 kb product, 
consistent with a deletion of exon 5.  Therefore the index case was found to be 
hemizygous for the exon 5 deletion which is consistent with a severe 
haemophilia A phenotype. 
 
Specific analysis for the familial deletion mutation had been previously carried 
out on the mother who had a FVIII:C level of 72 IU/dL.  Long PCR amplification 
of exons 4-6 (utilising the same primer pair which detected the ~6.5 kb 
truncated product) showed compound heterozygosity for the ~6.5 kb truncated 
product and the ~8.5 kb wild type product, which was consistent with 
carriership for the deletion.  The deletion still remains to be fully mapped 
therefore it was suggested that the result should be further corroborated by the 
development of a direct screening assay for this test when this has been 
carried out. 
 
MLPA analysis was only carried out on a DNA sample from the mother as the 
sample from the index case had been depleted.  This confirmed the 
heterozygous deletion of exon 5 in the mother shown in the MLPA histogram 
(Figure 3.13) which is consistent with carriership. 
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Figure 3.13: MLPA Histogram for Patient 13.  The histogram for Patient 13 
shows the presence of a heterozygous deletion of exon 5 where the probe 
representing exon 5 (indicated by arrow) is half the height of the internal 
reference probes (blue bars). 
 
 
 
3.3.2.7 Patient 14 
Patient 14 was a severe haemophilia A affected male and had developed a 
FVIII inhibitor.  His baseline FVIII:C level had not been reported. Mutation 
analysis had been previously carried out to determine the underlying candidate 
mutation associated with haemophilia in this family.  Amplification of the 
essential regions of F8 from genomic DNA failed to amplify exons 7-10.  
Subsequent long PCR utilising a primer pair designed to amplify exons 6 
through to 11 produced a ~5.5 kb fragment instead of the expected ~28 kb 
fragment, indicating the presence of a partial deletion of F8 between introns 6-
10.  Limited DNA sequencing of the ~5.5 kb fragment confirmed the identity of 
the product but did not map the precise deletion boundary.  However the 
deletion removed exons 7 to 10 and was consistent with the haemophilia A 
phenotype seen in the patient.  Therefore long PCR encompassing exons 6 to 
11 could be applied to carrier diagnosis of female members of this family. 
 
The results from MLPA analysis confirmed a large deletion of exons 7-10.  This 
can be clearly seen in the MLPA histogram (Figure 3.14) where the peaks are 
absent for exons 7-10.  The genotype is consistent with a diagnosis of severe 
haemophilia A. 
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Figure 3.14: MLPA Histogram for Patient 14.  The histogram for Patient 14 
illustrates the hemizygous deletion of exons 7-10 (indicated by the bracket) 
where the probe representing these exons are absent. 
 
 
 
3.3.2.8 Patient 15 
Patient 15 was a severe Haemophilia A affected male with a high titre FVIII 
inhibitor.  He had an unreported FVIII:C baseline level and was normal for the 
intron 22 inversion.  He was reported to have a deletion encompassing exons 7 
to 9 of F8.  Previous PCR amplification of the essential regions of F8 failed to 
amplify exons 7-9 inclusive which corroborated this earlier observation.  A long 
PCR protocol using a primer pair designed to amplify exons 6 through to 10 
produced a 14 kb fragment instead of the expected ~24 kb fragment, indicating 
that Patient 15 had a deletion of around 10 kb.  The deletion removed exons 7 
to 9 and was consistent with the haemophilia A phenotype seen in the patient.   
 
MLPA analysis confirmed the deletion of exons 7-9 in this sample, shown in the 
MLPA histogram by absence of the respective peaks (Figure 3.15). 
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Figure 3.15: MLPA Histogram for Patient 15.  The histogram for Patient 15 
illustrates the hemizygous deletion of exons 7-9 (indicated by the bracket) 
where the probes representing these exons are absent. 
 
 
 
3.3.2.9 Patients 16 and 17  
Patient 16 was a deceased female haemophiliac with a FVIII:C level of 4% 
(with a phenotype similar to a severe haemophiliac) and normal intron 22 
inversion results.  Her father was a haemophiliac (now deceased) therefore she 
was an obligate carrier of haemophilia A which was probably inherited from the 
paternal side of the family.  Her mother was also an obligate carrier as she had 
a brother who probably had severe haemophilia and died of a haemorrhage. 
The sister of Patient 16 also had a severe haemophiliac son (Patient 17) (see 
Figure 3.16 for family tree).  Therefore it is thought that Patient 16 may have 
also inherited a haemophilia associated allele from the maternal side of the 
family (of which there is a 50% chance) which would make her compound 
heterozygous for two haemophilia associated alleles.  However there was no 
hard evidence to support this supposition, although it may have explained the 
low FVIII levels seen in Patient 16. 
 
Patient 17 (now deceased) was the nephew of Patient 16 and was an affected 
male with severe haemophilia A, although there was no baseline level reported.  
He had also been reported to be normal for the intron 1 and intron 22 
inversions.  Sequence analysis within the coding regions of F8 failed to identify 
any mutations.  MLPA analysis carried out by Newcastle Haemophilia Centre 
 103 
failed to identify any duplications or deletions.  Therefore the causative 
mutation in this patient remained unidentified.   
 
Figure 3.16: Family tree for Patients 16 and 17 
 
 
MLPA analysis for Patient 16 suggested a large duplication of exons 1-22 
combined with a heterozygous deletion of exon 24.  The sample analysed for 
this patient was very old and the data quality for individual probes was variable 
as can be seen in Figure 3.17a, however the internal reference probes in blue 
were fine.  The duplication is illustrated in the MLPA histogram (Figure 3.17a) 
by the peak heights of the probes for exons 1-22 which are twice the height of 
the internal reference probes.  The heterozygous deletion is illustrated by the 
reduced probe height for exon 24 which is half the height of the internal 
reference probes.   
 
MLPA analysis for Patient 17 (Figure 3.17b) showed normal dosage quotients 
for all exons within F8, therefore the underlying genetic mechanism for the 
haemophilia within this patient remains unidentified.  This also was an 
independent validation of the results obtained from Newcastle. 
 Patient 16 
Severe  
female  
haemophiliac 
 
 
Mother of Patient 17 
Obligate carrier 
 
Patient 17 
Severe  
haemophiliac 
Sister 1 
Carrier  
status  
unclear 
Sister 2 
Carrier 
status  
unclear 
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Figure 3.17: MLPA Histograms for Patients 16 and 17.  The histogram for a) 
Patient 16 illustrates the presence of a possible combined duplication and 
deletion event.  The duplication of exons 1-22 (underlined by the bracket) is 
indicated by the probes representing these exons which are twice the height of 
the internal reference probes (blue bars).  The heterozygous deletion of exon 
24 (indicated by the arrow) is half the height of the internal reference probes.  
The histogram for b) Patient 17 shows normal probe heights for all the exons of 
F8 indicating that neither the duplication nor deletion is present. 
 
a) 
 
b) 
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3.3.2.10 Patients 18 and 19 
Patient 18 was a severe haemophilia affected male with a FVIII:C level of <1 
IU/dL and a FVIII inhibitor. Mutation analysis of F8 had been previously carried 
out in this patient and had identified a DNA 14 base duplication 
c.5644_5657dup14 within exon 17.  This nucleotide sequence duplication 
predicted a frame shift mutation affecting amino acid histidine at position 1886 
in the FVIII protein, creating a downstream premature stop codon p.(Gly1887*).  
The c.5644_5657dup14 nucleotide duplication was not listed on the F8 
mutation databases and its absence had not been confirmed in an unaffected 
male from the maternal side of the family.  However, given the nature of the 
mutation it was highly likely to account for the haemophilia A phenotype present 
in the family.  Patient 18 was hemizygous for the F8 c.5644_5657dup14 
mutation which was consistent with his diagnosis of severe haemophilia A.   
 
Carrier diagnosis had also been carried out on the sister (Patient 19) of Patient 
18 to investigate for the presence of the familial duplication by means of direct 
DNA sequencing.  Patient 17 had normal FVIII:C levels of 40 IU/dL. She was 
found to be heterozygous for the F8 c.5644_5657dup14 mutation which was 
consistent with a diagnosis of carriership for haemophilia A. 
 
MLPA analysis for Patient 18 showed drop out of the probe for exon 17 due to 
the 14 bp duplication.  This is illustrated in the MLPA histogram (Figure 3.18a) 
by complete absence of the peak for exon 17.  MLPA analysis for Patient 19 
(Figure 3.18b) showed the heterozygous 14 bp duplication by the reduced peak 
height of exon 17 which was half the height of the internal reference probes.  
The presence of a mutation or polymorphism in the sequence detected by a 
probe can cause a reduction in the relative peak height.  Figure 3.19 shows the 
gene transcript for exon 17 and the location of the F8 MLPA probe highlighted 
in pink and green.  The location of the c.5644_5657dup14 mutation is 
highlighted in purple which is present within the probe sequence.  Therefore the 
presence of this mutation will cause a reduction in peak height of the probe.   
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Figure 3.18: MLPA Histograms for Patients 18 and 19.  The histogram for a) 
Patient 18 illustrates the probe drop out for exon 17 (indicated by the arrow) 
due to the hemizygous 14 bp duplication.  The histogram for b) Patient 19 
shows a reduced probe height for exon 17 caused by the heterozygous 14 bp 
duplication.  
 
a) 
 
b) 
 
 
 
 
 
 
 
 
 
 107 
Figure 3.19: F8 transcript for exon 17.  The transcript shows the location of 
the exon 17 probe (highlighted in pink and green) and the location of the 
c.5644_5657dup14 mutation (highlighted in purple) which can lead to complete 
absence or reduction in height of the probe. 
 
 
       Y  M                        Y                                
  5701 CCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTTGACCTGGAA 
  5530 CCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTTGACCTGGAA 
  1844 =P==T=-K--D--E--F--D--C--K-=A=-W--A--Y--F--S--D--V--D--L--E- 
 
          D      R                 S                                
  5761 AAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAACACACTGAAC 
  5590 AAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAACACACTGAAC 
  1864 -K-=D=-V-=H=-S--G--L--I--G-=P=-L--L--V--C--H--T--N--T--L--N- 
 
                                                                    
  5821 CCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACCATCTTTGAT 
  5650 CCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACCATCTTTGAT 
  1884 -P--A--H--G--R--Q--V--T--V--Q--E--F--A--L--F--F--T--I--F--D- 
 
       R                                                      SS    
  5881 GAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCTCCCTGCAAT 
  5710 GAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCTCCCTGCAAT 
  1904 =E=-T--K--S--W--Y--F--T--E--N--M--E--R--N--C--R--A--P-=C=-N- 
 
                                                           R        
  5941 ATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATCAATGGCTAC 
  5770 ATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATCAATGGCTAC 
  1924 -I--Q--M--E--D--P--T--F--K--E--N--Y--R--F--H--A--I-=N=-G--Y- 
 
 
3.4 RESULTS OF MLPA ANALYSIS IN THE TYPE 3 VWD PATIENT GROUP 
In total, ten patients were investigated for large deletion/duplications in VWF 
(see Table 3.4).  These included seven type 3 VWD patients who had been 
previously identified to have the novel exon 4-5 deletion (c.221-
977_532+7059del mutation) discovered in a type 3 VWD study in Manchester.  
Patients T3-1, T3-3 and T3-4 were previously found to be compound 
heterozygous for the exon 4-5 deletion and another mutation in exon 8, 37 and 
42 respectively.  The remaining three patients had been previously found to 
have either a small deletion or duplication, or a point mutation.   
 
 
 
 
Exon 17 
Exon 18 
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Table 3.4: Type 3 VWD patients investigated by MLPA analysis following 
screening for mutations within the VWF. 
PATIENT M/F FVIII  
(U/DL) 
VWF: AG 
(U/DL) 
VWF:RCO 
(IU/DL) 
MULTIMERS RESULT PRIOR TO  
MLPA ANALYSIS  
T3-1 F 2 1 <5  Compound heterozygous for 
Exon 4-5 deletion and 
c.992_993delGCinsAA 
mutation in exon 8 
T3-2 F 19 4 <5 None detected Heterozygous for  
Exon 4-5 deletion 
T3-3 F 4 10 12  Compound heterozygous for 
Exon 4-5 deletion and 
c.6397del14 mutation  
in exon 37  
T3-4 M 13 3 <10 Reduced Compound heterozygous for 
Exon 4-5 deletion and 
c.7182T>G mutation  
in exon 42 
T3-5 M 1  <20 None detected Homozygous for  
Exon 4-5 deletion 
T3-6 M 2 <5 <5 None detected Homozygous for  
Exon 4-5 deletion 
T3-7 M 2 Not  
detected 
Not  
detected 
None detected Homozygous for 
 Exon 4-5 deletion 
T3-8 F 12 <10 <10 Markedly  
reduced 
Heterozygous for 
c.5083delCTC mutation  
in exon 29 
T3-9 M 12 
 
0-2 <10 None detected Compound heterozygous for 
the c.5200C>T and  
c.7730-3C>G mutations 
T3-10 M 3 3 <10  Heterozygous for  
c.1657dupT mutation 
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3.4.1 Investigation of Type 3 VWD patients with the exon 4-5 deletion by 
MLPA 
Seven patients were investigated for the presence of the exon 4-5 deletion 
which had been identified in a type 3 VWD study by Sutherland et al. (2009).  In 
the initial study, patients T3-5, T3-7 and T3-8 (patients T3-7 and T3-8 are 
siblings) had demonstrated failure to amplify exons 4 and 5 using genomic 
DNA, which suggested that these exons had undergone a homozygous 
deletion.  Sutherland et al. (2009) had employed the method of ‘primer walking’ 
to confirm the deletion and the approximate breakpoints by utilising primer sets 
which had been designed in overlapping segments.  By using these primer sets 
a PCR product of 1788 bp was produced, rather than the expected product size 
of 10.4 kb.  To be able to map the exact deletion breakpoint by DNA 
sequencing, a further set of deletion mapping (Delmap) primers were designed 
which produced a product of 1084 bp rather than the expected 9715 bp in the 
patients homozygous for the exon 4-5 deletion.  A total in-frame deletion of 
8631 bp from within intron 3 to a point within intron 5 was identified by 
sequencing of the 1084 bp product. 
 
Sutherland et al. (2009), also identified four patients (T3-1, T3-2, T3-3 and T3-
4) to be heterozygous for the exon 4-5 deletion.  In these patients, sequencing 
of genomic DNA had failed to explain the type 3 VWD phenotype (either no 
mutation or heterozygosity for only one mutation in VWF).  Initial PCR analysis 
of platelet derived VWF cDNA produced a truncated PCR product of 683 bp 
(instead of the expected wild type product of 995 bp) comprising VWF exons 2 
to 7.  Following sequencing analysis of the truncated product, the deletion of 
the entire coding sequence for exons 4 and 5 was identified (see Figure 3.20).  
Therefore at the genomic DNA level, the wild type sequence on the other VWF 
allele had masked the presence of the heterozygous deletion during PCR 
amplification. In all four patients the heterozygous nature of the deletion was 
confirmed by designing an assay containing two primer sets.  One set of 
primers amplified across the breakpoint (1084 bp product) and the second set 
amplified across exons 4 and 5 (1694 bp product) as a control.  Both products 
were amplified in all four patients. 
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Figure 3.20: Example of the identical exon 4-5 deletion breakpoints in 
patients homozygous and heterozygous for the mutation as identified by 
Sutherland, et al. (2009).  
 
 
As the presence of the exon 4-5 deletion had been identified by sequencing 
alone in the Sutherland et al. (2009) study, the MLPA method was used as an 
extra confirmation as it is specifically applicable to the identification of large 
deletions/duplications.  This is especially pertinent for those mutations of a 
heterozygous nature which are often masked by the wild type allele during 
standard PCR amplification. 
 
3.4.2 Confirmation of homozygosity for exon 4-5 deletion by MLPA 
Mutation analysis had been previously performed with an aim to identify the 
underlying candidate mutation associated with the type 3 VWD in patients T3-5, 
T3-7 and T3-8.  All three were identified to be homozygous for the exon 4-5 
deletion of VWF which results in a deletion of 8631 bp from the VWF sequence.  
The region that is deleted contains the coding sequence for exons 4 and 5 and 
is located in the multimerisation domain of VWF.  The mutation predicts a 
deletion of amino acids from aspartate at position 75 to glycine at position 178 
inclusive.  It is predicted that this mutation will result in either no functional or a 
truncated VWF protein.  Given the nature of the exon 4-5 deletion mutation and 
the detection of the mutation in all three individuals with type 3 VWD, 
homozygosity for this mutation is highly likely to account for the type 3 VWD 
phenotypes seen in these patients.   
 
Heterozygote 
Homozygote 
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MLPA analysis carried out on this group of three patients clearly identified the 
homozygous deletions of exon 4-5 within VWF. The analysis was performed at 
least twice on different occasions for each patient, thereby confirming the initial 
result.  As VWF is so large, the MLPA method is split into two kits.  The 
histograms in Figure 3.21 show both kits for VWF applied to a DNA sample 
from patient T3-5.  The probes for each exon were amplified apart from exon 5 
in kit 1 and exon 4 in kit 2, indicating the presence of a homozygous deletion of 
exons 4 and 5.  Each of the samples for all three patients displayed the same 
complete absence of amplification of these probes, confirming the previous 
sequencing results.  No evidence of any other large deletions or duplications 
was identified in any of the samples.  The best results were obtained for patient 
T3-5 with both kits passing quality control.  However for T3-7 and T3-8 only kit 
1 passed quality control with kit 2 repeatedly failing because of an outlying 
internal reference probe.  Although this increases the possibility of making an 
incorrect diagnosis, despite this the samples repeatedly showed absence of the 
exon 4 probe in kit 2, therefore it was clearly obvious that the exon 4-5 deletion 
was present in these samples.   
 
Figure 3.21: MLPA Histograms for Patient T3-5. The histogram for a) Kit 1 
shows complete absence of the probe for exon 5 (indicated by the arrow).  
There is also complete absence of the probe representing exon 4 in histogram 
b) Kit 2 (indicated by the arrow).  Together they illustrate the presence of a 
homozygous deletion of exon 5 and exon 4 of VWF. 
a) 
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b) 
 
 
3.4.3 Confirmation of heterozygosity for exon 4-5 deletion by MLPA 
Mutation analysis had been previously performed with an aim to identify the 
underlying candidate mutation associated with the type 3 VWD in patients T3-1, 
T3-2 and T3-3 and T3-4.  All four were identified to be heterozygous for the 
exon 4-5 deletion (c.221-977_532+7059delGCinsAA) of VWF which results in a 
deletion of 8631 bp from the VWF sequence.   
 
Patient T3-1 had been previously found to have compound heterozygosity for 
two mutations detected within exons 4-5 and exon 8 of the VWF sequence.  
The second mutation found was the c.992_993delGCinsAA nucleotide change 
in exon 8 which predicts an insertion-deletion mutation at amino acid 331 
causing the deletion of a cysteine amino acid and the insertion of a premature 
stop codon p.(Cys331delins*).  Given the nature of these mutations, compound 
heterozygosity involving these is highly likely to account for the type 3 VWD 
phenotype seen in this patient.   
 
Patient T3-2 had been previously diagnosed to have type 3 VWD (FVIII 19 
IU/dL, VWF:Ag 4 IU/dL and VWF:RCo <5 IU/dL) however as no other mutation 
was detected by DNA and RNA analysis in combination with the heterozygous 
exon 4-5 deletion, a diagnosis of type 3 VWD could not be confirmed by the 
genotype.  Also the reported VWF:Ag level of 4 IU/dL for this patient is more 
indicative of a diagnosis of severe type 1 VWD rather than type 3 VWD.  It is 
unlikely that heterozygosity for the exon 4-5 deletion alone would account for 
 113 
the severe phenotype as other heterozygous carriers of this mutation have 
been seen in mild/moderate type 1 VWD.   
 
Patient T3-3 had been previously found to be compound heterozygous for two 
mutations with exons 4-5 and exon 37 of the VWF sequence.  The second 
mutation identified was the c.6397del14 deletion mutation in exon 37 which 
predicts a frame shift mutation at amino acid 2133 causing the amino acid 
valine to be replaced by proline and the insertion of a premature stop codon 12 
codons downstream p.(Val2133Profs*12).  It is predicted that this mutation will 
result in a null allele and so no mature VWF protein will be produced.  Given 
the nature of the exon 4-5 deletion mutation and c.6397del14 mutations, 
compound heterozygosity for these mutations is highly likely to account for the 
severe phenotype seen in this patient. 
 
Patient T3-4 had also been previously found to be compound heterozygous for 
the exon 4-5 mutation and a c.7182T>G nucleotide change in exon 42 which 
predicts a missense mutation at amino acid 2394 p.(Cys2394Trp).  It is 
predicted that this removal of the cysteine amino acid may cause disruption to 
the tertiary structure of the mature VWF protein resulting in a dysfunctional 
protein.  In this respect, it is worth noting that patient T3-4 has a reported 
VWF:Ag level of 3 IU/dL and a diagnosis of severe type 1 VWD rather than type 
3 VWD cannot be excluded.  Given the nature of the exon 4-5 deletion mutation 
and c.7182T>G mutations, compound heterozygosity for these mutations is 
highly likely to account for the severe type 1 VWD phenotype seen in this 
patient. 
 
MLPA analysis carried out on this group of four patients clearly revealed the 
heterozygous deletions of exon 4-5 within VWF.  Patient T3-1 was the only 
patient from this group who displayed good quality results for both kits 
(standard deviation of <0.1).  The histograms in Figure 3.22 show both kits for 
VWF applied to a DNA sample from this patient.  It can be seen that the probe 
heights for exon 5 in kit 1 and exon 4 in kit 2 are significantly reduced and when 
measured against the internal reference probes are half the height, indicating 
the presence of a heterozygous deletion of exons 4 and 5.    This was also 
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observed in the other three patients, however at least one kit failed quality 
control on numerous occasions for each of these patients.  With respect to 
patients T3-1, T3-3 and T3-4 who were shown to have compound 
heterozygosity by previous mutation analysis, this was not evident by MLPA.  
The insertion-deletion mutation (c.992_993delGCinsAA) in exon 8 identified in 
patient T3-1 did not have an effect on the peak height of the probe for exon 8.   
The small deletion mutation (c.6397del14) found in patient T3-3 which results in 
the deletion of 14 bases from exon 37 also was not found to have an effect on 
the peak height of the probe for exon 37 and therefore provided no evidence to 
the presence of this mutation.  This was also the same for patient T3-4 who is 
heterozygous for the missense mutation c.7182T>G in exon 42 which results in 
a single amino acid substitution in the mature VWF protein.  No evidence of a 
reduced peak height was seen for exon 42, which would indicate the presence 
of this mutation. 
 
Although only 1 out of the 4 patient samples passed quality control, together 
with the initial results from mutation analysis the presence of the heterozygous 
exon 4-5 deletion was clearly identifiable.  Following this confirmation in a 
diagnostic laboratory setting, this information could be used in future genetic 
family studies as required. 
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Figure 3.22: MLPA Histograms for Patient T3-1. The histogram for a) Kit 1 
shows a reduced peak height of the probe for exon 5 (indicated by the arrow).  
There is also a reduced peak height of the probe representing exon 4 in 
histogram b) Kit 2 (indicated by the arrow).  Together they illustrate the 
presence of a heterozygous deletion of exon 5 and exon 4 of VWF. 
a) 
 
 
b) 
 
 
3.4.4 Investigation of type 3 patients with no causative mutation by MLPA 
The three remaining patients in the type 3 VWD group to be investigated had 
also previously had mutation analysis of VWF carried out in order to identify the 
underlying candidate mutation associated with their type 3 VWD diagnoses. 
 
Patient T3-8 had previously been found to be heterozygous for a previously 
unreported c.5083delCTC deletion mutation within exon 29 which results in a 
deletion of 3 base pairs from the VWF sequence.  As a result the amino acid 
leucine at position 1695 is deleted.  It is predicted that this mutation may result 
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in an abnormal tertiary protein structure which may reduce the function of the 
mature VWF protein.  No other mutation was detected by DNA or RNA analysis 
in combination with this mutation and therefore the diagnosis of type 3 VWD 
could not be confirmed by the genotype.  As patient T3-8 had a reported 
VWF:Ag level of <10 IU/dL with detectable VWF multimers, a diagnosis of 
severe type 1 VWD rather than type 3 VWD may be more likely.  It is not clear 
how heterozygosity for the identified p.Leu1695del mutation would alone 
produce a severe VWD phenotype. 
 
Patient T3-9 was previously found to show compound heterozygosity for two 
DNA single base changes.  The c.5200C>T base change within exon 30 was 
identified which predicts the nonsense mutation glutamine 1734X, or 
p.(Gln1734X), of the mature VWF protein.  The second base change identified 
was the c.7730-3C>G base change which is likely to affect a splice site at the 
intron 45, exon 46 boundary.  Although neither of these VWF mutations have 
been previously reported, given their nature they are highly likely to account for 
the severe VWD phenotype seen in this patient. 
 
Patient T3-10 was previously diagnosed to have haemophilia A, however more 
recent phenotypic laboratory tests indicated a revised diagnosis of severe 
VWD.  Previous mutation analysis of VWF had identified heterozygosity for a 
DNA single base duplication within exon 14 of the VWF sequence 
(c.1657dupT).  This nucleotide duplication predicts the amino acid substitution 
tryptophan 553 to leucine, resulting in a frame shift mutation which introduces a 
premature stop signal 97 codons downstream p.(Trp553Leufs*97) in the VWF 
protein.  There is a previous report of this mutation on the ISTH VWF database 
in association with type 3 VWD when inherited in compound heterozygosity 
with a second VWF mutation.  It is unlikely that heterozygosity for this mutation 
would alone account for the severe VWD phenotype seen in this patient.  A 
second VWF mutation was not identified, however it cannot be excluded that an 
additional mutation is present that cannot be detected using conventional DNA 
sequencing methodology. 
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MLPA analysis was performed on these three patients to try and identify 
whether a large deletion may be present which would account for their severe 
phenotype.  Both patients T3-9 and T3-10 showed good quality results for both 
kits (standard deviation of <0.1), however for patient T3-8 VWF kit 2 was just 
over the 0.1 threshold.  This was probably due to the fact that the DNA sample 
for patient T3-8 was much older than the DNA used for analysis for the other 
two patients.  However it was still possible to obtain a clear picture of any 
mutations that may be responsible for the severe type 3 phenotype.  Both T3-8 
and T3-10 showed normal peak heights for all 52 exons within VWF.  Although 
patient T3-8 had previously been identified to have a small deletion of 3 bp from 
exon 29 this was not identified by the MLPA kit.  A similar result was found for 
patient T3-10 who had previously been identified to have a single base 
duplication within exon 14, which was not detected by the MLPA kit.   
 
As described earlier, patient T3-9 had previously been found to be compound 
heterozygous for two different base changes. MLPA analysis showed a 
reduced peak height for the probe for exon 30 which coincided with the 
presence of the c.5200C>T base change within exon 30 that had been 
previously detected.  This is illustrated in Figure 3.23 which shows the results 
for patient T3-9 using VWF kit 2 and the drop out of exon 30.  There was no 
evidence in kit 1 of the second base change (c.7730-3C>G) affecting the peak 
heights of the probes for either 45 or 46.  It is well known that the presence of a 
mutation or polymorphism in the sequence detected by a probe can cause a 
reduction in the relative peak height which had also been seen in a haemophilia 
family using the F8 kit (see section 3.3.2.10).  Figure 3.24 shows the gene 
transcript for exon 30 and the location of the VWF MLPA probe highlighted in 
pink and green.  The location of the c.5200C>T base change is highlighted in 
purple which is present within the probe sequence.  Therefore if this base 
change is present it will cause the reduction in peak height of a probe, 
indicating a potential limitation of the MLPA method.  
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Figure 3.23: MLPA Histogram for Patient T3-9. The histogram for VWF Kit 2 
shows a reduced peak height of the probe for exon 30 (indicated by the arrow) 
caused by the c.5200C>T base change within exon 30 in this patient. 
 
 
Figure 3.24: VWF transcript for exon 30.  The transcript shows the location of 
the exon 30 probe (highlighted in pink and green) and the location of the 
c.5200C>T base change (highlighted in purple) which leads to a reduction in 
height of the probe. 
 
    
                 M              30Y      ***        W               
  5401 GCTTTCATTTCAAAAGCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTAT 
  5146 GCTTTCATTTCAAAAGCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTAT 
  1716 -A--F--I-=S=-K--A--N--I--G-=P=-R-=L=-T--Q--V-=S=-V--L--Q--Y- 
 
 
                                                                    
  5461 GGAAGCATCACCACCATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTG 
  5206 GGAAGCATCACCACCATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTG 
  1736 -G--S--I--T--T--I--D--V--P--W--N--V--V--P--E--K--A--H--L--L- 
 
                  Y*                                  K31     *     
  5521 AGCCTTGTGGACGTCATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGC 
  5266 AGCCTTGTGGACGTCATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGC 
  1756 -S--L--V--D-=V=-M--Q--R--E--G--G--P--S--Q--I--G--D--A-=L=-G- 
 
 
3.5 RESULTS OF MLPA ANALYSIS IN THE TYPE 1 VWD PATIENT GROUP 
In total, sixteen patients were investigated for large deletion/duplications in 
VWF who had originally been recruited into a UK national study (Cumming, 
Grundy et al. 2006).  In the original study, genomic DNA from thirty-two index 
cases and their families was analysed for mutations in VWF which may account 
for the type 1 VWD bleeding phenotype.  Mutations had not been found in all 
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patients and families studied therefore RNA work was undertaken by 
Sutherland et al. (2009) to search for mutations which could not be detected 
using the conventional DNA PCR techniques.  This also included the aim of 
investigating these patients for the presence of the large heterozygous exon 4-
5 deletion  which had been detected at a high frequency in the type 3 VWD 
patient cohort.  Of the initial 32 index cases, only 16 had DNA samples 
available which could be used for MLPA analysis.  Phenotypic data for the 
sixteen patients in whom MLPA analysis was completed are shown in table 3.5.  
Of the sixteen cases, two index type 1 VWD patients were included who had 
been previously identified by Sutherland et al. (2009) to be heterozygous for the 
novel exon 4-5 deletion (c.221-977_532+7059del mutation).  The remaining 
fourteen patients had been previously found to either have no mutation found or 
putative for mutations which did not co-segregate with their VWD phenotype.   
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Table 3.5: Type 1 VWD index patients investigated by MLPA analysis 
following screening for mutations within VWF.  The phenotypic laboratory 
data were provided by the referring centre and by the central testing laboratory. 
PATIENT M/F 
 
VWF: AG 
(U/DL) 
VWF:RCO 
(IU/DL) 
VWF:CB 
(IU/DL) 
BLOOD  
GROUP 
RESULT PRIOR TO  
MLPA ANALYSIS 
T1-2  M 30, 22, 76 33, 37 (70) (77) O None 
T1-3 
 
F 13, 16, 13,  
21 
11, 10, 18,  
10, 13 
12, 9 O p.Tyr1584Cys Ex 28 
Heterozygous for  
Exon 4-5 deletion 
T1-5 
 
F 33, 51, 59,  
69 
18, 54, 56,  
87 
176 O None 
T1-8  
 
F 35, 76 41, 63 30, 106 A None 
T1-10  M 30, 27, 40 23, 24, 22 46, 55 A p.Arg924Gln Ex 21 
c.5843-8C>G Int 34 
T1-12 
 
F 27, 31, 37, 
 46 
33 (58) 35,27,68  
(49) 
A None 
T1-14  F 81, 54, 60,  
66, 48 
41, 56, 71,  
50 (43) 
(84) O p.Gly2705Arg 
T1-15 
 
F 31, 44 25 (56) (36) O p.Arg924Gln Ex 21 
p.Val1850Met Ex 32 
c.5834-8C>G Int 34 
T1-16 
 
F 36, 38 14 (44) (50) O p.Tyr1584Cys Ex 28 
T1-18 
 
F 34, 19, 66 32, 25, 72 86 O c.5170+10C>T Int 29 
T1-19  M 48, 61, 57,  
51 
60 23, 59,  
41, 73 
O c.Tyr1584Cys Ex 28 
T1-20 
 
F 46, 87 33, 78 106 O None 
T1-23 
 
F 20, 27, 13,  
26 
115, 53, 28,  
87, 22, <10 
3 O Heterozygous for  
Exon 4-5 deletion 
T1-25  F 45, 61, 82, 45, 61, 
66, 67, 30,  
74 
44, 68, 82,  
44, 68, 110,  
54, 62 
39 O p.Tyr1584Cys Ex 28 
T1-28 
 
F 36, 38, 40 36, 39, 42 38 O p.Asp141Gly Ex 5 
T1-30  M 39, 36, 36,  
22, 34, 40,  
49, 73, 59,  
72, 63, 82,  
61 
28, 23, 42,  
16, 21, 21,  
41, 61, 70,  
55, 59, 92,  
63 
Not tested O p.Thr2647Met 
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3.5.1 Investigation of Type 1 VWD index patients with exon 4-5 deletion by 
MLPA 
In order to corroborate the work by Sutherland et al. (2009), two index cases 
(T1-3 and T1-23) that had been identified to be heterozygous for the exon 4-5 
deletion were investigated by MLPA analysis.  They had previously been 
analysed for the exon 4-5 deletion using the Delmap primers at the genomic 
DNA level, with confirmation by a multiplex assay.  No candidate VWF mutation 
had been previously identified in the study carried out by Cumming, Grundy et 
al. (2006).  Sequencing of the exon 4-5 deletion PCR products from the Delmap 
primers confirmed that the deletion carried exactly the same breakpoints that 
had been identified in the type 3 VWD patients with the mutation (c.221-
977_532+7059del).  Previous haplotype analysis carried out in family members 
in both families indicated that the mutation segregated with the same common 
haplotype and therefore was causative of the type 1 VWD.  The VWF 
polymorphism p.Tyr1584Cys also found in patient T1-3 did not segregate with 
the disease phenotype. 
 
MLPA analysis carried out on these two index patients clearly revealed the 
heterozygous deletions of exon 4-5 within VWF. Patients T1-3 and T1-23 
displayed good quality results for both VWF kits (standard deviation of <0.1).  
The histograms in Figure 3.25 show both kits for VWF applied to a DNA sample 
from patient T1-3.  It can be seen that the probe heights for exon 5 in kit 1 and 
exon 4 in kit 2 are significantly reduced and when measured against the 
internal reference probes are half the height, indicating the presence of a 
heterozygous deletion of exons 4 and 5.    The same was observed in the DNA 
sample for patient T1-23.   
 
The VWF polymorphism p.Tyr1584Cys found in patient T1-3 which is a 
missense mutation c.4751A>G in exon 28 was not found to have an effect on 
the peak height of the probe for exon 28, and therefore its presence was not 
evident by MLPA. 
 
Following this confirmation in a diagnostic laboratory setting, this information 
could be used in future genetic family studies as required. 
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Figure 3.25: MLPA Histograms for Patient T1-3.  The histogram for a) Kit 1 
shows a reduced peak height of the probe for exon 5 (indicated by the arrow).  
There is also a reduced peak height of the probe representing exon 4 in 
histogram b) Kit 2 (indicated by the arrow).  Together they illustrate the 
presence of a heterozygous deletion of exon 5 and exon 4 of VWF. 
 
a) 
 
b) 
 
 
3.5.2 Investigation of type 1 VWD index patients with no causative 
mutation by MLPA 
The fourteen remaining index patients in the type 1 VWD group to be 
investigated had previously had mutation analysis of VWF carried out in order 
to identify the underlying candidate mutation associated with their type 1 VWD 
diagnoses.  These patients were either found to have no putative mutations or 
the identified putative mutation did not co-segregate with the VWD phenotype.  
Therefore in an attempt to ascertain whether a large deletion may be present 
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which may be responsible for the type 1 VWD phenotype, MLPA analysis was 
carried out. 
 
MLPA analysis carried out on this group of type 1 VWD patients failed to 
identify any large deletions within VWF.  In this group there was a high failure 
rate with respect to samples passing quality control.  Even though analysis was 
performed at least three times for each kit, samples repeatedly failed.  Only four 
out of the fourteen patient samples analysed passed quality control for both kits 
1 and 2 for VWF.  These four patients (T1-2, T1-8, T1-14, T1-19) produced 
normal results with no evidence of large deletions which may be responsible for 
their phenotype. 
 
Three of the fourteen patients (T1-10, T1-15 and T1-16) completely failed 
quality control for both kits and therefore could not be analysed.  On many 
occasions probes failed to ligate to target DNA sequences which was made 
apparent by the complete lack of probe amplification.  Figure 3.26 shows the 
histograms for patient T1-16 where for both kits the internal reference probes 
failed together with inadequate amplification of probes for each exon.  Figure 
3.26a is an example of how this result could lead to an incorrect diagnosis of a 
large deletion if the standard deviation is not taken into account as several of 
the probes for individual exons have failed to amplify.  When MLPA analysis 
was repeated on this sample, all the probes were amplified although the 
sample still failed quality control.   The remaining seven patients could only 
partially be analysed as only kit 1 passed quality control and kit 2 repeatedly 
failed, therefore a complete diagnosis by MLPA was not obtained for these 
patients. 
 
It was difficult to ascertain whether some of the putative VWF polymorphisms 
identified by DNA sequencing in some of the patients had an effect on probe 
height.  This was due to the fact the majority of the exons in which they were 
present were part of the VWF kit 2 which consistently failed for many patients. 
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Figure 3.26: MLPA Histograms for Patient T1-16.  The histograms for both a) 
Kit 1 and b) Kit 2 illustrate irregular probe amplification for the internal reference 
probes (blue bars) and individual exons (green bars).  This results in sample 
failure as the standard deviation will be >0.1. 
a) 
 
b) 
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4.1 INTRODUCTION  
Haemophilia A is caused by a broad spectrum of mutations which are spread 
throughout the 26 exons of F8.  These mutations can be identified through 
mutation screening which facilitates carrier detection in female family members 
and can be helpful in determining the risk of complications such as inhibitor 
formation in affected males.  Several techniques are used for mutation 
screening including long-range and/or inverse PCR for detection of the 
inversions of introns 1 and 22 which account for 45-50% of severe haemophilia 
A patients, and sequencing of the coding regions of F8 to identify point 
mutations, deletions or splice-site mutations in the majority of remaining cases.  
However a small proportion of haemophilia patients do not have a mutation that 
can be identified using these techniques.  Duplications of part of F8 are not 
easily detected by these means as gene dosage is not established.  It is also 
difficult to determine carrier status in female relatives of males with large F8 
deletions using simple targeted PCR as they are masked by amplification of the 
normal X chromosome.  
 
The diagnosis of VWD is primarily based on clinical and phenotypic information, 
however more recently genetic analysis has become available to confirm or 
support the initial diagnosis and provide information for family studies and 
prenatal diagnosis which is particularly important in type 3 VWD.  Genetic 
analysis is useful in the differential diagnosis of VWD type 2N and mild 
haemophilia A, or VWD type 2B and platelet type pseudo-VWD.  Genetic 
investigation is not routinely used in type 1 VWD as it has been shown to be 
complicated due to a causative mutation not always being detectable 
(Cumming, Grundy et al. 2006; Goodeve 2007; James, Notley et al. 2007).  A 
large range of mutations have been reported to be associated with VWD 
including missense, nonsense and splice site mutations, small 
deletions/insertions and large deletions.  Large deletions responsible for VWD 
are relatively uncommon, however they usually result in a complete deficiency 
of VWF protein (Schneppenheim, Castaman et al. 2007).  To date, twelve large 
deletions have been reported for type 3 VWD, ranging in size from a single 
CHAPTER 4: DISCUSSION 
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exon to the entire gene.  Large deletions are difficult to detect in autosomal 
conditions as amplification of the normal allele masks the failure of the other 
allele to amplify.  Therefore, false-negative results may be obtained for carriers 
of heterozygous large deletions.   
 
MLPA is a method which has the potential to overcome the above limitations.  It 
has recently been employed to identify large deletions and duplications within 
F8 and VWF  (Rost, Loffler et al. 2008; Lannoy, Abinet et al. 2009; 
Zimmermann, Oldenburg et al. 2010; Cabrera, Casana et al. 2011; Rafati, 
Ravanbod et al. 2011; Theophilus, Baugh et al. 2011; Yadegari, Driesen et al. 
2011). The method is used to screen for the presence of deletions or 
duplications by quantitatively comparing the copy numbers of a set of DNA 
sequences in a patient sample to those in a control sample.  
 
The aim of this study was to apply MLPA to investigate the molecular basis of 
disease in patients with haemophilia A and VWD where no causative mutation 
had been identified using the ‘gold standard’ method of direct sequencing.  In 
order to do this, it was essential to first develop, optimise and validate the 
MLPA assays for F8 and VWF in order to identify large deletions/duplications.  
The methodology was then applied to a selected cohort of patients with 
Haemophilia A and VWD to further investigate the underlying cause of their 
disease. 
 
4.2 MLPA METHOD EVALUATION 
When MLPA was selected as the method to detect large deletions and 
duplications it was important to take into account a number of considerations 
before starting such as available resources, ease of method implementation in 
the laboratory, experimental set-up, sample treatment and interpretation of 
results. 
 
The necessary equipment for MLPA consists of a thermocycler and capillary 
sequence equipment which was already available in the laboratory, therefore 
the initial investments costs were low.  An important part of the initial 
experimental set-up was to test the thermocycler to be used for excessive 
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evaporation as this can affect MLPA results.  Excessive evaporation can be 
caused by a particular type of tube, the pressure of the heated lid on the tube or 
whether the heated lid is working properly.  The plastic of the tubes can be 
weak at high temperatures and lead to deformation of the tubes when the 
pressure of the lid is too high which results in tube leaks and excessive 
evaporation.  A test for excessive evaporation was carried out on the 
thermocycler using two different brands of tubes.  One brand of tube was found 
to have less evaporation than the other and was used in all further experiments.  
The other brand had warped overnight in the thermocycler and caused more 
evaporation which was probably due to a weaker plastic used in tube 
manufacture.   
 
MLPA kits contain everything that is required for an assay (probemix, buffers, 
ligase, polymerase, dNTP’s and labelled PCR primers) without the need to buy 
additional reagents.  An advantage of MLPA is that it can be used for many 
different applications and the only difference between MLPA assays is the 
probemix specific to each target region of DNA.  This was of particular value for 
this study as the method could be evaluated for both Haemophilia A and VWD 
at the same time with the same conditions.   
 
An important factor that was taken into account was the sensitivity of the MLPA 
method as this can often be a limitation.  MLPA literature states that it is a very 
sensitive technique where only 20 ng of human DNA is required in an assay 
and results do not vary depending on the amount of sample DNA used.  It can 
distinguish sequences differing in only a single nucleotide, if a specific probe 
has been designed for this purpose and is able to detect small copy number 
variations in a DNA sample.  It can also detect deletions or duplications of a 
single exon as it detects sequences of only ~60 nt (evidence of this is 
described in section 4.3.1). 
 
MLPA assays for F8 and VWF were first performed on control DNA samples 
from healthy individuals which provided good initial results. It is necessary to 
include reference samples in each experiment as minor differences between 
different experiments may affect the MLPA peak pattern.  As recommended the 
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control samples were derived from the same type of tissue and extracted using 
the same protocol as the test samples.  Although it is recommended that at 
least five control samples should be included in each run, it was decided that 
seven controls should be used.  This proved to be advantageous as having two 
extra controls covered for any inter assay control failures which may occur, 
meaning that the whole run would not have to be repeated.  It is not essential to 
include positive controls, therefore this was not incorporated into the final 
protocol for MLPA. 
 
4.2.1 Sample treatment 
The starting material for analysis was of particular importance for MLPA.  The 
treatment of DNA (storage and extraction method) may affect MLPA results.  
Although special DNA extraction methods are not required for MLPA analysis, 
the extraction method should not leave behind a high concentration of 
contaminants such as salt.  A high salt concentration can compromise MLPA as 
it prevents complete denaturation of the CG rich parts of the sample DNA 
(CpG) islands.  Incomplete denaturation can lead to false positive MLPA 
results, including an apparent deletion of several probes.  It is also not 
recommended to use heparinised blood as traces of heparin can still be present 
in DNA preparations which can lead to distortion of the MLPA PCR reaction.  
Fortunately all DNA samples used in the study had been previously extracted 
from peripheral blood samples in EDTA by an ammonium acetate method, 
therefore this did not pose an initial problem.  However it is also recommended 
that for best results the DNA should be extracted from fresh samples and that a 
concentration of between 50-250 ng of DNA in 5 μl should be used for each 
MLPA reaction.  As the samples used in this study were from patients who had 
already had previous genetic studies carried out, they were obtained from 
stocks that had been frozen for a number of years.  Therefore DNA degradation 
had occurred and the concentration was often low.  This led to consistently 
poor results for some patients with very old samples where only a fresh sample 
would give results that could be reliably reported.  Impurities in the extracted 
DNA which have an effect on MLPA results can also be lowered by reducing 
the amount of sample DNA, therefore any impure samples were diluted to a 
working stock of 10-20 ng/μl.  This was found to be beneficial in a few 
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circumstances but generally led to ligation and amplification failure.  RNA 
contamination of the DNA samples can also affect the results of a small number 
of probes that detect sequences in genes that are highly expressed e.g. globin 
α and β.  This is due to RNA molecules reducing the effective probe 
concentration by binding to the probe or by competing with the probes for 
binding to the same target sequence on the genomic DNA.  The amount of 
RNA also differs from sample to sample, which results in a high variability of 
certain probes.  Although F8 and VWF are not transcribed in abundance, it was 
necessary to test whether the addition of an RNase treatment would be of 
benefit to those samples with consistently poor results.  Similarly to reducing 
the DNA concentration to reduce impurites, the addition of the RNase treatment 
was advantageous for some failed samples but not all. 
 
Following these attempts to optimise sample treatment it was concluded that 
the best results were obtained from DNA extracted from fresh peripheral blood 
samples in EDTA.  In the general setting of a routine genetic service, MLPA 
analysis will potentially be included as part of the initial diagnostic algorithm and 
therefore fresh samples will be analysed.  However in cases where 
retrospective analysis needs to be carried out on older samples such as in this 
study, this may pose a problem in generating reliable results for reporting.  
Lowering the concentration of an impure stock DNA sample did not have any 
major beneficial effect and if possible a new sample should be obtained.  
However the implementation of the RNase treatment as a standard part of the 
sample treatment is deemed to be useful as it can only have a positive effect 
and not a negative one.  
 
4.2.2 Method Optimisation 
Attempts were made to optimise the MLPA protocol in order to achieve the 
most consistent results.  A standard protocol is supplied by MRC-Holland but 
slight changes to this may result in minor improvements to data quality.  Initial 
experiments were all tested according to the standard protocol, however for 
those samples that consistently failed quality control it was decided that a 
slightly different protocol optimised by Edinburgh Royal Infirmary should be 
tested to establish whether better quality results could be obtained.  The main 
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difference between the two protocols was the number of PCR cycles for the 
PCR reaction.  The standard protocol uses 35 PCR cycles however the 
Edinburgh protocol had reduced the number of cycles to 33 which can slightly 
improve the linearity of relative probe signal with target sequence copy number.  
Samples were tested in parallel using the two protocols and data quality proved 
to be better using the standard protocol with better peak amplification and 
morphology.  Therefore it was decided that the standard protocol would be 
adopted as the routine method for all future samples. 
 
4.2.3 Data analysis 
The correct evaluation of data is crucial for the reliable implementation of MLPA 
analysis.  Firstly, the peaks generated by fragment analysis need to be visually 
evaluated in order to prevent false positive results.  Based upon this evaluation 
the MLPA procedure may need to be repeated, e.g. samples may need to be 
tested again on the capillary sequencer when peaks are either above the 
fluorescence maximum of the sequencer or when they are very low.  Other 
problems may be identified through visual examination of the peak patterns of 
the size-called data, including the size standard, such as the use of 
deteriorated capillary electrophoresis gel matrix, old capillaries or low quality 
formamide.  It is also important to assess the control fragments with 
amplification products between 64 nt and 105 nt and the ‘no DNA control’ 
reaction.  The four DNA quantity control fragments (Q-fragments) and one 
ligation-dependant control fragment should be evaluated to ensure that 
sufficient sample DNA was present and that the ligation reaction was 
successful.  The two DNA denaturation fragments (D-fragments) should also be 
assessed for incomplete denaturation together with the X-chromosome specific 
and Y-chromosome specific control fragments.  The ‘no DNA control’ reaction 
should only generate a probe signal for the Q-fragments as they do not require 
a ligation reaction or the presence of sample DNA to be amplified.  However 
non-specific peaks may be seen in the ‘no DNA control’ due to the MLPA PCR 
reaction which includes a high number of long MLPA probe oligonucleotides 
that each contain an exact copy of one of the PCR primers.  However, in most 
cases, the non-specific peaks do not have an effect on the MLPA results of 
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normal samples as they are outcompeted by genuine MLPA probe amplification 
products. 
 
Non-specific fragments also occur in the region of the control fragments.  A 
non-specific fragment was often seen at ~88 nt.  This was due to the use of the 
ABI POP7 gel matrix for capillary electrophoresis and it could be ignored as it 
represents non-specific amplification of a long primer-dimer that has the same 
mobility as one of the quality fragments.  If the non-specific peak affected the 
analysis of the 88 nt D-fragment then only the 96 nt D-fragment peak was used. 
 
4.2.4 Result interpretation 
Data for both F8 and VWF were normalised using spreadsheets obtained from 
the NGRL Manchester.  In order to verify whether the calculated ratios are 
reliable, it is essential to be familiar with the MLPA technique and the gene it is 
being applied to.  When interpreting the data a number or considerations need 
to be taken into account before a final conclusion can be made.  False positive 
results can be produced by sequence changes including single nucleotide 
polymorphisms (SNPs) or point mutations in the target sequence detected by a 
probe.  The probe signal can be inhibited by mutations/SNPs in close proximity 
to the ligation site (1-5 nt) as they can prevent ligation of the two probe 
oligonucleotides.  Mutations/SNPs that are further away from the probe ligation 
site (at least 20 nt) can produce a lower probe signal by unbalancing the 
binding of the probe oligonucleotide to the sample DNA.  Although the assays 
have been designed to avoid SNPs if possible, the increasing number of 
described SNPs shows it is likely that in some individuals rare SNPs may 
interfere with probe binding.  With this in mind, confirmation by another method 
is always required for copy number changes that are detected by a single probe 
only.  Sequencing is usually the method of choice for determining whether there 
is a polymorphism or mutation present in the probe target sequence whereas 
long range PCR and qPCR are often used to determine exon deletions (see 
section 4.3).  The frequency of single exon deletions is generally higher in 
genes with large introns than in small genes with very short introns which was 
worth noting in this study as both F8 and VWF are large genes.  The 
pathogenic nature of any deletions or duplications detected by MLPA also 
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needs to be determined as not all result in disease.  Partial gene duplications 
within the gene may disrupt that copy of the gene resulting in a pathogenic 
outcome, while a duplication of the complete gene at a different chromosomal 
location might not.  In the majority of diseases the underlying genetic defect is 
due to a small point mutation which will most probably not be detected using 
the MLPA approach, unless a probe has been designed specifically to detect 
these.  Also MLPA will not pick up most inversions, translocations or copy 
number changes which are not within the sequence detected by the probes.  
This was an important factor to consider when using MLPA to investigate 
haemophilia A and VWD and section 4.5 describes how MLPA has been 
incorporated into the mutation detection strategies for both diseases. 
 
4.2.5 Advantages and Limitations of MLPA 
The application of MLPA for copy number detection offers many advantages 
over other techniques.  Methods such as sequencing which were mainly 
developed for detection of point mutations, small deletions and insertions, 
usually fail to detect copy number changes.  Depending on the size, not all 
deletions can be amplified by sequencing if the primers from neighbouring 
exons are too far apart, particularly if the deletion has not been mapped.  This 
is why MLPA offers an advantage as an indirect screening assay in a 
diagnostic context when the presence of a deletion or duplication has not yet 
been identified.  It offers a faster alternative to developing bespoke direct 
assays for the detection of deletions and it is a standardised, robust method 
covering an entire gene or locus.  By introducing MLPA to initially screen for a 
deletion/duplication a direct assay can then be designed when the location of 
the deletion/duplication has been determined, if required.  However, although 
the approach of designing a long PCR reaction followed by sequencing may 
detect fewer deletions than MLPA, it is the ‘gold standard’ method as it gives 
direct confirmation of the nature of the deletion.  In this study, MLPA was used 
to support the identification of large deletions/duplications initially discovered 
through direct assays, for example the novel exon 4-5 deletion (c.221-
977_532+7059del mutation) found in type 1 and type 3 VWD patients. 
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MLPA is used mainly to detect genomic deletions/duplications and is not 
suitable for identifying unknown point mutations.  However probes can be 
designed so that the ligation site is located exactly at the position of a known 
(point) mutation.  Therefore, ligation will only occur when the mutation is not 
present and in the case of a mutation will result in a decreased fluorescent 
signal.   
 
As discussed in section 4.2.4, MLPA is sensitive to small deletions, insertions 
and mismatches which could affect the probe signal.  Therefore a non-
pathogenic polymorphism could be mistaken for a deletion due to a decreased 
probe signal.  The latest databases are used to avoid SNPs when designing 
MLPA probes, however it is impossible to exclude all cases.  This is why MLPA 
findings should be confirmed by another method.  In this study, a reduced 
probe signal (caused by mutations in the sequence detected by the MLPA 
probe) was observed in two haemophilia cases (Patients 18 and 19) and one 
type 3 VWD case (patient T3-9).  Patient 18 was a severe haemophiliac who 
had previously been found to have a small 14 bp duplication within exon 17 of 
F8.  His sister (Patient 19) had also been investigated and was found to be a 
carrier of the same small duplication mutation.  When MLPA analysis was 
carried out on samples from these patients a reduction in the relative peak 
height was clearly seen for exon 17 due to the presence of the mutation within 
the sequence detected by the probe.  In the case of patient T3-9, previous 
mutation analysis had identified compound heterozygosity for two base 
changes.  One of the base changes within exon 30 of VWF (c.5200C>T) 
caused a reduction in the peak height for exon 30 due to the presence of the 
mutation within the sequence detected by the probe. In these three cases, the 
reduction of the peak height could be misinterpreted as a deletion, however the 
presence of these mutations had already been confirmed by other methods 
before MLPA was carried out.  In a normal routine diagnostic setting, indirect 
screening for deletions/duplications using MLPA would initially be carried out 
followed by the design of a direct assay. 
 
Although MLPA has proved to be a sensitive and robust method when 
performed to a high standard, it does have some limitations.  Compared to 
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conventional PCR, MLPA reactions are more sensitive to contaminants such as 
phenol, ethanol, heparin and guanidinium salts.  However the presence of 
contaminants will be readily detected as strongly reduced probe signals will be 
seen for the longer probes.  To overcome this problem it is possible to clean 
contaminated samples by ethanol precipitation or use smaller amounts of DNA 
in the MLPA reaction to reduce the number of impurities. 
 
Currently MLPA probe sets are available from MRC-Holland and to develop in-
house probe sets would be complicated, expensive and time-consuming.  Each 
probe requires primer design and preparation of a phage M13 clone, 
purification of its single-stranded DNA and subsequent digestion with expensive 
restriction endonucleases.  However it is possible to send in requests to MRC-
Holland for new probe mixes.   
 
MLPA does not have the ability to analyse single cells, such as in the case of 
FISH.  MLPA analysis will give the average copy number per cell in a DNA 
sample with a mixed cell population.  Therefore if DNA was extracted from a 
sample that contained less than 50% cancer cells, it would be difficult to detect 
deletions of a certain gene, which would be the case in tumour analysis. 
 
4.3 HAEMOPHILIA A PATIENTS  
In the present study, large deletions were confirmed by MLPA analysis in seven 
of the fourteen index cases investigated.  All of the large deletions had been 
previously identified through routine screening, however not all of the cases 
had direct assays designed to determine the breakpoints of the deletions 
identified.  MLPA was also applied to the definition of carrier status in five 
female patients (four were relatives of the index cases investigated). Two 
females (Patients 8 and 13) were confirmed to be carriers of the large deletion 
found in the index case, while the remaining three (Patients 6, 10, 19) were 
found to be negative for any large deletions/duplications. One severe female 
haemophiliac (Patient 16) was found to have a possible combined duplication 
and deletion event whereas her severe haemophiliac nephew (Patient 17) was 
found to be mutation-negative, however, there were issues with the sample 
quality in these cases as they were old (see section 4.3.1.3).  A small 
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duplication mutation previously found in one severe index case (Patient 18) and 
his sister (Patient 19) showed how this caused dropout of the MLPA probe 
signal for one exon (see section 4.2.5).  All four of the mutation-negative mild 
haemophilia A cases investigated showed normal gene dosage results by 
MLPA analysis and failed to identify the presence of any large deletions or 
duplications.   
 
4.3.1 Severe Haemophilia A patients 
In seven of the severe patients, deletions of 1 to 8 exons of F8 were identified.  
MLPA confirmed deletions of exons 16-22, 7, 15-22, 24-25, 24, 7-10, and 7-9 in 
patients 5, 7, 9, 11, 12, 14 and 15 respectively.  All of these deletions have 
been previously associated with a severe phenotype according to the 
HAMSTERs database, although not all of the patients in this study previously 
had the breakpoints of their mutations determined therefore it is not known 
whether some of them are exactly the same as those previously reported.   
 
4.3.1.1 Application of direct assays 
Prior to the introduction of MLPA, the mapping of breakpoints of large deletions 
allowed the development of direct screening assays to determine the carrier 
status of female relatives.  Patient 5 is an example of an index case who had 
previously had the breakpoints of his large deletion mapped which allowed 
carriership to be determined in his sister (see Results section 3.3.2.1).  Initial 
amplification of the essential regions of the gene had failed to amplify exons 16 
to 21. A long PCR was then designed utilising a primer pair which amplified 
exons 15 through to 22.  This produced a much smaller fragment than expected 
which indicated the presence of a partial deletion between introns 15-21.  DNA 
sequencing was performed on the smaller fragment across the breakpoint 
which confirmed the identity of the product and indicated that the deletion 
removed exons 16 to 21.  Long PCR encompassing exons 15 and 22 was then 
applied to his sister (Patient 6) which amplified the normal fragment and 
confirmed non-carriership of the large deletion.  MLPA analysis confirmed both 
of the previous results in these patients. 
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In the case of Patient 7, it had not been previously possible to confirm the 
carrier status of his mother (Patient 8) using routine screening methods.  Initial 
sequencing of F8 had failed to amplify exon 7 in Patient 7.  Repeat sequencing 
analysis indirectly confirmed this but as attempts to map this region failed a 
possible genotype of a suspected hemizygous deletion involving exon 7 was 
reported.  Carrier diagnosis for the mother was therefore not possible as the 
precise nature of the mutation had not been confirmed and the deletion would 
have been masked by the normal allele on the other chromosome.  MLPA 
analysis was able to confirm the exon 7 deletion originally identified by routine 
screening in Patient 7 and demonstrate its heterozygous presence in his carrier 
mother (see Results section 3.3.2.2) 
 
This was also the case for Patient 9 who had a large deletion spanning exons 
15-22.  A long PCR was performed using primers for exons 14-23 which 
produced a smaller truncated fragment than expected.  The boundaries of the 
deletion breakpoint were never mapped but the carrier diagnosis of his niece 
(Patient 10) was performed using the same primer pair.  The truncated product 
was not detected which was suggestive of non-carriership but this needed to be 
corroborated by a direct screening assay.  MLPA analysis confirmed the 
previous results for both patients and was an independent validation of MLPA 
results already obtained by the Sheffield Haemophilia service (see Results 
section 3.3.2.3). 
 
4.3.1.2 Determination of carrier status 
MLPA can be used to determine the carrier status in females when there is no 
index case available.  An example of this is Patient 13 who was the mother of a 
severe haemophiliac.  A deletion of exon 5 had been previously reported in her 
severe haemophiliac son.  Specific analysis had been previously carried out on 
Patient 13 and she was shown to be potential carrier for the familial deletion but 
this required corroboration by a direct assay (see Results section 3.3.2.6).  In 
this study, MLPA analysis was only performed on the mother as the sample for 
the son had been depleted.  The heterozygous deletion of exon 5 was 
demonstrated in the mother, consistent with carriership.  Disregarding the fact 
that the specific familial deletion had been previously determined, this 
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demonstrates that MLPA can reliably identify a large heterozygous deletion in a 
carrier in the absence of an index case.  It can also be used to identify sporadic 
haemophilia carriers where ‘de novo’ mutations arise in the male germ cells.  
This was illustrated in a study by Lannoy, Abinet et al. (2009) where two girls 
with isolated FVIII deficiency and no history of familial haemophilia A were 
found to carry two different large gene deletions.  They concluded that, in 
patients where evidence of inversion mutations involving intron 22 and 1 and 
point mutations have been eliminated, the presence of a F8 deletion should be 
investigated by MLPA analysis.   
 
4.3.1.3 Identification of large duplications 
Until recently, large duplications had been rarely identified as the underlying 
cause of haemophilia A.  This may have been due to the fact that whole-exon 
duplications were difficult to detect by PCR-based methods, but now with the 
development of MLPA, the presence of these rearrangements can be readily 
detected.  In this study, MLPA data obtained for Patient 16 were suggestive of 
the presence of a large novel duplication of exon 1-22 combined with a single 
deletion of exon 25.  Patient 16 (now deceased) was a severe female 
haemophiliac who may have been compound heterozygous for two 
haemophilia associated alleles which would correspond with the results 
obtained by MLPA.  Her father was a haemophiliac and her mother was an 
obligate carrier of haemophilia A, however the mutation mechanisms in both 
had never been investigated.  Interestingly, MLPA analysis for her severe 
haemophiliac nephew (Patient 17, also deceased) showed normal dosage 
quotients for all exons within F8, which confirmed the results previously 
obtained from the Newcastle haemophilia service (see Results section 3.3.2.9).  
Therefore the underlying genetic mechanism for the haemophilia phenotype 
within this patient was never identified.  In this case, the MLPA results obtained 
for Patient 16 were undermined by the MLPA results in the index case (Patient 
17).  Although the samples for both patients passed quality control, they had 
been taken more than 10 years before so the sample quality would have to be 
questioned.  The only way to resolve this case would be to repeat analysis on 
fresh samples, however as both patients were deceased this is not possible.  
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Samples obtained from living family members may possibly uncover the genetic 
mechanism within this family.   
 
It is predicted that many duplications will result in a frame-shift of the F8 mRNA 
and protein sequence if located in tandem orientation which is consistent with 
the severe phenotype of the disease (Rost, Loffler et al. 2008).  In the study by 
Rost et al. (2008), they detected seven novel large duplications and one 
recently described duplication of exon 13 within F8.  Large duplications have 
been reported for other genes and unequal crossing-over between Alu repeats 
had been described for the Duchenne/Becker muscular dystrophies 
(DMD/BMD) (Hu, Ray et al. 1991).  The intronic sequences of F8 are very rich 
in Alu repeats, especially introns 22 and 25.  It has now been illustrated by 
Zimmerman et al. (2010), that repetitive elements such as LINEs and SINEs 
are usually located close to the breakpoint of F8 duplications. 
 
4.3.1.4 Presence of large deletions and link with development of inhibitors 
Inhibitor development to the FVIII protein represents the major complication in 
patient care and can render classical substitution therapy ineffective. Inhibitor 
formation occurs at a frequency of 20-30% in severe haemophilia A, but is seen 
less frequently in mild and moderate cases.  The evaluation of inhibitor risk and 
management of individuals is vital to lower morbidity and mortality rates of 
haemophilia A.  Genetic factors such as particular types of mutations have 
been associated with a higher risk of developing an inhibitor e.g. intron 1 and 
22 inversions and a small percentage of large deletions which are estimated to 
occur in ~50% of severe haemophilia A patients (Miller, Benson et al. 2012) .  
The inhibitor status was determined for each index case in this study (apart 
from one deceased case which was unknown).  All of the severe haemophilia A 
patients had developed an inhibitor whilst the mild cases had not.  The 
prevalence of an inhibitor was 100% in those with a large deletion (7/7).  
Therefore results from this study corroborate the observation that the presence 
of a large deletion is a highly significant risk factor for the development of an 
inhibitor in severe haemophilia A (Oldenburg, El-Maarri et al. 2002).  This is 
because mutations such as large deletions result in the absence or severe 
truncation of the FVIII protein which indicates that a key motivator in inhibitor 
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development is the presentation of a novel antigen to the patient’s immune 
system (Oldenburg, Schroder et al. 2004).   
 
The only patient found to have a possible large duplication was a severe female 
haemophiliac with no history of inhibitor development.  It has been previously 
reported that patients with large duplications were also inhibitor-negative (Rost, 
Loffler et al. 2008).  In this study, inhibitor risk in patients with no mutation was 
0%, which is in agreement with a previous study which found a low inhibitor risk 
(~5%) in those without a mutation identifiable (Goodeve 2003).  
 
4.3.2 Mild Haemophilia A cases 
In all four mild haemophilia A cases investigated, FVIII:C levels had been 
reported as >5%, which occurs in 30-40% of cases of haemophilia A.  The fact 
that MLPA analysis did not detect any large deletions or duplications was to be 
expected, as it has been shown that large deletions are not generally 
responsible for the mild form of the disease.  A study by Bogdanova et al. 
(2007) investigated the spectrum of mutations and mutation detection rate in 
patients with mild and moderate haemophilia.  Through sequence analysis they 
found that the vast majority of mutations within mild/moderate cases of 
haemophilia A are represented by missense mutations.  In the mildly affected 
patients they accounted for ~76% of all cases, although other studies have 
shown that they can account for up to 86% (Schwaab, Oldenburg et al. 1995; 
Margaglione, Castaman et al. 2008; Castaman, Mancuso et al. 2009).  These 
mutations result in the production of an abnormal FVIII protein or its reduced 
synthesis and/or release into the circulation (Jacquemin, De Maeyer et al. 
2003).  Although the mutations are spread throughout the entire sequence of 
F8, they are predominantly found in the A2 (mainly exon 11 and the A2/B 
boundary) and C1 (mainly exon 23) domains.  Splicing errors were also found 
to be the cause of 9% of mild haemophilia A cases.  The mutation detection 
rate in the mild cases investigated in this study was ~88% compared to 
mutation detection rate in severely affected males which was >95% in the study 
by Bogdanova, Markoff et al. (2005).  Therefore analysis on the genomic level 
fails to detect the underlying molecular defect in up to 12% of mildly affected 
patients.  Other studies have been published recently which report similar 
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mutation detection rates (Citron, Godmilow et al. 2002; Cutler, Mitchell et al. 
2002; Liu, Nakaya et al. 2002; Habart, Kalabova et al. 2003).   
 
Specific variants of coagulation proteins that directly interact with FVIII such as 
VWF, FII, FIX and FX may affect the amount and function of FVIII.  In some 
cases mutations in VWF associated with the VWD variant type 2N, have an 
impact on the level of FVIII in the circulation and are responsible for the 
bleeding phenotype seen in these patients, indistinguishable from the one 
dependent upon mutations in F8 itself.  Both disorders display reduced levels of 
FVIII:C (~5-40 IU/dL) and normal-to-borderline-low levels of VWF.  Three of the 
four mild haemophilia A patients investigated in this study had also previously 
been screened for type 2N associated mutations.  All three were found to not to 
have any mutations associated with type 2N VWD therefore this theory could 
be excluded.  However for the fourth patient (Patient 1) this could possibly be a 
second line of investigation. 
In addition, variations in other proteins involved in folding, secretion, trafficking 
or stability of FVIII can lead to inherited bleeding disorders which could be 
mistaken for mild haemophilia A, such as F5F8D (see Introduction section 
1.4.3.2).  The combined F5F8D exhibits a mild to moderate bleeding tendency 
(Zhang and Ginsburg 2004).  It is completely independent of FV deficiency and 
FVIII deficiency and arises because of mutations in two genes (LMAN-1 and 
MCFD2).  F5F8D is extremely rare but has an increased frequency in 
populations where there is a high incidence of consanguineous marriages.  
Only one of the four mild haemophilia A patients investigated in this study 
(Patient 4) had FV:C levels measured which may have been carried out in 
relation to his ethnic origin.  Patient 4 had a FV:C level of 193 IU/dL which 
excluded the possibility of a F5F8D.  His brother (Patient 3) had no recorded 
FV:C level and this may have been based on the test results of patient 4. 
However this is another area for investigation to consider for patients with no 
detectable mutation. 
The fact that haemophilia A patients exist with no identifiable F8, VWF, or 
known loci involved in combined defects such as F5F8D indicates that there 
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are other unidentified loci that may be involved in the disease phenotype.  The 
four mutation-negative patients were all male, suggesting X-chromosomal 
inheritance.  Therefore the underlying genetic defect may be associated with 
the F8 locus itself or in some kind of localised interaction with F8 or the FVIII 
protein.  The location of these mutations could possibly be in regions which are 
not routinely scanned or that may be undetectable by current methods, in the 
patients in this study this encompasses both DNA sequencing of the essential 
regions of F8 and MLPA analysis  One theory is that some patients with no 
mutation identifiable in the coding sequence and proximal intronic regions could 
be affected by either distant intronic variations impacting on splicing efficiency 
or duplications of certain exons which may be detectable at the RNA level.  A 
mRNA-based approach has been adopted in studies attempting to uncover the 
mutations in severe haemophilia A patients with no detectable mutation (El-
Maarri, Herbiniaux et al. 2005; El-Maarri, Singer et al. 2006).  Apart from the 
discovery of rare mutations resulting in a lack of mRNA production, these 
attempts have shown disappointing results and this method has rarely been 
implemented in patients with mild haemophilia A (Castaman, Giacomelli et al. 
2010).  A recent study by Castaman and Tosetto (2011) investigated a number 
of mild haemophilia A patients in whom no F8 mutations had been identified 
and who also had a reduced biologic response to the infusion of desmopressin.  
In five of the six patients investigated, three different intronic mutations were 
identified after sequencing the introns associated with the observed F8 mRNA 
abnormality.  The mild phenotype was explained by the fact that mRNA 
evaluation indicated the presence of a normal mRNA transcript as well as the 
aberrant mRNA.  These variations were not identified in normal controls and 
were always present as heterozygous traits in the carrier female relatives of the 
patients.  The study showed that alternative pathologic mRNA splicing in mild 
haemophilia A may be caused by deep intronic point variations which are 
probably responsible for abnormal mRNA processing forming the basis of 
disease in these patients.  Therefore this should be considered for the small 
number of patients in whom no mutation can be identified although these 
aberrations need to be further characterised before they can be used in genetic 
diagnosis.   
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In these cases, MLPA would not be expected to detect the mutation as these 
different mutation mechanisms are not suited to the MLPA approach that has 
been adopted in this current study.  
 
4.4 VWD PATIENTS 
In total, twenty-six VWD patients were investigated by MLPA analysis in this 
study.  Ten of the twenty-six patients had been diagnosed with type 3 VWD and 
had undergone genetic investigation as part of a type 3 VWD study at the MDC.  
Seven of the ten type 3 VWD patients had been previously found to have the 
novel exon 4-5 deletion (c.221-977_532+7059del mutation) discovered in the 
study.  Three of the seven were also previously found to be compound 
heterozygous for the exon 4-5 deletion and another mutation.  MLPA confirmed 
the presence of the large deletion in all seven patients.  The remaining three 
patients without the large deletion had been previously found to have a small 
deletion, duplication, or point mutation.  MLPA analysis eliminated the presence 
of a large deletion in these three cases, however a small point mutation 
previously found in one patient (T3-9) illustrated how this caused dropout of the 
MLPA probe signal for one exon (see section 4.2.5).  Patient T3-9 had been 
previously found to show compound heterozygosity for two DNA single base 
changes (c.5200C>T and c.7730-3C>G).  Although neither of these VWF 
mutations have been previously reported, due to their nature they are highly 
likely to account for the severe VWD phenotype seen in this patient.  Therefore 
this patient would not be considered suitable for MLPA analysis, however they 
were included in the study to illustrate how a mutation underneath the MLPA 
probe can affect the probe signal. 
  
The remaining sixteen patients had been diagnosed with type 1 VWD and had 
been previously recruited into a UK national study of type 1 VWD for genetic 
investigation.  Two of the sixteen type 1 VWD patients had previously been 
identified to be heterozygous for the exon 4-5 deletion as part of the type 3 
VWD study.  This was confirmed by MLPA analysis in this study.  The 
remaining fourteen type 1 VWD patients had previously been found to have no 
causative mutation responsible for their phenotype.  No large deletions were 
identified by MLPA analysis in this group of patients. 
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4.4.1 Confirmation of the Exon 4-5 deletion in VWD patients 
Large deletions are considered to be a rare cause of VWD, which generally 
result in a complete absence of VWF protein (Schneppenheim, Castaman et al. 
2007).  So far, only twelve large deletions have been reported in association 
with type 3 VWD, varying in size from a single exon to the entire gene.  An 
additional large deletion has been described for type 2A, which spans all VWF 
A domains (www.vwf.group.shef.ac.uk).  The exon 4-5 deletion was first 
discovered by Sutherland et al. (2009) in a group of patients from the North 
West of England using direct sequencing of VWF at the genomic DNA level and 
of VWF mRNA derived cDNA.  In this study, MLPA analysis confirmed the 
presence of the exon 4-5 deletion in the same cohort of patients originally 
investigated in the type 3 study.   
 
4.4.2 Confirmation of heterozygosity for the exon 4-5 deletion  
Large deletions in VWF are easily identified in homozygous VWD patients by 
an absence of PCR products of the deleted fragment.  However conventional 
PCR methods cannot identify heterozygous large deletions in relatives due to 
the amplification of exons present in the normal chromosome.  Of the seven 
type 3 VWD patients found to have the deletion, three were found to be 
homozygous for the mutation, and the remaining four patients were 
heterozygous for the deletion.  Three of the four patients heterozygous for the 
deletion were also compound heterozygous for a second VWF mutation, which 
explained their type 3 VWD phenotype.  MLPA was clearly able to confirm the 
homozygous or heterozygous nature of the deletion in all of these individuals 
but did not identify compound heterozygosity for the second VWF mutation 
seen in some patients.  This validates one of the limitations of MLPA in that it is 
not suitable for identifying unknown point mutations.  Therefore in the case of 
compound heterozygosity for a large deletion and a point mutation, both direct 
sequencing and MLPA analysis would be required in order to determine the 
underlying genetic defect in a patient.   
 
4.4.3 Confirmation of the exon 4-5 deletion in type 1 VWD patients 
Sutherland et al. (2009) had investigated the possibility of the occurrence of the 
exon 4-5 deletion in type 1 VWD.  This was due to the high overall frequency of 
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the deletion mutation in the type 3 VWD cohort, and the fact that heterozygosity 
for this mutation may not be identified by conventional analysis at the genomic 
DNA level.  The two index type 1 cases (T1-3 and T1-23) identified as being 
heterozygous for the exon 4-5 deletion were chosen for investigation by MLPA 
in this study.  Of the two cases one was heterozygous for the mutation (T1-23) 
whilst the other was compound heterozygous for a second VWF mutation (T1-
3).  MLPA confirmed the heterozygous nature of the deletion in both individuals 
but did not identify compound heterozygosity for the second VWF mutation 
seen in patient T1-3.   
 
The fact that the exon 4-5 deletion was identified in both type 1 and type 3 
VWD patients is unusual as both types have different inheritance patterns and 
genetics.  Type 3 is inherited in an autosomal recessive manner and VWF 
mutations are usually present in the homozygous or compound heterozygous 
state in individuals with the disease phenotype.  Individuals with heterozygous 
mutations are usually asymptomatic. However it has been reported that when 
certain mutations associated with type 3 VWD are inherited in the heterozygous 
state, they have the ability to reduce plasma VWF levels to those consistent 
with a type 1 VWD phenotype (Anvret, Blomback et al. 1992; Schneppenheim, 
Krey et al. 1994; Zhang, Blomback et al. 1994; Lethagen, Isaksson et al. 2002).  
Expression studies (peformed by Mackenzie Bowman, Queen’s University, 
Kingston, Canada) indicate that heterozygosity for the exon 4-5 deletion leads 
to defective multimerisation and decreased secretion of the mutant VWF 
protein produced, resulting in a marked reduction in normal VWF multimers 
present in the circulation.  This would be consistent with the phenotype seen in 
the two type 1 VWD index cases studied and supports the theory of a 
dominant-negative effect of the deletion and its association with type 1 VWD 
(Sutherland et al. 2009).  
 
4.4.4 Overview of the exon 4-5 deletion  
All of the individuals found to have the exon 4-5 deletion were of British 
Caucasian origin.  Haplotype analysis by Sutherland et al. (2009) demonstrated 
that in the majority of cases the deletion originated from a single founder event 
which originated in Britain. However there was evidence for at least one 
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independent occurrence or a possible recombination event.  Therefore 
combined with the proposed mechanism for the deletion (see Introduction 
section 1.14.3), it is possible that the exon 4-5 deletion may not be confined to 
British Caucasians (Sutherland et al. 2009).  A recent study by Bowman et al. 
(2013) investigated the mutational spectrum of a cohort of Canadian type 3 
VWD patients.  They identified one index case as being homozygous for the 
exon 4-5 deletion, which they confirmed using the deletion-specific PCR 
described by Sutherland et al. (2009) and MLPA.  They also found that two 
family members enrolled in the study, a sibling and mother, diagnosed with type 
1 VWD were heterozygous for the exon 4-5 deletion.  Analysis of the haplotype 
of these individuals was found to be different than the common haplotype 
reported in the UK population (Sutherland et al. 2009).  Likewise, in the 
Canadian and European type 1 VWD studies, no common haplotype was found 
between individuals with the same mutations (Goodeve 2007; James, Notley et 
al. 2007).  Another founder mutation which has been identified in type 3 VWD is 
the single cytosine deletion in exon 18 of VWF (c.2435delC) which has been 
shown to be prevalent in the Swedish and Dutch populations due to its 
mechanism (Eikenboom, Ploos van Amstel et al. 1992; Zhang, Falk et al. 1992; 
Zhang, Blomback et al. 1993; Zhang, Blomback et al. 1994).   
 
MLPA is ideally suited to the detection of large deletions such as the exon 4-5 
deletion, once point mutations have been eliminated, however mutations such 
as the single cytosine deletion will be unsuitable for detection by MLPA.  The 
current probe kit for VWF does not distinguish it, therefore a specific MLPA 
probe would have to be developed in order to identify the mutation. 
 
4.4.5 Type 1 VWD with no causative mutation 
MLPA analysis of the fourteen remaining type 1 VWD patients failed to identify 
any large deletions within VWF that may have been responsible for the 
molecular pathogenesis of their disease.  This was to be expected as large 
deletions are considered to be a rare cause of VWD and are more usually 
associated with an autosomal recessive mode of inheritance, meaning that 
individuals heterozygous for such deletions are likely to be asymptomatic.  This 
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meant that overall no causative VWF mutation had been found to account for 
the type 1 VWD phenotype present in these patients.   
 
Previous DNA sequencing studies had identified VWF polymorphisms in nine of 
the fourteen type 1 VWD patients.  The highly polymorphic nature of VWF could 
potentially lead to defective binding of one or more MLPA probes to their target 
sequences, causing a reduction in probe peak height which could be 
misinterpreted as a deletion (see section 4.2.5).  The VWF polymorphism 
p.Tyr1584Cys, a missense mutation c.4751A>G in exon 28, had been 
previously identified in four of the nine patients.  This was not found to have an 
effect on the peak height of the probe for exon 28 and therefore its presence 
was not evident by MLPA.  In the remaining five patients it was difficult to 
ascertain whether some of the putative VWF polymorphisms identified by DNA 
sequencing in some of the patients had an effect on probe height.  This was 
due to the fact the majority of the exons in which they were present were part of 
the VWF kit 2 which consistently failed for these patients. 
 
In type 1 VWD, approximately 75% of mutations are missense, some of which 
may result in single amino acid substitutions with a dominant negative effect 
that may interfere with the intracellular transport of VWF subunits, leading to a 
reduction in VWF secretion ((Haberichter, Castaman et al. 2008).  Recent 
studies have identified other mutations that result in the rapid clearance of VWF 
from the circulation.  In the case of these mutations, VWF is synthesised and 
secreted normally but is removed from the circulation more quickly than 
expected (Sztukowska, Gallinaro et al. 2008; Sadler 2009).  The impaired 
secretion and increased clearance are most likely the common molecular 
mechanisms that lead to type 1 VWD. 
 
As indicated above, the majority of point mutations would not be routinely 
detected by MLPA and the application of the method should only be employed 
after elimination of point mutations by DNA sequencing.  Exceptions may 
include the application of MLPA to the detection of known deletions prevalent in 
local populations, such as the exon 4-5 deletion discussed. 
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Type 1 VWD accounts for more than 70% of VWD cases and is regarded as 
the most frequent form of VWD.  However due to a number of factors, it is not 
unusual that in many cases a causative VWF mutation is not found to account 
for the type 1 VWD diagnosis.  A number of environmental factors such as age, 
stress and pregnancy can lead to variations in VWF levels as well as genetic 
modifiers at loci away from VWF, such as ABO blood group (Ginsburg and 
Bowie 1992; Ginsburg 1999; Keightley, Lam et al. 1999; Levy and Ginsburg 
2001; Laffan, Brown et al. 2004).  In this study, eleven of the fourteen patients 
with no causative mutation identified were of blood group O (see Results, Table 
3.5).  If individuals are blood group O with the polymorphism p.Tyr1584Cys as 
in the case of patients T1-16, T1-19 and T1-25, this may lead to decreased 
VWF levels and increased susceptibility to bleeding (Bowen 2003; O'Brien, 
James et al. 2003; Bowen, Collins et al. 2005; Bowen and Collins 2006).  The 
other polymorphisms previously identified in the type 1 VWD patients (see 
Results, Table 3.5) including p.Arg924Gln, c.5834-8C>G, p.Gly2705Arg, 
p.Val1850Met, c.5170+10C>T, p.Asp141Gly and p.Thr2647Met are not thought 
likely to directly cause the disease phenotype in these patients as they did not 
segregate with the disease in the families in the initial study (Cumming, Grundy 
et al. 2006; Hickson, Hampshire et al. 2010).  Although, it has been reported 
that the presence of the polymorphism p.Arg924Gln will result in a reduction in 
VWF levels, especially if in association with blood group O, however single 
inheritance of this polymorphism may be insufficient for VWD diagnosis 
(Hickson, Hampshire et al. 2010). 
 
Therefore in conclusion, type 1 VWD is a disorder that is likely to be influenced 
by genetic modifiers for which the current MLPA approach is not suited.  MLPA 
analysis has not made a significant contribution to identifying the underlying 
genetic defect within this group of type 1 VWD patients, and further 
investigations would need to be carried out to reveal the pathogenic 
mechanisms associated with their disease.  Genome wide linkage could 
possibly be used to identify genetic loci away from VWF itself that influence 
VWF:Ag levels. 
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4.5 MUTATION DETECTION STRATEGIES – THE ROLE OF MLPA 
The molecular diagnosis of both haemophilia A and VWD follow practice 
guidelines that have been written by the UKHCDO.  MLPA is a technique which 
has been recommended to be used in addition to gold standard techniques 
already employed to overcome any limitations they may have.  This study was 
carried out in order to assess how MLPA will fit into the currently used mutation 
screening protocols for both haemophilia A and VWD within the MDC. 
 
4.5.1 Proposed Mutation Screening Algorithm incorporating MLPA for 
Haemophilia A and VWD 
4.5.1.1 Haemophilia A 
The severity of the haemophilia A in the family determines the diagnostic 
strategy which is applied.  Severe haemophiliacs are first screened for the F8 
intron 22 inversion mutation followed by the F8 intron 1 inversion mutation 
which should identify the underlying mutation in 45-50% of patients.  The 
remaining severe haemophilia A families should then have full mutation 
analysis of F8 carried out.  As a common mutational mechanism is not 
associated with mild or moderate haemophilia A, full mutation analysis is 
required in all cases. 
 
The gold standard for mutation detection in affected males, or in obligate carrier 
females where an affected male is not available, is DNA sequencing.  Although 
DNA sequencing has a very high level of sensitivity, a small proportion of 
patients have a mutation which lies outside of the regions being analysed which 
will go undetected.  The current DNA sequencing strategies have been shown 
to detect mutations or candidate mutations in 98% of severe haemophilia A 
males (Klopp, Oldenburg et al. 2002).  However, approximately 2-18% of 
patients overall have not been found to have a causative mutation (Oldenburg, 
Ivaskevicius et al. 2001; Jayandharan, Shaji et al. 2005; Bogdanova, Markoff et 
al. 2007).  Some of these cases may have mutations which are located deep 
within introns and therefore may only be detectable at the RNA level (Bagnall, 
Waseem et al. 1999) or be mediated by mutation mechanisms yet to be 
explained (El-Maarri, Herbiniaux et al. 2005).  DNA sequencing may also miss 
mutation events such as sequence duplications (Acquila, Pasino et al. 2004; 
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Rost, Loffler et al. 2008) and heterozygous large deletions where a female 
carrier is used for initial mutation screening.  Therefore if no mutation is 
identified through sequencing, MLPA should be performed in order to detect the 
presence of possible large deletions/duplications responsible for the disease 
(see Figure 4.1).  Large deletions are associated with an increased risk for the 
development of inhibitors, therefore the introduction of MLPA will also help to 
classify a higher proportion of those at high risk, should it identify deletion 
mutations that were masked previously.  Following positive identification of a 
large deletion/duplication, results from the initial assay should always be 
confirmed by repeat testing with an independent method where this is possible.  
For those with no mutation identified, further investigations such as mRNA 
analysis may be carried out. 
 
Figure 4.1: Mutation screening algorithm incorporating MLPA for 
haemophilia A patients 
 
 
 
Severe Haem A patients/? Carrier 
females 
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F8 gene intron 1 and 22 inversion testing  
Positive  Negative 
F8 Full Gene Screen  
Positive  Negative 
MLPA 
Positive Negative 
Confirmatory testing Further studies 
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4.5.1.2 VWD 
The classification of VWD is initially based on clinical and phenotypic data, 
which is fundamental to the investigation of the disorder.  Genetic testing is not 
always required in VWD and varies for the different VWD subtypes e.g. Type 2 
requires screening of specific functional domains represented by exons 18-20 
and exon 28. In type 3 VWD, genetic testing is beneficial due to the severe 
bleeding phenotype and autosomal recessive pattern of inheritance.  No 
universal mutation hotspots have been identified in type 3 VWD, therefore 
mutation analysis is carried out by direct DNA sequencing of the essential 
regions of VWF.  Mutation pre-screening methods are not useful in VWD 
analysis due to the highly polymorphic nature of VWF which can result in 
unnecessary sequencing of amplicons (Hashemi et al. 2007).  If no mutations 
are identified through sequencing, or if a patient appears to be homozygous for 
a given mutation, the prospect of an insertion, rearrangement or whole or 
partial gene deletion on the other VWF allele should be taken into account.  As 
in the case of haemophilia A, MLPA should then be performed in order to 
detect the presence of possible large deletions, with positive results confirmed 
by an independent method, where possible.  Further studies may be required 
for mutation-negative cases (see Figure 4.2). 
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Figure 4.2: Mutation screening algorithm incorporating MLPA for VWD 
patients 
 
 
 
4.6 CONCLUSIONS AND FUTURE WORK 
The results of this study show that MLPA, once it has been optimised within the 
laboratory, can be applied to the investigation of large deletions/duplications in 
haemophilia A and VWD patients and that the method can be easily 
incorporated into a diagnostic genetic screening service.  MLPA provides a 
streamlined approach to the identification of genetic variants which previously 
were either difficult to detect or were masked and allows for a more 
comprehensive explanation of the molecular pathogenesis of the disease in a 
greater number of index cases.  However some cases still remain unexplained 
following extensive mutation analysis which suggests that there may be 
undetermined mechanisms underlying a small number of cases or possible 
misdiagnosis.   
 
In haemophilia A, for the small number of cases in whom no mutation can be 
identified, the bleeding phenotype may be explained by mutations in VWF that 
affects the level of FVIII in these patients (type 2N VWD), which produces a 
disease phenotype which is very similar to the one reliant on mutations in F8 
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itself.  Also mutations within the LMAN1 and  MCFD2 genes result in combined 
FVIII and FV deficiency and produce a FVIII deficiency phenotype (Zhang, 
McGee et al. 2006).  However in haemophilia A cases where no relevant 
mutations can be identified in F8, or implicated loci including VWF, LMAN1 and 
MCFD2, suggests that the underlying genetic mutations or modifiers are either 
located in regions that are yet to be identified or are of a type that has not been 
identified.  It has been shown that deep intronic point variations which are 
probably responsible for abnormal mRNA processing may form the basis of 
disease in a proportion of these patients.  Therefore future work should 
consider mRNA studies in these patients or potentially using next generation 
sequencing techniques to sequence all intronic and exonic regions for 
mutations that might lie deep within the introns or to identify further loci which 
may modify FVIII levels in these individuals.  This would require further 
characterisation before being considered for genetic diagnosis.   
 
MLPA kits are also available for the factor 9 gene (F9) and therefore would be 
useful for identifying deletions/duplications responsible for haemophilia B.  The 
number of haemophilia B investigations performed by the MDC is lower and to 
date no patients investigated for the presence of F9 mutations have had 
unexplained phenotype at the genetic level.  If there was a requirement for this 
within the genetic service at the MDC it would be very easy to set up this assay 
as the only difference would be the probemix and therefore would only require 
validation of results. 
 
Carrier and prenatal diagnosis are often requested in families of haemophilia A 
and type 3 VWD.  Once a large deletion/duplication has been characterised in 
an individual by MLPA, a direct assay can be designed in most cases, if the 
breakpoints of the mutation have been established.  Further work is required for 
some haemophilia A patients in this study to characterise their deletions by 
breakpoint mapping and develop specific assays for use within their families.  If 
the mutation has not been characterised in a particular family, by all methods 
available then segregation analysis using polymorphic markers may be 
considered (Hallden, Knobe et al. 2012).  However, these assume linkage to 
the gene and cannot be employed in sporadic cases.  
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In type 3 VWD, a causative VWF mutation(s) can be identified in the majority of 
cases to account for the bleeding phenotype, however there are cases when 
the phenotype cannot be fully explained by the genotype using conventional 
DNA screening methods.  It has been shown by Sutherland et al. (2009) that 
RNA analysis methods may be used to identify aberrant splicing events or large 
heterozygous deletions which are masked during DNA analysis.  The novel 
exon 4-5 deletion mutation was identified and found to cause type 3 VWD, 
when inherited in homozygosity or compound heterozygosity, and type 1 VWD 
when inherited in heterozygosity (Sutherland et al. 2009).  The MLPA technique 
was successfully employed to detect this large deletion in both VWD subtypes.   
However, there are cases of type 3 VWD where the genetic cause remains 
unclear.  This could point to unexplained underlying mechanisms such as 
apparently silent sequence variations in VWF located outside of consensus 
splice sites that disrupt the normal VWF mRNA splicing, deep intronic 
mutations or distant regulatory elements outside of VWF.  In some cases it may 
even suggest a revision of diagnoses based on historical phenotypic data which 
may be inaccurate.  Future work involving expression studies or whole gene 
sequencing in these individuals may enable the fully comprehensive 
understanding of the molecular basis of type 3 VWD. 
 
The causative molecular defect in type 1 VWD underlying the disorder is 
unknown in a significant number of cases and even in those cases where a 
causative VWF mutation is known, the associated molecular pathology is not 
necessarily understood.  MLPA analysis did not detect the presence of 
heterozygous large deletions in this cohort of patients (apart from the exon 4-5 
deletion previously identified in 2 index cases), therefore failing to further 
elucidate the underlying genetic defect in these individuals.  This supports the 
principle that there is limited clinical use for genetic diagnosis in type 1 VWD 
(Keeney and Cumming 2001; Keeney, Bowen et al. 2008).  Future work to 
further understand the molecular basis of type 1 VWD may involve genome 
wide linkage analysis to search for modifying genes or factors away from the 
VWF locus that affect VWF levels.  
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This project has evaluated the application of MLPA in a diagnostic setting for 
the bleeding disorder service covering the North West (NW) of England.  This 
has shown that it can be considered to be a useful diagnostic tool when 
conventional mutation screening has failed to identify a causative mutation, as 
long as its limitations are understood and where possible it is not relied upon 
solely.  
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Appendix 1: SALSA MLPA P178-B1 F8 Probemix 
Length SALSA MLPA probe Chromosomal position 
64-70-76-82 Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA 
88-92-96 D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation 
100 X-fragment: Specific for the X chromosome 
105 Y-fragment: Specific for the Y chromosome 
   
136 Reference probe 07103-L14743 Xp22.11 
142 F8 probe 05610-L05060 Exon 1 
148 F8 probe 05618-L0568 Exon 7 
154 F8 probe 05627-L06055 Exon 14 
160 F8 probe 05633-L05083 Exon 20 
166 Reference probe 02927-L03721 Xq27.3 
172 F8 probe 05612-L05062 Exon 2 
179 F8 probe 05619-L14947 Exon 8 
186 F8 probe 06290-L17545 Exon 6 
191 F8 probe 05626-L17546 Exon 14 
197 F8 probe 05634-L17547 Exon 21 
202 Reference probe 13203-L14524 Xq13.1 
209 F8 probe 05611-L17548 Exon 1 
215 F8 probe 05620-L17549 Exon 9 
221 F8 probe 06288-L05892 Exon 5 
229 F8 probe 05641-L05091 Exon 27 
238 Reference probe 06910-L06490 Xq22.1 
247 F8 probe 05617-L05067 Exon 7 
256 F8 probe 05621-L05071 Exon 10 
265 F8 probe 05628-L05078 Exon 15 
274 F8 probe 07044-L05899 Exon 12 
283 Reference probe 06035-L05490 Xq13.1 
292 Reference probe 02920-L02314 Xp21.3 
298 F8 probe 05614-L05891 Exon 4 
305 F8 probe 06287-L06058 Exon 11 
313 F8 probe 06506-L06340 Exon 3 
319 F8 probe 05629-L05079 Exon 16 
328 F8 probe 05637-L05087 Exon 24 
337 Reference probe 02932-L02323 Xq28 
346 Reference probe 05125-L04515 Xq26.2 
355 F8 probe 05623-L05893 Exon 12 
364 F8 probe 05630-L05080 Exon 17 
372 F8 probe 14164-L15766 Exon 25 
382 Reference probe 02908-L02302 Xq23 
391 F8 probe 07045-L05898 Exon 22 
400 F8 probe 05624-L05074 Exon 13 
409 F8 probe 05631-L05081 Exon 18 
418 F8 probe 13707-L15181 Exon 26 
APPENDICES 
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426 Reference probe 13207-L14528 Xp11.3 
434 Reference probe 13118-L15558 Xq21.2 
444 F8 probe 05613-L14948 Exon 3 
452 F8 probe 05625-L14949 Exon 14 
460 F8 probe 05632-L14950 Exon 19 
468 F8 probe 13708-L15182 Exon 27 
476 Reference probe 01391-L01039 Xp21.1 
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Appendix 2a: SALSA MLPA P011-B1 (Kit 1) VWF Probemix 
Length SALSA MLPA probe Chromosomal position 
64-70-76-82 Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA 
88-92-96 D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation 
100 X-fragment: Specific for the X chromosome 
105 Y-fragment: Specific for the Y chromosome 
   
124 Reference probe 09176-L09350 17q11 
130 VWF probe 11314-L12040 Exon 5 
136 VWF probe 11332-L12057 Exon 39 
141 Reference probe 10301-L10813 11q14 
148 VWF probe 11335-L12060 Exon 45 
154 VWF probe 11325-L12050 Exon 24 
160 VWF probe 11330-L12055 Exon 36 
169 VWF probe 11321-L12046 Exon 14 
178 VWF probe 11339-L12064 Exon 50 
185 VWF probe 11328-L12053 Exon 33 
195 Reference probe 10375-L12864 9q34 
202 VWF probe 11320-L12045 Exon 13 
208 VWF probe 11331-L13985 Exon 38 
214 VWF probe 11319-L12044 Exon 9 
226 VWF probe 11324-L12049 Exon 23 
232 VWF probe 11338-L12063 Exon 49 
238 Reference probe 10137-L10599 18q11 
247 VWF probe 113226-L12051 Exon 26 
256 VWF probe 11334-L14242 Exon 43 
265 VWF probe 13422-L14877 Exon 2 
274 VWF probe 11336-L12061 Exon 46 
283 VWF probe 11329-L12054 Exon 34 
301 Reference probe 09986-L10445 7q22 
310 VWF probe 11316-L12042 Exon 6 
319 VWF probe 11333-L12058 Exon 42 
337 VWF probe 13423-L14878 Exon 2 
346 VWF probe 11322-L12047 Exon 18 
355 VWF probe 11318-L12043 Exon 8 
364 VWF probe 11323-L12048 Exon 20 
373 Reference probe 10718-L11300 6p12 
383 VWF probe 11327-L12052 Exon 28 
391 VWF probe 13426-L14881 Exon 47 
400 Reference probe 08949-L09044 4q32 
409 Reference probe 10053-L10477 8q22 
418 VWF probe 11340-L12065 Exon 52 
426 VWF probe 11315-L12041 Exon 6 
434 Reference probe 10876-L11546 15q12 
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Appendix 2b: SALSA MLPA P012-B1 (Kit 2) VWF Probemix 
Length SALSA MLPA probe Chromosomal position 
64-70-76-82 Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA 
88-92-96 D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation 
100 X-fragment: Specific for the X chromosome 
105 Y-fragment: Specific for the Y chromosome 
   
124 Reference probe 09176-L09350 17q11 
130 VWF probe 11346-L12071 Exon 12 
136 VWF probe 11362-L12087 Exon 40 
148 VWF probe 11355-L12080 Exon 28 
154 VWF probe 11356-L12081 Exon 29 
160 VWF probe 11359-L12084 Exon 32 
172 VWF probe 11352-L12077 Exon 22 
178 VWF probe 11354-L12079 Exon 27 
184 VWF probe 11350-L12075 Exon 19 
193 Reference probe 03861-L03244 3p24 
202 VWF probe 11366-L12091 Exon 51 
208 VWF probe 11363-L12088 Exon 41 
215 VWF probe 11342-L12067 Exon 4 
223 VWF probe 12799-L14243 Exon 37 
232 VWF probe 11341-L12066 Exon 1 
238 Reference probe 08951-L09046 4q32 
247 VWF probe 11351-L12076 Exon 21 
256 VWF probe 11349-L12074 Exon 17 
265 Reference probe 08345-L08277 17q21 
274 VWF probe 11358-L12083 Exon 31 
283 VWF probe 11364-L12089 Exon 44 
292 VWF probe 13425-L14880 Exon 47 
301 Reference probe 09986-L10445 7q22 
310 VWF probe 11344-L12069 Exon 10 
322 VWF probe 11353-L12078 Exon 25 
328 VWF probe 11348-L12073 Exon 16 
337 Reference probe 10376-L10928 9q34 
346 VWF probe 11360-L12085 Exon 35 
355 VWF probe 11365-L12090 Exon 48 
364 VWF probe 11347-L12072 Exon 15 
373 Reference probe 06745-L06349 8q12 
382 VWF probe 11343-L12068 Exon 7 
391 VWF probe 11357-L12082 Exon 30 
400 Reference probe 10174-L10922 18p11 
409 Reference probe 09893-L10306 16p13 
418 VWF probe 11345-L12070 Exon 11 
427 VWF probe 06683-L06261 Exon 3 
434 Reference probe 11665-L12432 14q24 
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Appendix 3: VWF sequence with probe locations 
Partial sequence (20 nt adjacent to ligation site) of the VWF MLPA probes are 
indicated for the 52 exons of VWF. 
 Key 
 Exons – red text 
MLPA probes adjacent to ligation site – highlighted in green and 
pink 
 
        E1 
 
CTCAACTTCC CTGGAGTCCA GCCCTGGAAG CTGGATCAGG AAGCTGTGTT GTTCTACTGT 
GATTCCCCCT GGCCTGTATC AGCTTGCCCT GAAACAACCA GCATTCCTGG TTATCCCACA 
CAGGTGGGGC ACTCTAGGAA GACCAGGGAT CAAGTGTGGG GGTGTAGGGA TAGGGGGTGT 
TTGGGGAGGG CAAGGCAGTT AATTAAGGCA GCTGCCAGGA GGTCTCCCTC CAAACTCTAC 
AAAGCTTTAT CAGCTTGGAG GTACTTCTAA TACCATTTCC TTTCATTGTT TCCTTTTGGT 
AATTAAAAGG AGGCCAATCC CCTGTTGTGG CAGCTCACAG CTATTGTGGT GGGAAAGGGA 
GGGTGGTTGG TGGATGTCAC AGCTTGGGCT TTATCTCCCC CAGCAGTGGG GACTCCACAG 
CCCCTGGGCT ACATAACAGC AAGACAGTCC GGAGCTGTAG CAGACCTGAT TGAGCCTTTG 
CAGCAGCTGA GAGCATGGCC TAGGGTGGGC GGCACCATTG TCCAGCAGCT GAGTTTCCCA 
GGGACCTTGG AGATAGCCGC AGCCCTCATT TGCAGGGGAA GGTATGGCCT TTGGAAGGAG 
AGCTGGCTCA GTTGTGGGAG GAAGATGCAG GACTGACTGA TCCCTGCTCC TGGGGAGCTG 
GAGTTCTCTG TCGCTGGACT AGAAGGGCTT TGTTTGGAGG GGCAATTCAA TTCAGCCAGG  
 
 
E2 
 
TGAGGCCCAG CGGGCCTGGA GGGAAGGCAG CGTTTTCCTC CTGTCTTGGG CCTGGGACTG 
CTGTCTGTGG AAAGGTGCCC ACAGGTCCCA GCTCACAGCG ATTGTTACCC TTGGGCCTGG 
CACTGGCCAG GGGTTTTTTC GGGGGCCAGA AGTCCATGTT CAAAGGGGAA AAGGGGGTCA 
CGAGGATCAA TCTTTTCTCC TGCTTTAAAG AAATGTTTTT GCTACTGCAT GCCCTGATAG 
TCGCCACACC AGCAGCCGCC TACCTGGGCA GCAATGACCA GCTCACGTCT CTTGCTTCTT 
TGCAGATGAT TCCTGCCAGA TTTGCCGGGG TGCTGCTTGC TCTGGCCCTC ATTTTGCCAG 
GTAGGTACAA AAGGGCCTCC ATTTCTCATT CCTGCCCCAG GGCCATCTGG AGTGACACCT 
TTCCGGGAAT CAGCAGGTGT GTCTGGAGCT CACCTGTGTG CCCAGCCCTA ACTTAGGCTG  
 
 
E3 
 
CAGCCCAGTT TCTATCAGAG GCAGTCTAAT TTCTACGAGG CCAGAGAGGT TTGAGCTGAT 
GGTCCCAGTT GTGCCCTGAG ATCACCAGCC CAACCTGTGG CCTCTCCCTC CAGGGACCCT 
TTGTGCAGAA GGAACTCGCG GCAGGTCATC CACGGCCCGA TGCAGCCTTT TCGGAAGTGA 
CTTCGTCAAC ACCTTTGATG GGAGCATGTA CAGCTTTGCG GGATACTGCA GTTACCTCCT 
GGCAGGGGGC TGCCAGAAAC GCTCCTTCTC GATTATTGGT GAGTTCTGGG CACTGCAGGG 
AGGACTTCAG AGGGAGGGCT GGCTGAGCTC AGCCCTGGTG TGGGGGAGGA TTCCTGCTCT 
CAGGACAGTG TCTGAGTGGA AAGGTCACTG CTGAGAACAA GGAGAGGAAC AGCCTTTCTG 
TGACACGTAG CCCCTCTTGG CTTTCCCCGG GTCTCTCCCC ACGGGAGCCG GGTGGGATGG 
ATGAAGAGAG TCTTCATCTT TGGTAGTCCA CTGTGTCCGT TGCTCTGGGG CCCGGCGATG 
CCCTGGGAAC TCCACAGCAT CAAGGCAAAT GATGAACTAG AGAAGGTGCT TTGGAACGTG 
TAAAACTCCT TGCCAGAGAG AAGACTCGTT GTTGTTTTCT TGGTGGCCTG TGGATCAGAA  
 
 
 
 
 178 
E4 
 
TTTAGATGAA TGGAAAAATG GGTGAGAAAA TGAGATTTTT AGGGAGATTT TTGTTGCTCG 
CTTGTAAAGA CTTTTTGGGG CGTTTTCTGC TGAGAAAAGG TTACGTAGAT AATGATTCTT 
AATCAATGTA TTCATTTTTT GAGAGGAGTA ATAATCACTA CTATTGACTT TTTTCTCTTT 
CAGGGGACTT CCAGAATGGC AAGAGAGTGA GCCTCTCCGT GTATCTTGGG GAATTTTTTG 
ACATCCATTT GTTTGTCAAT GGTACCGTGA CACAGGGGGA CCAAAGGTAA GCCAACAATG 
TCTGAGTTAG AAAGGACCCT AGGGATCCCC TGACACAACC CCCTCATTTT TAGATGAGGA 
AGCTGGGGCC CAGAGAATGG AAGCAAATGT TCCAAGGAAG TGAGTAGCAG GGCTGGGTGA  
 
E5 
 
CCTCAGCCAC TTTGCACCAT GTTCTGAACC CTACAACATG GGGTTGGGGT TAGAAGGTGG 
GAGAGACATC CAGAAAATGC ACAAGAAGCC CACTTCTGAA CTTAGCCTTT GCCCTCCAGA 
GTCTCCATGC CCTATGCCTC CAAAGGGCTG TATCTAGAAA CTGAGGCTGG GTACTACAAG 
CTGTCCGGTG AGGCCTATGG CTTTGTGGCC AGGATCGATG GCAGCGGCAA CTTTCAAGTC 
CTGCTGTCAG ACAGATACTT CAACAAGACC TGCGGGCTGT GTGGCAACTT TAACATCTTT 
GCTGAAGATG ACTTTATGAC CCAAGAAGGT AAGATGTTCT GGGATACCAT TTCCCTAAAG 
TGTGGCCATG CTTTTTATTT CCTTGCTCAT AAACCTTCAC TAACATGCCT TCCCTGGCAT 
TCAAGCCTCA CTGTGACCTC ACCTCAATTT ATGTTGCCAA CCTTATCTCT TTGCATTCCA  
 
 
E6 
 
AGAGATGGGT CAAGTCAAAA CTCCTGTGCT GCTCAGTAGT GGGATTGCAC TTGTGAATAG 
CCGCTGCACT CCAGCCTGGG AAACATAGCC AGACCCTGTC TCTTTATAAA AAATTAAAAC 
AAAACACACA AAACCACCAG CAGACCTAGA ATTTTCACCC AGAAGTTCTG GGACAGGCAT 
AACTGAAGCA TTACTTTCCT GAAACTTTCC TCCACAGGGA CCTTGACCTC GGACCCTTAT 
GACTTTGCCA ACTCATGGGC TCTGAGCAGT GGAGAACAGT GGTGTGAACG GGCATCTCCT 
CCCAGCAGCT CATGCAACAT CTCCTCTGGG GAAATGCAGA AGGTGGGTGT GGACTGGCCT 
GGGTGCACCT GGATGGTGTG TGATTTCTGG ATCTAAAAGA CAGAAGGACT CAGTCTCATA 
TCCTTCCATC TGGGGGAGGA ATGGACTTAC GCAGGGCCAT TTCCTCCAAA ACTAACTGTG 
GCTAGAGTCT AATTCTAATA CATCTCGAGC CTGAAGCTCT AAAAATGAGT CTGGGCTAAT 
GACTTGGTGT AGTGTCTCAG TCCATTTGTG CTGCTATAAC AAATGCCTGA GACTGGGTAA 
TTTTAAGGAA CATAAATTAT CTTTTATAGT TCTGGAGGCT AGGCAGCCCA 
 
 
E7 
 
TGGTGCATTG AACACATGCA TGTGCTTGGT GCCAGCCTGT CCCAGGTGCT GAGGGAGCTG 
CCTTGGTTTC CCTAGCAGGG CTAAGTCTCA GTGCCACACT CAGGGAGACA CTAACGGAGC 
ATACCGCTGA GGCGGCCCCT CTTCCTGCAG GGCCTGTGGG AGCAGTGCCA GCTTCTGAAG 
AGCACCTCGG TGTTTGCCCG CTGCCACCCT CTGGTGGACC CCGAGCCTTT TGTGGCCCTG 
TGTGAGAAGA CTTTGTGTGA GTGTGCTGGG GGGCTGGAGT GCGCCTGCCC TGCCCTCCTG 
GAGTACGCCC GGACCTGTGC CCAGGAGGGA ATGGTGCTGT ACGGCTGGAC CGACCACAGC 
GCGTGCAGTA AGTCGGCCCC CTGCCCCGTC CTGCCCTGCC GGGGATGAAC GGTCTGTCCT 
GGGTGGTGTC CCTTAGGGTG CTTCGGGGCT GTGTCACGTA TGTGCGGCTT TACCACACCC  
 
 
 
 
 
 
 
 
 179 
E8 
 
GGGGGGCACG TGGCTCACTG GGGGTGAGAA GGACCTGGAA GCCTGAAGAC AGAGGGGAGC 
AGTCAGAGTG GGCACGAGAG GCTCAGGCTG TGGCATGGCT GGTGAGATGA TGCACCGGTG 
GGACCTGCCC TGGGTAGACC CCTTTGATGT TCCTTTTCAG GCCCAGTGTG CCCTGCTGGT 
ATGGAGTATA GGCAGTGTGT GTCCCCTTGC GCCAGGACCT GCCAGAGCCT GCACATCAAT 
GAAATGTGTC AGGAGCGATG CGTGGATGGC TGCAGCTGCC CTGGTAATGA ACTTCCCACT 
TTATTTACAG ATCAGAGACC TTGCCAGCAC CCTTGGCTTT GGGAAGTGAG ATGAAGGCCA 
CTTGTGTTTG CTCCCCGTTG CTGAAATCAG AAGCCTTTTA TTAAGTTTTT AAATGTCTTT  
 
 
E9 
 
CCTTCCTTAT ATTGCATTAT GTGAAAGATA AACACCACAG AACAAGTTCT TTGAGCTTCC 
TGGAAGAAAC CCAACCATTG TCCCTGGGGA TTCTATAGTT GTGGGATGAG TGACGCAATG 
ACAATGTTGA GGCCTTTGTC TTGATGCCCT TGACCCCAGA GGGACAGCTC CTGGATGAAG 
GCCTCTGCGT GGAGAGCACC GAGTGTCCCT GCGTGCATTC CGGAAAGCGC TACCCTCCCG 
GCACCTCCCT CTCTCGAGAC TGCAACACCT GGTAATGGGG GCTGCGCAGC GTGCTCTGGG 
AGACCTGCCT GGGGGACTGG GGAGGGAAGC TGGGTCAGCA GGGGTGGTGG CAGGTGGAAA  
 
 
E10 
 
CACATCCCTT CGTTTGGGGA CTGTGATAAC TACCATGAGC TCTAAATCCA TTTGCATACC 
CTTGTGTTTG CAGAACCACC AATGACCTGT GCTTTTTCCC TCCAACAGCA TTTGCCGAAA 
CAGCCAGTGG ATCTGCAGCA ATGAAGAATG TCCAGGTAGG CGACCTGCCG CTCATTCTCT 
TCCTCCTTCC CTGAATCGGG GAGGCGTCTC CTCCTCTCTT ACCAGACAGG GAGGGCCACA 
ACTCAAGGCA GCGAGAAGTT GCCCTCTCTG CACAGGTTGG CTGCAACCAC GTGACCCCAG 
 
 
 
E11 
 
GGTTTGGGCA AAGGACGTCC ATGCAGTTTT GGGGAAGGGC ACCCTGCTTG CATATGCATT 
CCACCTTGGC CACCCCAGGG GAAGTGCCCT CACCTCCCAT TCTTCTCCCT TCCTCTGTGT 
CTCTCCAGGG GAGTGCCTTG TCACAGGTCA ATCACACTTC AAGAGCTTTG ACAACAGATA 
CTTCACCTTC AGTGGGATCT GCCAGTACCT GCTGGCCCGG GATTGCCAGG ACCACTCCTT 
CTCCATTGTC ATTGAGACTG TCCAGGTGAG CTTTGCCAGC CCGGCTGCTG GTCGGGTGGT 
AGCCCAAGGT GCTGCATAGC TGCTAGGCTG AATGGGCAGT CCCTGGAAGG CGTGGGGCAT  
 
 
E12 
 
TTATGAGAAG GCCAGAGGCT CTCGGGTTGA GGCCTTTCTC TGATTAAGAG GGTCCTGGGC 
TGGGGAGCTG GATAGGCAGG GGGTGCAGCA AAGTCACCCT GTGTTCCCTC TTGGCAGTGT 
GCTGATGACC GCGACGCTGT GTGCACCCGC TCCGTCACCG TCCGGCTGCC TGGCCTGCAC 
AACAGCCTTG TGAAACTGAA GCATGGGGCA GGAGTTGCCA TGGATGGCCA GGACGTCCAG 
CTCCCCCTCC TGAAAGGTAT GCTTCGTCCT GCTCCATCAG GCCTGGGGCT GGCACAGCCC 
ATCCCTTAGC ACCCTCCTTC TCAACCCTGG CCACTGTCCT TAAGGACCTG CATGCCTCTT  
 
 
 
 
 
 180 
E13 
 
CCTCATGGCC ACCCCATCTG CCCCTAAGTC ATTGCTCTTC AGTGCTACCA TCCTTTTGAG 
ACACCCCATT TCCTCCCAAA TACATCTGCC TGCCACCACC CTGTCCTCTC CCCACCTCTG 
CCTGAGTCCT GTCCTGCTGG GTTCCAGGTG ACCTCCGCAT CCAGCATACA GTGACGGCCT 
CCGTGCGCCT CAGCTACGGG GAGGACCTGC AGATGGACTG GGATGGCCGC GGGAGGCTGC 
TGGTGAAGGT AGGTGCCCTC ACGGGGTACT GGCTCCCTGC GGCCCGACCC TTACAAAGTA 
CCCCTTGTGC TCTGGGTAGA ATGGCTTTGT GTGGTGGGAG AAGAATTCCT TTCTCCTCAT  
 
 
E14 
 
CAGGGATGGA GCTGGTAAAT TTACACTGCA GTTCACTTTC CCCCGCCCCC CCTTTTGCAG 
CCTAGGGCTT AGCTGCCTTT TATTACATTC ATATTTATGT TTCACCCGGG GAACTTTTTT 
TTTTTTATTA AAACCATCTC ATTAGCTAAA CAACTATGCC GCTGCTTTCG CGGCAGCGGC 
TCCAGAGTGG CCTGGTCTCT CCTGCAGCTG TCCCCCGTCT ATGCCGGGAA GACCTGCGGC 
CTGTGTGGGA ATTACAATGG CAACCAGGGC GACGACTTCC TTACCCCCTC TGGGCTGGCG 
GAGCCCCGGG TGGAGGACTT CGGGAACGCC TGGAAGCTGC ACGGGGACTG CCAGGACCTG 
CAGAAGCAGC ACAGCGATCC CTGCGCCCTC AACCCGCGCA TGAGTATGTG AACCCGGGGG 
CAAGGCAGGG ACCTCGCAGA ATCTCGAGGT CTCCACATTA GTGCAGTGCG TTCCGGAGGC  
 
 
E15 
 
CGTTAGATGA TTGTAAGATA AATGGACTTG GGGGTGGGGG TGGCATTTGC AGATTTCTCT 
GCGTGACCTT GCAGCCCTCT ATTAGCAGCA CTGGGCTATT TCCAGGGGAG TGTTGACCGG 
GAGGGCGTGG CCCCCACTCC TCCCCACCAC ATCCCAGGCT CGCTCCTCTC GCCCCACAGC 
CAGGTTCTCC GAGGAGGCGT GCGCGGTCCT GACGTCCCCC ACATTCGAGG CCTGCCATCG 
TGCCGTCAGC CCGCTGCCCT ACCTGCGGAA CTGCCGCTAC GACGTGTGCT CCTGCTCGGA 
CGGCCGCGAG TGCCTGTGCG GCGCCCTGGC CAGCTATGCC GCGGCCTGCG CGGGGAGAGG 
CGTGCGCGTC GCGTGGCGCG AGCCAGGCCG CTGTGGTGCG TGCCCTCCCT GCCCGCAGCC 
CTCCGGGCCG CCCCCCAAAT CCGTCCACGT GTGCTTTTCG AAGCCCTTTC TCTGCGTTGT 
TTCCTGTGGA AAGAGGGCGT AGGGCATTGT GACAAACACG GGTGGGGAGG ACGGTTCATT  
 
 
E16 
 
GATCTTTCTG CATTACTTCT TGTAATTGCA AGCAAGTCTA CAATTATCTC AATAAAAATT 
TTAATTAAAT AATTGGGGGT CACAGCTACA AGGGGTGGCA AGTCCTAGAA CCACAGTCCT 
TGCTGTCCAA CATTCCCGCT GAGGCCTTAC TTCTCCTCTC TCTTCTAGAG CTGAACTGCC 
CGAAAGGCCA GGTGTACCTG CAGTGCGGGA CCCCCTGCAA CCTGACCTGC CGCTCTCTCT 
CTTACCCGGA TGAGGAATGC AATGAGGCCT GCCTGGAGGG CTGCTTCTGC CCCCCAGGGC 
TCTACATGGA TGAGAGGGGG GACTGCGTGC CCAAGGCCCA GTGCCCCTGT TACTATGACG 
GTGAGATCTT CCAGCCAGAA GACATCTTCT CAGACCATCA CACCATGTGG TAAGTGCAGG 
CAGCAGTGTC AGGGACCTCT AAAACAGCAG AGCTGGGGAG GAAAACGGGA CCCCCAAGTC 
CTTTACTTCA TGGATGGGTA AACTGGGGCC CAAGGAAGGA AGTGACTTGT CCAGAACTGT 
ACAGCAAGTC AGAAGCGGAG CTGGGATTTG GTCCAGGTCT TCTGACTTCC TTACTACACA 
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E17 
 
AAGTCCCATG GGATTTAGTG ACGTGGGGAT CATCCATTGG TAACGTTAGC AAGCTGTGCT 
TCAGGAGGGG TTATGGGACT GGGACCTGGT TGGAAGGGGC AGAGAGTGAG TGGGAGGTGA 
AGATGTGGAG GCAGCGAGTA TAGACGAGTC TCGTGAAGCT CGGCTATGAT TTTCTTCTCT 
GCAGCTACTG TGAGGATGGC TTCATGCACT GTACCATGAG TGGAGTCCCC GGAAGCTTGC 
TGCCTGACGC TGTCCTCAGC AGTCCCCTGT CTCATCGCAG TGAGTACTGT CCCCCTGGAA 
GGCCCATTGA CTCCATCCTG CCCAGATTCC TCACGTGTGG AATGGCGGGA GAGAGCTGGG  
 
 
E18 
 
TCCTGATTCA ATGTAACCTG CTATAGCAAG GTTAAGGGTG ATGACAAGTA TGGGACATTA 
GATGAGAGCT GGGGTCAGAA GAGCTGCCAC CAATGTAAGC CAGAGGTCAG AAGCCCAGGT 
GAGAAGATGC CCTCCCAGTC CCACACAGGG ACCCTGGCTC AGGCAGCTGC TGGTCCCCGT 
GAGTGGGCAA CTCTGAGTCT CTTGAATTTA GTCACAGACT CTAGGGGACC AAAGGACAGT 
GTGGAAGGTA GGTCCATTCT CTCCTTCACT AATCATCTCT TTGCTTTTCC TACCTTCGAG 
GCAAAAGGAG CCTATCCTGT CGGCCCCCCA TGGTCAAGCT GGTGTGTCCC GCTGACAACC 
TGCGGGCTGA AGGGCTCGAG TGTACCAAAA CGTGCCAGAA CTATGACCTG GAGTGCATGA 
GCATGGGCTG TGTCTCTGGC TGCCTCTGCC CCCCGGGCAT GGTGAGTCAC CAGGCACAGA 
GCTGGTGCCT GCCCTTCAGT TTTCTTGTAG GCAGGGATGA GTGAGGGGGC TGTGCAGCCA 
GAGAGAGGAA GAAACAAGGG CTAAACACGG ATAGCAATGG AGGTGGTGCT GGTAATGGGG 
 
 
E19 
 
TGGGCTTACC CGTAGGCTCA AGTCTCAGAC AACACTTCCT GGAGCGGGCT GGAGGAGGGC 
TTTAGATCAG TCACTGTGGC CCTGAGGACT TTTGGATTCT TTTCTCTTAG GTCCGGCATG 
AGAACAGATG TGTGGCCCTG GAAAGGTGTC CCTGCTTCCA TCAGGGCAAG GAGTATGCCC 
CTGGAGAAAC AGTGAAGATT GGCTGCAACA CTTGGTGAGG CTCAGTGAGG GGCTGCGCCG 
GGGACCCAGG CCCTGCGGGT GGAGTGAGGG TGCACGCGGC CACAGGACCT TCCGCACTTG 
CCTCCAGCCC CCTGTGGGAA CCTGGTTACT CTCTGCCTTT CCTCCGTGCC TGTGTTTCTC  
 
 
E20 
 
TTGGGCTTCC TGGAGGGTTG GGAGGCACCC AGAGTATTCT GTGTTCCTTC ATTGCCTCCA 
TGGCCCAGAT GGGCCCCTCA AACCCAAGGT GCCCAACTTG TCATCTCTGC CATGACTGCT 
CCTAGTGTCT GTCAGGACCG GAAGTGGAAC TGCACAGACC ATGTGTGTGA TGCCACGTGC 
TCCACGATCG GCATGGCCCA CTACCTCACC TTCGACGGGC TCAAATACCT GTTCCCCGGG 
GAGTGCCAGT ACGTTCTGGT GCAGGTGAGA GGTGGGGAGA TGGGGAGAGG GTGCTGTTTC 
TTTCTAGGAG GGGTGGGAGG TGTGGCCTCA GGTTGGGTTC TGTGGATCTG TCTGCAGAAA 
CAACTCTGGG GTCTGGTTTC TACTGGAGTA CTTCCCAGTC CTTCACAGAA GTGCCTGAAG  
 
 
E21 
 
CTGGGCATAT CCCCCGTCCC CCAGACACAC ACAGAGGCAC ATATGCGCAG CCATGGACGT 
GGCAAGATCC TGTGACACGT ACTCAAAGGC CTGTGATGAA GAGATGCCAA TCTTCTGGTC 
TGGTGAGAGC CAGTGGGGAT AATGGTCTTC TCCTGGCACT CCTCTTTCCC CAGGATTACT 
GCGGCAGTAA CCCTGGGACC TTTCGGATCC TAGTGGGGAA TAAGGGATGC AGCCACCCCT 
CAGTGAAATG CAAGAAACGG GTCACCATCC TGGTGGAGGG AGGAGAGATT GAGCTGTTTG 
ACGGGGAGGT AAGTGCAGCC TCATCTCCAC CCTCATGTCC CGCTTTGTGC TTCTGCCACT 
TAATAGGAAC ATTTTCCAAG CATTCATTTA GAGCTCGTGT GAATGGAATA ACGCACAGCC  
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E22 
 
GACTAATTGT CAATAAAATA CCTGCTCATT GGTTTCATAG TACTTTAATT TCATAATCAT 
GATTTTGCTG CTACCTCTGT TACCGTCTCT TGGTCATGGA TGCCTGGAGA GTGGTGGTGG 
TGAGATGGTC ACAGACATGT CCTGGCGTGG GGCTGGCCCT GCAGGGGTGC AGTGGCAGGT 
GGGGTCCTGG AGGGGTGGCA GTGCCTGCAC TCGTGGGCAC TGAAGACAGA TGGGCAGGTG 
TAGAGTGGAG GGAGGATCTG GCTGTCGAGC CTGCCCTTCA TCCTCCTGGA TTTCTTGCTT 
TGTCTTCCTC CAGGTGAATG TGAAGAGGCC CATGAAGGAT GAGACTCACT TTGAGGTGGT 
GGAGTCTGGC CGGTACATCA TTCTGCTGCT GGGCAAAGCC CTCTCCGTGG TCTGGGACCG 
CCACCTGAGC ATCTCCGTGG TCCTGAAGCA GACATACCAG GTCAGTGGCT TTCTTGCTTC 
ATCTTGTTGG GGACTTGGCC TTTGGAGTGT TTTCTGCTCC CTGATCGTAG GTCTCTAAGG 
ACTTGCTTTA TGAATCCAGG TGCTCCTGTG TTGGGTGCAT ATATATTTAG GATAGTTAGC 
 
 
E23/24 
 
TCTCAGGGCC AAGGCTGCCT GATTCCCACC TCTGCCCTTG GCTGACTATG TGACATGGGC 
ATGTTGCCTC TCTGTTTCCA TAGCTTTAAA TAAAATGGGG CCAGCAAGGA AGCTCAGGAA 
TGGGTCTTGG CAATGGCAAG GCTTTGCTGC TCACCTCGGG CCTCCTCTGA GTCTCTGTCC 
CGCTCCTCCT CCTCTTCCTC GAATGCCCTC TGCCTCCATT GCCGCCAGGA ATGTTCCCCT 
TTCCCCTGAG CCGGAGAGCA TGCTCCTGGG CTTGACGGTG CTCATCCCTC AACTTGTCTC 
TCAAGGAGAA AGTGTGTGGC CTGTGTGGGA ATTTTGATGG CATCCAGAAC AATGACCTCA 
CCAGCAGCAA CCTCCAAGTG GAGGAAGACC CTGTGGACTT TGGGAACTCC TGGAAAGTGA 
GCTCGCAGTG TGCTGACACC AGAAAAGTAC GTCTGGGTCT CTGTGTGGAC AGAGCCCTAG 
AGCTTGCTTC CTGGAATGTC CCTCTGTCCC CATTGTCATG GGGGCTGGAA GGGGGGTTGT 
GGGTGGTATG ACCTCCAGGT GGCTGCAGGG TGGGAAGGAG GGTCTCTTGG ATCCTTCTGG 
GCTGAATAAC CCCAGTTTGA CCAGCTGACG GCTGGCCTAT CTCTTGCCTG GTTCCCAGGT 
GCCTCTGGAC TCATCCCCTG CCACCTGCCA TAACAACATC ATGAAGCAGA CGATGGTGGA 
TTCCTCCTGT AGAATCCTTA CCAGTGACGT CTTCCAGGAC TGCAACAAGC TGGTGAGGAC 
CTTGAGGGTA GTGGGAAGCA GACGGTCCCA AGGCTTGGCC TGGTGGTATG GACACAGAGT 
GTGACCTTCT AACGTGGACA CTACCCTCGT GTCTTGACAT GATCTGCACC AAGACACCAC  
 
 
E25 
 
GGATTTGGAA TCAGAGTCTA GGCCCTATTG TCCTGCATAC CTGCCCCATA GCACTGCAGT 
GAGGCAGCTG CAGGGCCTGA TGTATTTCCC CATTCTCTTT GCTGAATTGA GGCAAAGAAA 
GACAGTGACC AGCACATATG TGTGTTTGTG TTTTTGTAAA AGCACCCACA TGCTCATGAG 
GCTAAGAGTG GGTTGTGAGG ACAGATGGGT GGCTGAGCAG GGAGGTAGGC AGAGGGACAG 
AGGGAATGTT CTTCTGGAAA ATCCTCAGGC TCATTGTGTT CTGCAGAAGG CCAGCAGCAC 
TGCATTATTC AACTCTTCTT GCTGGAATGC AGATTAGAAA CTAAGAATCT TGCCTTCCCA 
CTCATTCCCT CTTTGAGACC ATTGAGCTAC ATTTCTCCTT CTACCTGGAC CCCCTTATCC 
TTAAATTGAC CATCAGAACA TTTGCACCCA GACTAAGAGC CAGAGTTCCT GACACCTGGC 
CATAGGCCTG GGCCACCTGA GGCTGCCTTT GCAGGTGGAC CCCGAGCCAT ATCTGGATGT 
CTGCATTTAC GACACCTGCT CCTGTGAGTC CATTGGGGAC TGCGCCTGCT TCTGCGACAC 
CATTGCTGCC TATGCCCACG TGTGTGCCCA GCATGGCAAG GTGGTGACCT GGAGGACGGC 
CACATTGTGC CGTGAGTACT GACGCCCTCA TGTTCTCAGA TGCCCTCCCT TCTTCCCATG 
TGTCTATGCT TGAAGACCTT GTGAGTGCAG GGGGATATCT TCATGGGCGA GAGAAGACAG 
AGTGTTAGTA GGGACTGGAT GGCCAAGGGC TAAGGAGGGT TAAGACATTG GCTGTGTAAG 
AAGTTTATAT TACGGGTGAG GTGGGACATG GATTCAAGGC ATGAACATGT GGAGACTTTT 
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E26 – Ligation site is 367 nt before exon 26  
(Probe sequence: TAGAATCTTG-CTTCTTTGGA) 
 
CTTCAACAAT CCAGAAGTCT CTAATATTGG TGACGCCCAT AGTCCCCTAG TTCCCCAACA 
TTATCTCCAG ATGGCGCAGG CCATCACCAC ATGGGTCTGC AGTCCTGGAG GCTTTGCCTG 
TTGTGGCCAC AGCCTTGTCT CCTGTCTACA CAGCCCAGAG CTGCGAGGAG AGGAATCTCC 
GGGAGAACGG GTATGAGTGT GAGTGGCGCT ATAACAGCTG TGCACCTGCC TGTCAAGTCA 
CGTGTCAGCA CCCTGAGCCA CTGGCCTGCC CTGTGCAGTG TGTGGAGGGC TGCCATGCCC 
ACTGCCCTCC AGGTGAGGCC TCTATCCCTG GGGGTCAGGC TGGTGGGATG GGATAGGGAT 
GGATGGAAAG GTGCTTCTAG GTCTTGCTTC ATCTCAGCCT CCACCTGCCA CGTCCTATCT 
CTGACCTGCA AGGCTGCTGC AGGTTCCGTG GGTTCTTTCA TCAGAGTCAG GACAGTCGTG 
ATTTTTCTCA AGTCGAGCTC CTCCAAAATG CTTTTCTGTG CCTATTTATG GGATTCTCAC  
 
 
 
E27 
 
CCCGGAGATA AGATTTCATT TGTCCTGAGG CTTGGGGAGG TGAGGTAGGG TGAAGGAATC 
CCCGCTCCCA GTTTTGCAGA GGGATCAATC AAGGCACAAG CAGGAGAGAT GCTCCTTGAG 
TGATGGGGTG ACCCCTGGGA GTGCAGGCAG GAGGAGTTGG CTTCTAGGGC AGGAGGAGGA 
GTTGGCTCCT CCCTTTTAGT TAAAAATGAG GCTTCCTCGT GGGAAAGGGG AGCGTTTTGG 
TTCCTAATGA GAGCTTTCTT TTGCAGGGAA AATCCTGGAT GAGCTTTTGC AGACCTGCGT 
TGACCCTGAA GACTGTCCAG TGTGTGAGGT GGCTGGCCGG CGTTTTGCCT CAGGAAAGAA 
AGTCACCTTG AATCCCAGTG ACCCTGAGCA CTGCCAGATT TGGTAAAACA GATTCCTGGG 
TTGTTTGAAG TGATGAATCT TATTGCTTCT CCAGGGGCCA GCTTAGAGAC TAGGTTTTGG 
GTAAAAAGTC CTAGCCACAT GAGTTGAGAG ACTGAGTTTA TTTTATTTGT TTATTTATTT  
 
 
E28 
 
TAGGATGGGC TAAAGCTTTG GTTTCTAGAA TCAAAGGAAG TCGGCTATGT GTGTGTTTTG 
AAGGTGGGGG GCATGCTATT TGGGGACAGA TGTTAAACAA TGACATCTCA CTTGGATGTG 
GAATGGTCCA TGGGATCTCA AGTTCAGGTG GAACAGAGGA GATTCTGTGG GAATATGGAA 
GTCATTGTAC ACTGTAGGGC TCAGAAGTGT CCACAGGTTC TTCCTGAACC ATTTTAATTT 
CTTCGCTCTT TTCTGCAGCC ACTGTGATGT TGTCAACCTC ACCTGTGAAG CCTGCCAGGA 
GCCGGGAGGC CTGGTGGTGC CTCCCACAGA TGCCCCGGTG AGCCCCACCA CTCTGTATGT 
GGAGGACATC TCGGAACCGC CGTTGCACGA TTTCTACTGC AGCAGGCTAC TGGACCTGGT 
CTTCCTGCTG GATGGCTCCT CCAGGCTGTC CGAGGCTGAG TTTGAAGTGC TGAAGGCCTT 
TGTGGTGGAC ATGATGGAGC GGCTGCGCAT CTCCCAGAAG TGGGTCCGCG TGGCCGTGGT 
GGAGTACCAC GACGGCTCCC ACGCCTACAT CGGGCTCAAG GACCGGAAGC GACCGTCAGA 
GCTGCGGCGC ATTGCCAGCC AGGTGAAGTA TGCGGGCAGC CAGGTGGCCT CCACCAGCGA 
GGTCTTGAAA TACACACTGT TCCAAATCTT CAGCAAGATC GACCGCCCTG AAGCCTCCCG 
CATCACCCTG CTCCTGATGG CCAGCCAGGA GCCCCAACGG ATGTCCCGGA ACTTTGTCCG 
CTACGTCCAG GGCCTGAAGA AGAAGAAGGT CATTGTGATC CCGGTGGGCA TTGGGCCCCA 
TGCCAACCTC AAGCAGATCC GCCTCATCGA GAAGCAGGCC CCTGAGAACA AGGCCTTCGT 
GCTGAGCAGT GTGGATGAGC TGGAGCAGCA AAGGGACGAG ATCGTTAGCT ACCTCTGTGA 
CCTTGCCCCT GAAGCCCCTC CTCCTACTCT GCCCCCCGAC ATGGCACAAG TCACTGTGGG 
CCCGGGGCTC TTGGGGGTTT CGACCCTGGG GCCCAAGAGG AACTCCATGG TTCTGGATGT 
GGCGTTCGTC CTGGAAGGAT CGGACAAAAT TGGTGAAGCC GACTTCAACA GGAGCAAGGA 
GTTCATGGAG GAGGTGATTC AGCGGATGGA TGTGGGCCAG GACAGCATCC ACGTCACGGT 
GCTGCAGTAC TCCTACATGG TGACTGTGGA GTACCCCTTC AGCGAGGCAC AGTCCAAAGG 
GGACATCCTG CAGCGGGTGC GAGAGATCCG CTACCAGGGC GGCAACAGGA CCAACACTGG 
GCTGGCCCTG CGGTACCTCT CTGACCACAG CTTCTTGGTC AGCCAGGGTG ACCGGGAGCA 
GGCGCCCAAC CTGGTCTACA TGGTCACCGG AAATCCTGCC TCTGATGAGA TCAAGAGGCT 
GCCTGGAGAC ATCCAGGTGG TGCCCATTGG AGTGGGCCCT AATGCCAACG TGCAGGAGCT 
GGAGAGGATT GGCTGGCCCA ATGCCCCTAT CCTCATCCAG GACTTTGAGA CGCTCCCCCG 
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AGAGGCTCCT GACCTGGTGC TGCAGAGGTG CTGCTCCGGA GAGGGGCTGC AGATCCCCAC 
CCTCTCCCCT GCACCTGGTA TGCTGGCACC TTGTGTGCAG GTGGGAGGGC TGGGCGAGGG 
CTGGCATGGC CTTGGTGCTA CATGCATCTG CCAAGATACG ACTCGGGTTC TAATCCTGGC 
TTCCCTGGTC TGTGTGGCCT TGGTTGAAAC TTGCCTTCAA AGGGCCTGTG TTTCCTCACC 
TCCCTGGCAG GGAGACAAAC TGTGATCCTT TTTCGGGGGA AGATCTTTTC TTATTGTGTG  
 
 
E29/30 
 
ACCCCCCGCC CCCCTTGGTG GTGCCACGTG GTCAGCACGC CCTGCAGATC CTATTGGATG 
TCAGGTTGTA GGCCTGGTGG CCATTGTCCC TGCTGGCACC TGTGTGCTCA CCTTCCTGGT 
TGTCTTTGCA GACTGCAGCC AGCCCCTGGA CGTGATCCTT CTCCTGGATG GCTCCTCCAG 
TTTCCCAGCT TCTTATTTTG ATGAAATGAA GAGTTTCGCC AAGGCTTTCA TTTCAAAAGC 
CAATATAGGT GGGTGAGCGA GGCACCTGAA GCAGCAGGTG ACGAAGAGGC TCTTTTTGTG 
GCTCTACTTG ATTCAAAATA ATCCGCATTT TCTCGTTCCG TTTAGGGCCT CGTCTCACTC 
AGGTGTCAGT GCTGCAGTAT GGAAGCATCA CCACCATTGA CGTGCCATGG AACGTGGTCC 
CGGAGAAAGC CCATTTGCTG AGCCTTGTGG ACGTCATGCA GCGGGAGGGA GGCCCCAGCC 
AAATCGGTAA CGTTGGTGCC ACAGGCTGGA TGCAGAAGCT GCATTCTGGT TCTTATTTTT 
GGCATAAGTG ACTGTGTGAC CTCGGCCAGT CACTTTGCTC CTTGGCCTTA GTTTCTTCTC 
CTGGAAAGTG AGGGGCTAGA TGCTCTTCCA CGTCTCTCCA GATCTCAACT GGGTGTTCCT  
 
E31 
 
ACTGTGTGAC CTCGGCCAGT CACTTTGCTC CTTGGCCTTA GTTTCTTCTC CTGGAAAGTG 
AGGGGCTAGA TGCTCTTCCA CGTCTCTCCA GATCTCAACT GGGTGTTCCT TGGAGTTTCT 
GAATCATTCA GCTTTTAAGT GACTTAAGGA TCCACCGTTA AGACAGGGTG TCGAGCCGCA 
GTCAGTACTG ACTTGGCGTG ATCTGTTCTC CATCCTCAGG GGATGCCTTG GGCTTTGCTG 
TGCGATACTT GACTTCAGAA ATGCATGGTG CCAGGCCGGG AGCCTCAAAG GCGGTGGTCA 
TCCTGGTCAC GGACGTCTCT GTGGATTCAG TGGATGCAGC AGCTGATGCC GCCAGGTCCA 
ACAGTAAGAA TCTGGTGTAC AGTCCTCAAT TCAGGAGAGC GAGACTTCAG AAATGATAGA 
GGATTAAAAG TGGGCTGGGG TTACTTTTGG ATGTTGTGGC TGATATTAAA TATGCTCAAT 
ACCAACCTCT GTCCTGGTTT CAAACAGCAG GAAATTATCC AACCACGATG TGATTAGGAA 
ACCAAACAAT AAAAAGTGTG TATTGATCCT ATATCTTTAT AACTAATTAT AATCTTTAAT 
TTCTCCACAT TTTCCCTTTG TGTCCAGGAG TGATCATACC TCTATGCCCT 
 
 
E32 
 
TAATATCTGT TGACTGAACA TCTTCCTCAT AGGGCTGATG TATGTGACCA GCCTGGAAAA 
CATGAGGCTG TATTCAGATG CTGGATATAA CGTCAGGCCA GTCCATTTTG AGCCTTCTTG 
CCCACAGATC CTTTCTTGTC TCTTTGCTAA CTCTAGGAGT GACAGTGTTC CCTATTGGAA 
TTGGAGATCG CTACGATGCA GCCCAGCTAC GGATCTTGGC AGGCCCAGCA GGCGACTCCA 
ACGTGGTGAA GCTCCAGCGA ATCGAAGACC TCCCTACCAT GGTCACCTTG GGCAATTCCT 
TCCTCCACAA ACTGTGCTCT GGTGAGTCTT ATAATACCTT TCTTACTTCC CTCAAAAAAA 
AGTTCCAAAA TAAACCCGCC AAAGAAACAA AAATAGTATT CAAGAGACCC CAGGGTGCCC 
ATGCATAAGA TTTGGCCTTG AATGAAGATT ATTATATAGA CCAGGACCTT TAAGTTTCTG  
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E33 
 
TGGCATCATA ATTATTAATA ACTGCAGAGC ATGTCTGAAG AACCACAGGA TGACCACCTC 
AGCCTCATGT CCCTATGTCT CCACTGTTAA CCTTGTTCAG ATTCTTTTCA GAGTTGAGTT 
GACTTCAAAA ACTAGACCAG GTTGCTTAAG CAGACATTGT GAATGGTTCA GAATTTCTGG 
GTGAAAGATG GGAACTAAGG TCTTATTTGT GTCTGTTGCA GGATTTGTTA GGATTTGCAT 
GGATGAGGAT GGGAATGAGA AGAGGGTAAG TTCCTTTCTG TTGACTTTGA AAGAAAGGTT 
AGAGATGTGT TTGGGGCTCT TGTTCCCACT GGTTAATTTT TCCTCCTTTG GTCTTAGTCC 
AGTGCTTCCT TTTACTATTA TCTTGTTTTT GCGGGTCCAT CTGTACATCT TGTGTTTTGC 
TTCCTGTCTC ATGTACAGGG GGCCTCCTTG CTGTGTAGGC CTGTGTTCAA TTCTAGGGGT 
CAGTTGTCTG GCAGATGGGC TTAGAGTTGG AGTACCTCAT CTTATTCCCT GCCTGAATCT  
 
 
E34 
 
GTCTTAGTCC AGTGCTTCCT TTTACTATTA TCTTGTTTTT GCGGGTCCAT CTGTACATCT 
TGTGTTTTGC TTCCTGTCTC ATGTACAGGG GGCCTCCTTG CTGTGTAGGC CTGTGTTCAA 
TTCTAGGGGT CAGTTGTCTG GCAGATGGGC TTAGAGTTGG AGTACCTCAT CTTATTCCCT 
GCCTGAATCT GCTGTTTTCT TCTGCAGCCC GGGGACGTCT GGACCTTGCC AGACCAGTGC 
CACACCGTGA CTTGCCAGCC AGATGGCCAG ACCTTGCTGA AGAGTCATCG GGTCAACTGT 
GACCGGGGGC TGAGGCCTTC GTGCCCTAAC AGCCAGTCCC CTGTTAAAGT GGAAGAGACC 
TGTGGCTGCC GCTGGACCTG CCCCTGTGAG TCCTTTGCTT CTCCAGCCAG GGCAGCGTCA 
AAGGGGCAGT GCTTTTAGCT TGGCTGTGCA GAAAAGTAGA GCAGGCACCC ACCAGCCCAG 
AAGTACCCTT TCCCTCATCA CCACATGCAC AGTGCTACCT TCACTCACCT TCCTTTCCTC 
CTGTGCTCTT TGGACATGCA TGCAGCCAGT CTCAGGGATC ACTGCCCTCT TTCTCTGTCT 
TTGGAAGGCA CTTCCCCAGA TTATGCATAA CTGGAAGGAA GAATTGCTTT TCTGAGGTCA  
 
 
E35 
 
AGTTTCCTAA TCTGTAAAAA AAGGAGGAAA TTGTTCTATA TGACCTCAAA GGGCCTGTTC 
CGTTCTCTAC TGTATTTATC TGTGTGCAAC TTGGTCACAC CTGCCTGTCT GCATGTAGTA 
GGCATGGGGG TTTGGATAAC GTCGCATCCA TCCTCTGCTT CTCTCTGTCC AGGTGTGTGC 
ACAGGCAGCT CCACTCGGCA CATCGTGACC TTTGATGGGC AGAATTTCAA GCTGACTGGC 
AGCTGTTCTT ATGTCCTATT TCAAAACAAG GAGCAGGACC TGGAGGTGAT TCTCCATAAT 
GGTGCCTGCA GCCCTGGAGC AAGGCAGGGC TGCATGAAAT CCATCGAGGT GAAGCACAGT 
GCCCTCTCCG TCGAGCTGCA CAGTGACATG GAGGTGAGAA GTACTTTCTG TGGATCCGTG 
GTAAGGCAAT AGAATGTCAG GAAAACCACC TGGACCTGGT GGCAGTTGCT TTTAGTTGAT 
GCTCTTGTTA GGAGCTCTGC CTTCTGCTTA AGTGGAGGAG AGGAGTACCA CTTTCTTAGA 
GGGGTTTATT GCCATCCCCT TGTCTTGGCG TGATTTCATG TTGTTCCGGG CTCAGATTTG 
 
 
 
E36 
 
GCATGGCCAC CCGTACAGTA TTACAACAGC CTGTTTTCTG GTCAAGCTCT GTAAAGTCAA 
GCTCTGTTTT CTAGTCAAGC TCTTCTTTAT CTTAGAAGAG CTGCCGACAA ATATCAAGGT 
TTGTGGCTGA TGTTGCAGTT GAGTGTGATG AATGTGCAGG AACTCTCGGT AACTTCCCTA 
AAAACCTAGG ATTCCTCATT GCTAGGACTA CGGATGAGCT CTTTCTTCTT TGTGCAGGTG 
ACGGTGAATG GGAGACTGGT CTCTGTTCCT TACGTGGGTG GGAACATGGA AGTCAACGTT 
TATGGTGCCA TCATGCATGA GGTCAGATTC AATCACCTTG GTCACATCTT CACATTCACT 
CCACAAAACA ATGAGTTCCA ACTGCAGCTC AGCCCCAAGA CTTTTGCTTC AAAGACGTAT 
GGTCTGTGTG GTAAGAACAT TTTCTCAACT CCTCTTCTCC CCCTGCTATA CATTTATAAA 
CCTTACTTGC TCTACTCTGA GGCTCTTGGA TGCTTATATT TCAGGGTCTA GTAGCGAGGG 
TCAGATTCTG GTGAGGATCA AGAATGGCCT GTCTCTGGCA TCAATGTTTT TGTACCCAGG  
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E37 
 
GGCTCTTGGA TGCTTATATT TCAGGGTCTA GTAGCGAGGG TCAGATTCTG GTGAGGATCA 
AGAATGGCCT GTCTCTGGCA TCAATGTTTT TGTACCCAGG GCCACTCAGT TTATCTTTTT 
TTTGTTTGTT TGTTTCTCTA GGGATCTGTG ATGAGAACGG AGCCAATGAC TTCATGCTGA 
GGGATGGCAC AGTCACCACA GACTGGAAAA CACTTGTTCA GGAATGGACT GTGCAGCGGC 
CAGGGCAGAC GTGCCAGCCC ATCCTGGAGG AGCAGTGTCT TGTCCCCGAC AGCTCCCACT 
GCCAGGTCCT CCTCTTACCA CTGTTTGCTG AATGCCACAA GGTCCTGGCT CCAGCCACAT 
TCTATGCCAT CTGCCAGCAG GACAGTTGCC ACCAGGAGCA AGTGTGTGAG GTGATCGCCT 
CTTATGCCCA CCTCTGTCGG ACCAACGGGG TCTGCGTTGA CTGGAGGACA CCTGATTTCT 
GTGGTGAGTC TCCAAGTTAC CTCTGAAAAT CCTGGAGACC AGCTAACTGG GCTTGCTCAG 
CCTCTCTGTG CCCCAGATTC TTTATCTGGC TAATAAGGAT GAAAATCCCT GTATTTCGTA 
TGACCTGGAA TTCCAGTTAG GATCAAATAA GATGGAAGAT ATATATATAC 
 
 
E38 
 
TACACTTAGC TGCAAGAAAG GTTGGGAAAT ATAGTCCTCA TTCTGGTGGT CATATGCCCA 
GCCTAAAGTT CTGTTTCTAT GGAAGGTGGG GAGGATGAAG ATTGGTGGAA AATAGCCGTC 
TCTGCCCTGG CAAGTTTGTC TGATGATTAA CCATGTTGAA TCAGCTGTGC CCATTTCACT 
CTGGCTGGTG TGGGCCTTTG CAAGTGACCT CCTTCTCTGT CTACAGCTAT GTCATGCCCA 
CCATCTCTGG TCTACAACCA CTGTGAGCAT GGCTGTCCCC GGCACTGTGA TGGCAACGTG 
AGCTCCTGTG GGGACCATCC CTCCGAAGGC TGTTTCTGCC CTCCAGATAA AGTCATGTTG 
GAAGGCAGCT GTGTCCCTGA AGAGGCCTGC ACTCAGTGCA TTGGTGAGGA TGGAGTCCAG 
CACCAGGTAG GAGCCTGGGC CTTTCACTTC CCATGGGGCT GCTTCCCTCT TGGGTCAAAA 
GGGAGATATG TTCACCAGTG ATTGGCCTCT TCCAACTGTG GCAGCAGGGT TGACTCTTAC 
GGGGATCATT AGGGATAGGG AGGCAGTATT GTGTAATGGC CTTGCATTCA GATAGCTCTT  
 
 
E39/40 
 
CTCCTTTCAG CCTGCTTTTG TTTGCCTGTG AGGCTCTGTC AGAGGGCTGG GTCAGGGACT 
GGCCCTTGCC GGAGGCAGGG AGAGCTGACC TCTGTGAATT CTGGGCTTCG TACCTAGAAT 
GTCCTGTGCC CTTTCTGAAC CTTGCTTTGC CCTCAGTTCC TGGAAGCCTG GGTCCCGGAC 
CACCAGCCCT GTCAGATCTG CACATGCCTC AGCGGGCGGA AGGTCAACTG CACAACGCAG 
CCCTGCCCCA CGGCCAAAGG TGAGAGTCCT CCCCTCCCTG GTGCCTTCAT GGAGGAACAA 
GGGCCCCTGC AAGGCCCCCC AGCCACCCAT CTTCACCTCT GGCAGAGCAG ACTCAAACAC 
TGGCACCTAG AGTCCTAGAG TGGGTGGGCT TCCTTGCCCA GCCTGCATTT CCCATCACTG 
GGCCTGGGAG CCCCATTCTG CACCTGGGGT CGACATTCTC AGATTAACCC TCGCCTCTGG 
TCCCCAGCAA CGGTCAGACT TAAGAGTCCC CTGGAGGGTA AATGTGAGGG TGTCAACAGG 
AACATGGGGA CACTCATCTG TCAGAGGTCC CGTGGCCTGG ATCCTTGTGG GATGACCGTA 
CAGAACTCCT ACTAGTTTTC AGTGAGCAAG AACATTTCAA ATCCCTCTGA GGCTGTCCCA 
CCACTAATTT CTCTGACTTT TGTGGCCGTT CCTCTCCTCT AGCTCCCACG TGTGGCCTGT 
GTGAAGTAGC CCGCCTCCGC CAGAATGCAG ACCAGTGCTG CCCCGAGTAT GAGTGTGGTA 
TGTGTCCCAC CAGGGGGATG TCTCCAGGGC CCAACCCTAG CCCCAGGGGG CACCACGTTG 
AAGGTGCTGA AAGGTGTCTC TGTTCTCAGG CACAGGGTGT GTGAAAGGAG GTGGGTAAGG 
ACCGATTGGA TACTCCAAAA AAGTGGAAAG GGTTACCTCT GGAGAATAGG ATTTGCTTCC  
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E41 
 
TATCATTCTA TCTATCTATC TATCTATCTA TCTATCTATC TATCTATCTA TCCTAACCCA 
TGTAATCTCT GTCTCCATCA TCATCACTTA CCTAAAACAG TAGAAGTCTG CATGAATAGG 
AATGTAGCAT CCCACTCACA GGTAATAAAA GAGTAACCTT TCTGAACTCT GCATGGACGT 
CTCTCTTTCT GGCCCTCAGT GTGTGACCCA GTGAGCTGTG ACCTGCCCCC AGTGCCTCAC 
TGTGAACGTG GCCTCCAGCC CACACTGACC AACCCTGGCG AGTGCAGACC CAACTTCACC 
TGCGGTAAGG CCTCTGTGGA TGAGGAGGGG TGGTGTGGCC TCTCTCTGCT GGTGTGAGGG 
AGGCCATCCT CCTCAGGGAC CTCTTCCAAG ATCACGTCAT TTCCTGTTTT CTACCTAGCT 
GAATCTGGGT TGGGAGTACA TCTGGAACAG AGGGGTTAGG GTCACACCTG CACGGAATCC  
 
 
E42 
 
CTTCACATTT CCCTTTTTGA TTAATGTTCA TATTTTTCTG CAGATGGACT GCTTTTGGTA 
ACATTGAATA ACTCCCAGCC CGTGAGCTTG GCCCTCACAC ATTTCTGACT TAATCTTCTG 
AGTCTAAAGC TCCCTGGCAC CCTATAGCAT AGCTGAATAC TTACGAGCCC TGGCTGGGCG 
CAGTGCTCAG TGTGGCCTTG TCCTATCCTC AGCCTGCAGG AAGGAGGAGT GCAAAAGAGT 
GTCCCCACCC TCCTGCCCCC CGCACCGTTT GCCCACCCTT CGGAAGACCC AGTGCTGTGA 
TGAGTATGAG TGTGCCTGCA ACTGTGTCAA CTCCACAGTG AGCTGTCCCC TTGGGTACTT 
GGCCTCAACC GCCACCAATG ACTGTGGCTG TACCACAACC ACCTGCCTTC CCGACAAGGT 
AAGGACTGCT TGGCTATTAA CTATCAGTTA ATAGTTTACT CATTTATTTA TTGCTGTCAG 
TTTATCCTTC TATCCACCCA TCCATTCATC CATCCACCTA CCCATCCAAT ATTTGCTAAG 
CAACGTGTGC TCCTCATGGA AGATTTGCAT CCTACCCAGC ATTCCCTTCT TGCCCAAACC 
 
 
E43 
 
GCTGGTGGGC AGGGAAAGGA GGAGGACGAA ATCTGCTTTA TAAGCAGCCC TGCATATGGG 
CGGAGACCAC ATTTGGTTTT ATTTATTGCC ACATTCTCAG CACCTAGAGC GGCTTCTGTG 
TAGTAGGTGC TAACTCACCG CTTGTTTCAA TGAAACAAAT GAGTTCACTC ACGAAAACTT 
ATGTCTACAG GTGTGTGTCC ACCGAAGCAC CATCTACCCT GTGGGCCAGT TCTGGGAGGA 
GGGCTGCGAT GTGTGCACCT GCACCGACAT GGAGGATGCC GTGATGGGCC TCCGCGTGGC 
CCAGTGCTCC CAGAAGCCCT GTGAGGACAG CTGTCGGTCG GTGAGTGGGG CAGGGGCTGG 
GCATGCCTGC AGCTATCAGA GCGGGAAAGT AGAGGAGGGC ATCTTAGGAA GGGTAAGAAA  
 
 
E44 
 
GCTGGTTGAC AACAAAGATG AAAATGCCCA GACCAGTGAT CACTTGGCAC AACCCCAGGG 
CTCAGTACGC AGGAGGCGTA GGTAAGAGCC CCTGTGTCTT TGCTGCTGGC CTGTCCTTAC 
TCTGTTTTTT CTGCTTTTCC AGGGCTTCAC TTACGTTCTG CATGAAGGCG AGTGCTGTGG 
AAGGTGCCTG CCATCTGCCT GTGAGGTGGT GACTGGCTCA CCGCGGGGGG ACTCCCAGTC 
TTCCTGGAAG AGTGTAGGTC CAGGCCCCCG GGACGGGGAG GAGGGCAGAT TGGGGCCACT 
CCAGGGACCA GCGTTGACCT TGGTTTCATC TCATTCCCTG CCCTTTGCTT TCCCCACTGG 
GCATTTCACC CAGCTGTTGG TGTTATCCAG ATGCCAGCTG 
 
 
 
 
 
 
 
 
 188 
E45 
 
CCACTCATCC CCTCCGTGGG CCCTACCCTG TGGTGGGACT TACATGTTAA GCCAGGCTTC 
ACGTCTAGAA ACCACCTTCC TGAGAGAAGA GCACATTCCC AATGGGACCC TGGGCTCCAG 
CCCTGCCCCA GCTTGTTGGA CTAACTCTGG TGCCCTGCAG GTCGGCTCCC AGTGGGCCTC 
CCCGGAGAAC CCCTGCCTCA TCAATGAGTG TGTCCGAGTG AAGGAGGAGG TCTTTATACA 
ACAAAGGAAC GTCTCCTGCC CCCAGCTGGA GGTCCCTGTC TGCCCCTCGG GCTTTCAGCT 
GAGCTGTAAG ACCTCAGCGT GCTGCCCAAG CTGTCGCTGT GGTAAGGCAT GCAGGCTGGG 
GCTGGGCTGG ACCGGGCACC ACCTTTAAGC CTCTCTTTCC ACTTTTGGCT CCTGAATTCT 
TTGCCTTTTT AGCAACTTAG GGAAATGGAT AGGACCGAAA TCTTCCCATC TGCTCCTACT  
 
 
E46/47 
 
GGAGGCCGCT GTGGGCTCCA GCAGTAGGAC CCCCAGCGCT GGGTTGTGGG GTGGGGGGAA 
AGGGCCGACC GATACAGGAG GGAGGCCCAG ACACGGAGGA GGAGCCCCAA AGAGAGCAGC 
CTGCTCGCCG GTCTCACCAG GGTGTGTTTT GCCCACTCTC ACTCTGCACT TTTCTCTCCC 
CCAGAGCGCA TGGAGGCCTG CATGCTCAAT GGCACTGTCA TTGGGGTGAG CCGCTGTCCT 
CTTCTCCAGA GCAAGTGGTG GGGACAGGGA AGGGGGTACT GTGGGAAGGG GAGCAGGCAA 
GTCATTGTAA AGCAGAAATG AAGGAAACCA GAGAGACCCA ACCCCAGCTT TCCACTGCCT 
GTGGGACGTG CCTGGCATCA TGGAGCCCAG GCTAGGACCA TCTTCCTGAC TCTCCGGGCC 
TGTCTCACAC TCACTTCCTG GCCCCCACCT CAGGCACCTG TGCATTTCTT CTGTGTGCAG 
AGAAGCACTC TGAAGTCATT GTGCACGTTT TAGTTTGTCC CCTCTGCCAC TACCTGGGCT 
GCCTCTTTGG CATGAAAGTT CTCACTCTTA CCATCTCGAT ACTGGAGGTG GGAGGACGGG 
AAGGCAGTGG GCCATAGGAG ACAGGAGGAG CAGCAGAGCG ATGGCTCATG GGAGCTATGG 
GTGGGTGGGC AGGAGACAGG GTATGAGAGT GAGGTGAGTG GGGGGTTGGG GGATGCTGGG 
GGGCCTGACC CTGGTGCCTC TGCTTCCAGC CCGGGAAGAC TGTGATGATC GATGTGTGCA 
CGACCTGCCG CTGCATGGTG CAGGTGGGGG TCATCTCTGG ATTCAAGCTG GAGTGCAGGA 
AGACCACCTG CAACCCCTGC CCCCTGGTAA GAGAGGCTCA ATGGGGACCG AGGGCATGGA 
CTGGACGCGT GTGGGACCCA GGCAGTGGGA CCTCACTGCG GTCTTTAAAT AAATAAATCT  
 
 
E48 
 
CTACCTAGGG GACTGAGAAC TGACAAAAGC TGGTTGGAGT TGGATGTTGA CTTTCCGAAT 
TCTAGGTGAA ACTACTGGAT GAGAGAGATG AGAGGCCAGC AAAATCAGCC TACTTACAAT 
TGGGATGTTT TAAGGAGGTT AACTATGGCT GCTTTTTCCC CCTCTGGATG CAGGGTTACA 
AGGAAGAAAA TAACACAGGT GAATGTTGTG GGAGATGTTT GCCTACGGCT TGCACCATTC 
AGCTAAGAGG AGGACAGATC ATGACACTGA AGGTAGGAGC AAGCTGAATG CAGGGCTCCC 
TCACATATCA CCATCTTGCT TCCTTTTTTG GAAATTTTTC TTCAAGGAAG AGGGGCTAAG  
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E49/50 
 
TGGGTGTGGG GGCTTTATTA TACACTGTCT TCTTGTTTCA TGGTTCTGCA GATTGTTTCG 
TCATCTCCAT GGAGTCAAGC TCATGGTTTG AAGTGGCTTT GTGAACCAAA CACTGTCTCT 
GACTTTACCC ACTCCTCTTT CCTTCCAGCG TGATGAGACG CTCCAGGATG GCTGTGATAC 
TCACTTCTGC AAGGTCAATG AGAGAGGAGA GTACTTCTGG GAGAAGAGGG TCACAGGCTG 
CCCACCCTTT GATGAACACA AGTGTCTGGC TGAGGGAGTG AGTACTCATT CTGCTTTCCT 
CTTTACTGTC TCAATCTCTA AGAACAAGAT TCTTCTGAAT AGTGTGCATC CCAGCTCCGG 
CATAATTTCT CAGTGTCTGA GGCACATCTC TGGCCTAGTT GAAGAATCAG TGAGATTACG 
AAATCAAAGC CTACGGAGAG ATAAAATTCT CTGCAATATA GGATGTTTTA AAAAAATATT 
TTCCTTAAGG GAGGCTGAGT GTGTGATTCT TGAATAAAAT GTGAGATCAA ACTGATTTTT 
AGTCTCCCTG GGAATGAAGA TCCTGATGAC TCAACTGGAA GAGAATTCAG AATCATCAAA 
ATTGTTTCAG CCTGGTCAGG TAGGGTGGTC AAGCTGCTCA CATTTATGAT AGGAAAGCAT 
AGTTTACATC TGGGCACTTA AGCACAGGGC TGTGAGTTCG GAGCTAAAAA TTGGCCCGGA 
GTGACCTGAA AGCTGTCTAC TCTGTACTGT TTGTGCCTAA CCTGAAATTT TGCTGTTTTC 
TTAGGGTAAA ATTATGAAAA TTCCAGGCAC CTGCTGTGAC ACATGTGAGT GCGTTACTAA 
TATCTTGTCC CTTGAAACCC ATCAGAGCAA GTCCAGGGGC TCTTTGCAGC TTGCTCCTTG  
 
 
E51 
 
CTGCATATTT CGGGCCAGGA ACAGCTGAGG TGAACCAGGA TAACTGAATT CCCTCCCTGT 
GGCTGGCTTT ATTTGGTTAC TGTGAAAGGG ACCTATTTCC AGCCCAGTGA GGGCACTGGG 
GCTGAAGAGT GTTCTCTAGA ACCCCAGCCA GTCCTCAAGT TTCATCTCTC ACCTGTCCTG 
TAGGTGAGGA GCCTGAGTGC AACGACATCA CTGCCAGGCT GCAGTATGTC AAGGTGGGAA 
GCTGTAAGTC TGAAGTAGAG GTGGATATCC ACTACTGCCA GGTAAGGGCT CTGCTTCAAT 
AAGGGCTGGG TGTGGAGGGC TGAGCCTCCG TGTTCGGATA CCTATCCTTA GTTACATTCT 
AGAAGGATCT GGAAAATTCG CAGGGAAGAG AAGGGAAATA AACTGGAAGC ATTTTTTTTT  
 
 
E52 
 
GATCTTCCTT TACAAATTGC CTAGCTGTCC TGGGTGCTTC TGGGTGAGAT CAGACCTGCC 
TTGCTTGGAG GGGGTCAGGG AGAAAGCAGG CTGCCCCAGA GCCCTGCCTA AGCCAGGACT 
TCCCACCATT GTGAAGCTCC CATCTTCCTC TGCTTTCTTG CAGGGCAAAT GTGCCAGCAA 
AGCCATGTAC TCCATTGACA TCAACGATGT GCAGGACCAG TGCTCCTGCT GCTCTCCGAC 
ACGGACGGAG CCCATGCAGG TGGCCCTGCA CTGCACCAAT GGCTCTGTTG TGTACCATGA 
GGTTCTCAAT GCCATGGAGT GCAAATGCTC CCCCAGGAAG TGCAGCAAGT GAGGCTGCTG 
CAGCTGCATG GGTGCCTGCT GCTGCCTGCC TTGGCCTGAT GGCCAGGCCA GAGTGCTGCC 
AGTCCTCTGC ATGTTCTGCT CTTGTGCCCT TCTGAGCCCA CAATAAAGGC TGAGCTCTTA 
TCTTGCAAAA GGCTGCTGGT GCACTGTGTC GTAGGGCTGA GATGGCAACG GTGGGCAGGG 
GCTGAGTTCT GAGACCGGTT CTGAGGAAGG AAGCACAGGC CCCATCTGCA AGCCTCAGTG 
TCAGTGTGAG ATACTGCCAA CTTCTGGGGA AGAGTGATGT CTTTGCCTCC  
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Appendix 4: F8 sequence with probe locations 
Partial sequence (20 nt adjacent to ligation site) of the F8 MLPA probes  
are indicated for the 26 exons of F8. 
NM_000132.3 (ENST00000360256) NP_000123.1 (ENSP00000353393)  This transcript is a product 
of gene ENSG00000185010  This transcript is a member of the Human CCDS set: CCDS35457 This 
transcript corresponds to the following database identifiers: Transcript having exact match between 
ENSEMBL and HAVANA : OTTHUMT00000058869 
 Key 
 Exons-alternating text colour –blue/black 
 Codons – alternating background colour 
 Synonymous SNP –highlighted in green 
 Non–synonymous SNP – highlighted in yellow 
MLPA probes adjacent to ligation site – highlighted in purple 
and blue 
 Ambiguity code – underlined letter 
 
     1 GCTTAGTGCTGAGCACATCCAGTGGGTAAAGTTCCTTAAAATGCTCTGCAAAGAAATTGG 
       ............................................................ 
       ............................................................ 
 
                                                                    
    61 GACTTTTCATTAAATCAGAAATTTTACTTTTTTCCCCTCCTGGGAGCTAAAGATATTTTA 
       ............................................................ 
       ............................................................ 
 
                                                                    
   121 GAGAAGAATTAACCTTTTGCTTCTCCAGTTGAACATTTGTAGCAATAAGTCATGCAAATA 
       ...................................................ATGCAAATA 
       ...................................................-M--Q--I- 
 
                                                                    
   181 GAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCCACCAGAAGA 
    10 GAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCCACCAGAAGA 
     4 -E--L--S--T--C--F--F--L--C--L--L--R--F--C--F--S--A--T--R--R- 
 
                                       Y                          
   241 TACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTCGGTGAGCTG 
    70 TACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTCGGTGAGCTG 
    24 -Y--Y--L--G--A--V--E--L--S--W--D--Y--M--Q--S--D--L—G-E-L- 
 
                                                                    
   301 CCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAACACCTCAGTC 
   130 CCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAACACCTCAGTC 
    44 -P--V--D--A--R--F--P--P--R--V--P--K--S--F--P--F--N--T--S--V- 
 
                                         W                          
   361 GTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATCGCTAAGCCA 
   190 GTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATCGCTAAGCCA 
    64 -V--Y--K--K--T--L--F--V--E--F--T-=D=-H--L--F--N--I--A--K--P- 
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                                K                    W              
   421 AGGCCACCCTGGATGGGTCTGCTAGGTCCTACCATCCAGGCTGAGGTTTATGATACAGTG 
   250 AGGCCACCCTGGATGGGTCTGCTAGGTCCTACCATCCAGGCTGAGGTTTATGATACAGTG 
    84 -R--P--P--W--M--G--L--L-=G=-P--T--I--Q--A--E-=V=-Y--D--T--V- 
 
        W           M    R                     K                    
   481 GTCATTACACTTAAGAACATGGCTTCCCATCCTGTCAGTCTTCATGCTGTTGGTGTATCC 
   310 GTCATTACACTTAAGAACATGGCTTCCCATCCTGTCAGTCTTCATGCTGTTGGTGTATCC 
   104 =V=-I--T--L-=K=-N-=M=-A--S--H--P--V--S-=L=-H--A--V--G--V--S- 
 
                                 M R     R                          
   541 TACTGGAAAGCTTCTGAGGGAGCTGAATATGATGATCAGACCAGTCAAAGGGAGAAAGAA 
   370 TACTGGAAAGCTTCTGAGGGAGCTGAATATGATGATCAGACCAGTCAAAGGGAGAAAGAA 
   124 -Y--W--K--A--S--E--G--A-=E==Y=-D-=D=-Q--T--S--Q--R--E--K--E- 
 
                                                                    
   601 GATGATAAAGTCTTCCCTGGTGGAAGCCATACATATGTCTGGCAGGTCCTGAAAGAGAAT 
   430 GATGATAAAGTCTTCCCTGGTGGAAGCCATACATATGTCTGGCAGGTCCTGAAAGAGAAT 
   144 -D--D--K--V--F--P--G--G--S--H--T--Y--V--W--Q--V--L--K--E--N- 
 
        K Y                                                         
   661 GGTCCAATGGCCTCTGACCCACTGTGCCTTACCTACTCATATCTTTCTCATGTGGACCTG 
   490 GGTCCAATGGCCTCTGACCCACTGTGCCTTACCTACTCATATCTTTCTCATGTGGACCTG 
   164 =G==P=-M--A--S--D--P--L--C--L--T--Y--S--Y--L--S--H--V--D--L- 
 
                                                                    
   721 GTAAAAGACTTGAATTCAGGCCTCATTGGAGCCCTACTAGTATGTAGAGAAGGGAGTCTG 
   550 GTAAAAGACTTGAATTCAGGCCTCATTGGAGCCCTACTAGTATGTAGAGAAGGGAGTCTG 
   184 -V--K--D--L--N--S--G--L--I--G--A--L--L--V--C--R--E--G--S--L- 
 
                         M                                          
   781 GCCAAGGAAAAGACACAGACCTTGCACAAATTTATACTACTTTTTGCTGTATTTGATGAA 
   610 GCCAAGGAAAAGACACAGACCTTGCACAAATTTATACTACTTTTTGCTGTATTTGATGAA 
   204 -A--K--E--K--T--Q-=T=-L--H--K--F--I--L--L--F--A--V--F--D--E- 
 
                                                                    
   841 GGGAAAAGTTGGCACTCAGAAACAAAGAACTCCTTGATGCAGGATAGGGATGCTGCATCT 
   670 GGGAAAAGTTGGCACTCAGAAACAAAGAACTCCTTGATGCAGGATAGGGATGCTGCATCT 
   224 -G--K--S--W--H--S--E--T--K--N--S--L--M--Q--D--R--D--A--A--S- 
 
                                                                    
   901 GCTCGGGCCTGGCCTAAAATGCACACAGTCAATGGTTATGTAAACAGGTCTCTGCCAGGT 
   730 GCTCGGGCCTGGCCTAAAATGCACACAGTCAATGGTTATGTAAACAGGTCTCTGCCAGGT 
   244 -A--R--A--W--P--K--M--H--T--V--N--G--Y--V--N--R--S--L--P--G- 
 
                                       K                            
   961 CTGATTGGATGCCACAGGAAATCAGTCTATTGGCATGTGATTGGAATGGGCACCACTCCT 
   790 CTGATTGGATGCCACAGGAAATCAGTCTATTGGCATGTGATTGGAATGGGCACCACTCCT 
   264 -L--I--G--C--H--R--K--S--V--Y-=W=-H--V--I--G--M--G--T--T--P- 
                                                      
          W     D        
  1021 GAAGTGCACTCAATATTCCTCGAAGGTCACACATTTCTTGTGAGGAACCATCGCCAGGCG 
   850 GAAGTGCACTCAATATTCCTCGAAGGTCACACATTTCTTGTGAGGAACCATCGCCAGGCG 
   284 -E--V--H--S--I--F--L--E--G--H--T--F--L--V--R-=N=-H-=R=-Q--A- 
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                    Y                R                              
  1081 TCCTTGGAAATCTCGCCAATAACTTTCCTTACTGCTCAAACACTCTTGATGGACCTTGGA 
   910 TCCTTGGAAATCTCGCCAATAACTTTCCTTACTGCTCAAACACTCTTGATGGACCTTGGA 
   304 -S--L--E--I-=S=-P--I--T--F--L-=T=-A--Q--T--L--L--M--D--L--G- 
 
                 Y     V                                            
  1141 CAGTTTCTACTGTTTTGTCATATCTCTTCCCACCAACATGATGGCATGGAAGCTTATGTC 
   970 CAGTTTCTACTGTTTTGTCATATCTCTTCCCACCAACATGATGGCATGGAAGCTTATGTC 
   324 -Q--F--L-=L=-F-=C=-H--I--S--S--H--Q--H--D--G--M--E--A--Y--V- 
 
                                                              R    
  1201 AAAGTAGACAGCTGTCCAGAGGAACCCCAACTACGAATGAAAAATAATGAAGAAGCGGAA 
  1030 AAAGTAGACAGCTGTCCAGAGGAACCCCAACTACGAATGAAAAATAATGAAGAAGCGGAA 
   344 -K--V--D--S--C--P--E--E--P--Q--L--R--M--K--N--N--E--E--A--E- 
 
                                                                    
  1261 GACTATGATGATGATCTTACTGATTCTGAAATGGATGTGGTCAGGTTTGATGATGACAAC 
  1090 GACTATGATGATGATCTTACTGATTCTGAAATGGATGTGGTCAGGTTTGATGATGACAAC 
   364 -D--Y--D--D--D--L--T--D--S--E--M--D--V--V--R--F--D--D--D--N- 
 
                             R YY                                   
  1321 TCTCCTTCCTTTATCCAAATTCGCTCAGTTGCCAAGAAGCATCCTAAAACTTGGGTACAT 
  1150 TCTCCTTCCTTTATCCAAATTCGCTCAGTTGCCAAGAAGCATCCTAAAACTTGGGTACAT 
   384 -S--P--S--F--I--Q--I-=R==S=-V--A--K--K--H--P--K--T--W--V--H- 
 
           K           R                                            
  1381 TACATTGCTGCTGAAGAGGAGGACTGGGACTATGCTCCCTTAGTCCTCGCCCCCGATGAC 
  1210 TACATTGCTGCTGAAGAGGAGGACTGGGACTATGCTCCCTTAGTCCTCGCCCCCGATGAC 
   404 -Y-=I=-A--A--E-=E=-E--D--W--D--Y--A--P--L--V--L--A--P--D--D- 
 
                              K                                     
  1441 AGAAGTTATAAAAGTCAATATTTGAACAATGGCCCTCAGCGGATTGGTAGGAAGTACAAA 
  1270 AGAAGTTATAAAAGTCAATATTTGAACAATGGCCCTCAGCGGATTGGTAGGAAGTACAAA 
   424 -R--S--Y--K--S--Q--Y-=L=-N--N--G--P--Q--R--I--G--R--K--Y--K- 
 
        R                W                                          
  1501 AAAGTCCGATTTATGGCATACACAGATGAAACCTTTAAGACTCGTGAAGCTATTCAGCAT 
  1330 AAAGTCCGATTTATGGCATACACAGATGAAACCTTTAAGACTCGTGAAGCTATTCAGCAT 
   444 =K=-V--R--F--M--A-=Y=-T--D--E--T--F--K--T--R--E--A--I--Q--H- 
 
                                                                    
  1561 GAATCAGGAATCTTGGGACCTTTACTTTATGGGGAAGTTGGAGACACACTGTTGATTATA 
  1390 GAATCAGGAATCTTGGGACCTTTACTTTATGGGGAAGTTGGAGACACACTGTTGATTATA 
   464 -E--S--G--I--L--G--P--L--L--Y--G--E--V--G--D--T--L--L--I--I- 
 
 
 
                               YR     Y          R               R  
  1621 TTTAAGAATCAAGCAAGCAGACCATATAACATCTACCCTCACGGAATCACTGATGTCCGT 
  1450 TTTAAGAATCAAGCAAGCAGACCATATAACATCTACCCTCACGGAATCACTGATGTCCGT 
   484 -F--K--N--Q--A--S--R--P-=Y=-N-=I=-Y--P--H-=G=-I--T--D--V-=R= 
 
                                                                    
  1681 CCTTTGTATTCAAGGAGATTACCAAAAGGTGTAAAACATTTGAAGGATTTTCCAATTCTG 
  1510 CCTTTGTATTCAAGGAGATTACCAAAAGGTGTAAAACATTTGAAGGATTTTCCAATTCTG 
   504 -P--L--Y--S--R--R--L--P--K--G--V--K--H--L--K--D--F--P--I--L- 
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  1741 CCAGGAGAAATATTCAAATATAAATGGACAGTGACTGTAGAAGATGGGCCAACTAAATCA 
  1570 CCAGGAGAAATATTCAAATATAAATGGACAGTGACTGTAGAAGATGGGCCAACTAAATCA 
   524 -P--G--E--I--F--K--Y--K--W--T--V--T--V--E--D--G--P--T--K--S- 
 
       R     Y           BR          R                     R        
  1801 GATCCTCGGTGCCTGACCCGCTATTACTCTAGTTTCGTTAATATGGAGAGAGATCTAGCT 
  1630 GATCCTCGGTGCCTGACCCGCTATTACTCTAGTTTCGTTAATATGGAGAGAGATCTAGCT 
   544 =D=-P-=R=-C--L--T-=R=-Y--Y--S-=S=-F--V--N--M--E--R-=D=-L--A- 
 
                                              YY                    
  1861 TCAGGACTCATTGGCCCTCTCCTCATCTGCTACAAAGAATCTGTAGATCAAAGAGGAAAC 
  1690 TCAGGACTCATTGGCCCTCTCCTCATCTGCTACAAAGAATCTGTAGATCAAAGAGGAAAC 
   564 -S--G--L--I--G--P--L--L--I--C--Y--K--E-=S=-V--D--Q--R--G--N- 
 
                                                                    
  1921 CAGATAATGTCAGACAAGAGGAATGTCATCCTGTTTTCTGTATTTGATGAGAACCGAAGC 
  1750 CAGATAATGTCAGACAAGAGGAATGTCATCCTGTTTTCTGTATTTGATGAGAACCGAAGC 
   584 -Q--I--M--S--D--K--R--N--V--I--L--F--S--V--F--D--E--N--R--S- 
 
                                                               Y    
  1981 TGGTACCTCACAGAGAATATACAACGCTTTCTCCCCAATCCAGCTGGAGTGCAGCTTGAG 
  1810 TGGTACCTCACAGAGAATATACAACGCTTTCTCCCCAATCCAGCTGGAGTGCAGCTTGAG 
   604 -W--Y--L--T--E--N--I--Q--R--F--L--P--N--P--A--G--V--Q--L--E- 
 
                                                                    
  2041 GATCCAGAGTTCCAAGCCTCCAACATCATGCACAGCATCAATGGCTATGTTTTTGATAGT 
  1870 GATCCAGAGTTCCAAGCCTCCAACATCATGCACAGCATCAATGGCTATGTTTTTGATAGT 
   624 -D--P--E--F--Q--A--S--N--I--M--H--S--I--N--G--Y--V--F--D--S- 
 
                                                                    
  2101 TTGCAGTTGTCAGTTTGTTTGCATGAGGTGGCATACTGGTACATTCTAAGCATTGGAGCA 
  1930 TTGCAGTTGTCAGTTTGTTTGCATGAGGTGGCATACTGGTACATTCTAAGCATTGGAGCA 
   644 -L--Q--L--S--V--C--L--H--E--V--A--Y--W--Y--I--L--S--I--G--A- 
 
                                                                    
  2161 CAGACTGACTTCCTTTCTGTCTTCTTCTCTGGATATACCTTCAAACACAAAATGGTCTAT 
  1990 CAGACTGACTTCCTTTCTGTCTTCTTCTCTGGATATACCTTCAAACACAAAATGGTCTAT 
   664 -Q--T--D--F--L--S--V--F--F--S--G--Y--T--F--K--H--K--M--V--Y- 
 
 
                                                                    
  2221 GAAGACACACTCACCCTATTCCCATTCTCAGGAGAAACTGTCTTCATGTCGATGGAAAAC 
  2050 GAAGACACACTCACCCTATTCCCATTCTCAGGAGAAACTGTCTTCATGTCGATGGAAAAC 
   684 -E--D--T--L--T--L--F--P--F--S--G--E--T--V--F--M--S--M--E--N- 
 
                                                                    
  2281 CCAGGTCTATGGATTCTGGGGTGCCACAACTCAGACTTTCGGAACAGAGGCATGACCGCC 
  2110 CCAGGTCTATGGATTCTGGGGTGCCACAACTCAGACTTTCGGAACAGAGGCATGACCGCC 
   704 -P--G--L--W--I--L--G--C--H--N--S--D--F--R--N--R--G--M--T--A- 
 
                                                    R               
  2341 TTACTGAAGGTTTCTAGTTGTGACAAGAACACTGGTGATTATTACGAGGACAGTTATGAA 
  2170 TTACTGAAGGTTTCTAGTTGTGACAAGAACACTGGTGATTATTACGAGGACAGTTATGAA 
   724 -L--L--K--V--S--S--C--D--K--N--T--G--D--Y--Y-=E=-D--S--Y--E- 
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  2401 GATATTTCAGCATACTTGCTGAGTAAAAACAATGCCATTGAACCAAGAAGCTTCTCCCAG 
  2230 GATATTTCAGCATACTTGCTGAGTAAAAACAATGCCATTGAACCAAGAAGCTTCTCCCAG 
   744 -D--I--S--A--Y--L--L--S--K--N--N--A--I--E--P--R--S--F--S--Q- 
 
                                                                    
  2461 AATTCAAGACACCCTAGCACTAGGCAAAAGCAATTTAATGCCACCACAATTCCAGAAAAT 
  2290 AATTCAAGACACCCTAGCACTAGGCAAAAGCAATTTAATGCCACCACAATTCCAGAAAAT 
   764 -N--S--R--H--P--S--T--R--Q--K--Q--F--N--A--T--T--I--P--E--N- 
 
                                        R                           
  2521 GACATAGAGAAGACTGACCCTTGGTTTGCACACAGAACACCTATGCCTAAAATACAAAAT 
  2350 GACATAGAGAAGACTGACCCTTGGTTTGCACACAGAACACCTATGCCTAAAATACAAAAT 
   784 -D--I--E--K--T--D--P--W--F--A--H-=R=-T--P--M--P--K--I--Q--N- 
 
                                                                    
  2581 GTCTCCTCTAGTGATTTGTTGATGCTCTTGCGACAGAGTCCTACTCCACATGGGCTATCC 
  2410 GTCTCCTCTAGTGATTTGTTGATGCTCTTGCGACAGAGTCCTACTCCACATGGGCTATCC 
   804 -V--S--S--S--D--L--L--M--L--L--R--Q--S--P--T--P--H--G--L--S- 
 
                                                 14BF                   
  2641 TTATCTGATCTCCAAGAAGCCAAATATGAGACTTTTTCTGATGATCCATCACCTGGAGCA 
  2470 TTATCTGATCTCCAAGAAGCCAAATATGAGACTTTTTCTGATGATCCATCACCTGGAGCA 
   824 -L--S--D--L--Q--E--A--K--Y--E--T--F--S--D--D--P--S--P--G--A- 
 
                                                                    
  2701 ATAGACAGTAATAACAGCCTGTCTGAAATGACACACTTCAGGCCACAGCTCCATCACAGT 
  2530 ATAGACAGTAATAACAGCCTGTCTGAAATGACACACTTCAGGCCACAGCTCCATCACAGT 
   844 -I--D--S--N--N--S--L--S--E--M--T--H--F--R--P--Q--L--H--H--S- 
 
               14AR                                                     
  2761 GGGGACATGGTATTTACCCCTGAGTCAGGCCTCCAATTAAGATTAAATGAGAAACTGGGG 
  2590 GGGGACATGGTATTTACCCCTGAGTCAGGCCTCCAATTAAGATTAAATGAGAAACTGGGG 
   864 -G--D--M--V--F--T--P--E--S--G--L--Q--L--R--L--N--E--K--L--G- 
 
                                                                  
  2821 ACAACTGCAGCAACAGAGTTGAAGAAACTTGATTTCAAAGTTTCTAGTACATCAAATAAT 
  2650 ACAACTGCAGCAACAGAGTTGAAGAAACTTGATTTCAAAGTTTCTAGTACATCAAATAAT 
   884 -T--T--A--A--T--E--L--K--K--L--D--F--K--V--S--S--T--S--N--N- 
 
                                                                    
  2881 CTGATTTCAACAATTCCATCAGACAATTTGGCAGCAGGTACTGATAATACAAGTTCCTTA 
  2710 CTGATTTCAACAATTCCATCAGACAATTTGGCAGCAGGTACTGATAATACAAGTTCCTTA 
   904 -L--I--S--T--I--P--S--D--N--L--A--A--G--T--D--N--T--S--S--L- 
 
                                                                    
  2941 GGACCCCCAAGTATGCCAGTTCATTATGATAGTCAATTAGATACCACTCTATTTGGCAAA 
  2770 GGACCCCCAAGTATGCCAGTTCATTATGATAGTCAATTAGATACCACTCTATTTGGCAAA 
   924 -G--P--P--S--M--P--V--H--Y--D--S--Q--L--D--T--T--L--F--G--K- 
                                                                  
   
  3001 AAGTCATCTCCCCTTACTGAGTCTGGTGGACCTCTGAGCTTGAGTGAAGAAAATAATGAT 
  2830 AAGTCATCTCCCCTTACTGAGTCTGGTGGACCTCTGAGCTTGAGTGAAGAAAATAATGAT 
   944 -K--S--S--P--L--T--E--S--G--G--P--L--S--L--S--E--E--N--N--D- 
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               R   
  3061 TCAAAGTTGTTAGAATCAGGTTTAATGAATAGCCAAGAAAGTTCATGGGGAAAAAATGTA 
  2890 TCAAAGTTGTTAGAATCAGGTTTAATGAATAGCCAAGAAAGTTCATGGGGAAAAAATGTA 
   964 -S--K--L--L--E--S--G--L--M--N--S--Q--E--S--S--W--G--K--N-=V= 
 
                                             14CF                       
  3121 TCGTCAACAGAGAGTGGTAGGTTATTTAAAGGGAAAAGAGCTCATGGACCTGCTTTGTTG 
  2950 TCGTCAACAGAGAGTGGTAGGTTATTTAAAGGGAAAAGAGCTCATGGACCTGCTTTGTTG 
   984 -S--S--T--E--S--G--R--L--F--K--G--K--R--A--H--G--P--A--L--L- 
 
                                                                    
  3181 ACTAAAGATAATGCCTTATTCAAAGTTAGCATCTCTTTGTTAAAGACAAACAAAACTTCC 
  3010 ACTAAAGATAATGCCTTATTCAAAGTTAGCATCTCTTTGTTAAAGACAAACAAAACTTCC 
  1004 -T--K--D--N--A--L--F--K--V--S--I--S--L--L--K--T--N--K--T--S- 
 
                                                14BR                    
  3241 AATAATTCAGCAACTAATAGAAAGACTCACATTGATGGCCCATCATTATTAATTGAGAAT 
  3070 AATAATTCAGCAACTAATAGAAAGACTCACATTGATGGCCCATCATTATTAATTGAGAAT 
  1024 -N--N--S--A--T--N--R--K--T--H--I--D--G--P--S--L--L--I--E--N- 
 
                                              R                     
  3301 AGTCCATCAGTCTGGCAAAATATATTAGAAAGTGACACTGAGTTTAAAAAAGTGACACCT 
  3130 AGTCCATCAGTCTGGCAAAATATATTAGAAAGTGACACTGAGTTTAAAAAAGTGACACCT 
  1044 -S--P--S--V--W--Q--N--I--L--E--S--D--T-=E=-F--K--K--V--T--P- 
 
                                                                    
  3361 TTGATTCATGACAGAATGCTTATGGACAAAAATGCTACAGCTTTGAGGCTAAATCATATG 
  3190 TTGATTCATGACAGAATGCTTATGGACAAAAATGCTACAGCTTTGAGGCTAAATCATATG 
  1064 -L--I--H--D--R--M--L--M--D--K--N--A--T--A--L--R--L--N--H--M- 
 
                                                                    
  3421 TCAAATAAAACTACTTCATCAAAAAACATGGAAATGGTCCAACAGAAAAAAGAGGGCCCC 
  3250 TCAAATAAAACTACTTCATCAAAAAACATGGAAATGGTCCAACAGAAAAAAGAGGGCCCC 
  1084 -S--N--K--T--T--S--S--K--N--M--E--M--V--Q--Q--K--K--E--G--P- 
 
                                                                    
  3481 ATTCCACCAGATGCACAAAATCCAGATATGTCGTTCTTTAAGATGCTATTCTTGCCAGAA 
  3310 ATTCCACCAGATGCACAAAATCCAGATATGTCGTTCTTTAAGATGCTATTCTTGCCAGAA 
  1104 -I--P--P--D--A--Q--N--P--D--M--S--F--F--K--M--L--F--L--P--E- 
 
                                                                    
  3541 TCAGCAAGGTGGATACAAAGGACTCATGGAAAGAACTCTCTGAACTCTGGGCAAGGCCCC 
  3370 TCAGCAAGGTGGATACAAAGGACTCATGGAAAGAACTCTCTGAACTCTGGGCAAGGCCCC 
  1124 -S--A--R--W--I--Q--R--T--H--G--K--N--S--L--N--S--G--Q--G--P- 
 
                                                                    
  3601 AGTCCAAAGCAATTAGTATCCTTAGGACCAGAAAAATCTGTGGAAGGTCAGAATTTCTTG 
  3430 AGTCCAAAGCAATTAGTATCCTTAGGACCAGAAAAATCTGTGGAAGGTCAGAATTTCTTG 
  1144 -S--P--K--Q--L--V--S--L--G--P--E--K--S--V--E--G--Q--N--F--L- 
 
                                                                    
  3661 TCTGAGAAAAACAAAGTGGTAGTAGGAAAGGGTGAATTTACAAAGGACGTAGGACTCAAA 
  3490 TCTGAGAAAAACAAAGTGGTAGTAGGAAAGGGTGAATTTACAAAGGACGTAGGACTCAAA 
  1164 -S--E--K--N--K--V--V--V--G--K--G--E--F--T--K--D--V--G--L--K- 
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  14DF                                                  
  3721 GAGATGGTTTTTCCAAGCAGCAGAAACCTATTTCTTACTAACTTGGATAATTTACATGAA 
  3550 GAGATGGTTTTTCCAAGCAGCAGAAACCTATTTCTTACTAACTTGGATAATTTACATGAA 
  1184 -E--M--V--F--P--S--S--R--N--L--F--L--T--N--L--D--N--L--H--E- 
 
                  Y                                                 
  3781 AATAATACACACAATCAAGAAAAAAAAATTCAGGAAGAAATAGAAAAGAAGGAAACATTA 
  3610 AATAATACACACAATCAAGAAAAAAAAATTCAGGAAGAAATAGAAAAGAAGGAAACATTA 
  1204 -N--N--T--H--N--Q--E--K--K--I--Q--E--E--I--E--K--K--E--T--L- 
 
                    14CR                                                
  3841 ATCCAAGAGAATGTAGTTTTGCCTCAGATACATACAGTGACTGGCACTAAGAATTTCATG 
  3670 ATCCAAGAGAATGTAGTTTTGCCTCAGATACATACAGTGACTGGCACTAAGAATTTCATG 
  1224 -I--Q--E--N--V--V--L--P--Q--I--H--T--V--T--G--T--K--N--F--M- 
 
                                                         S          
  3901 AAGAACCTTTTCTTACTGAGCACTAGGCAAAATGTAGAAGGTTCATATGACGGGGCATAT 
  3730 AAGAACCTTTTCTTACTGAGCACTAGGCAAAATGTAGAAGGTTCATATGACGGGGCATAT 
  1244 -K--N--L--F--L--L--S--T--R--Q--N--V--E--G--S--Y-=D=-G--A--Y- 
 
                                                                    
  3961 GCTCCAGTACTTCAAGATTTTAGGTCATTAAATGATTCAACAAATAGAACAAAGAAACAC 
  3790 GCTCCAGTACTTCAAGATTTTAGGTCATTAAATGATTCAACAAATAGAACAAAGAAACAC 
  1264 -A--P--V--L--Q--D--F--R--S--L--N--D--S--T--N--R--T--K--K--H- 
 
                     M                                              
  4021 ACAGCTCATTTCTCAAAAAAAGGGGAGGAAGAAAACTTGGAAGGCTTGGGAAATCAAACC 
  3850 ACAGCTCATTTCTCAAAAAAAGGGGAGGAAGAAAACTTGGAAGGCTTGGGAAATCAAACC 
  1284 -T--A--H--F--S--K--K--G--E--E--E--N--L--E--G--L--G--N--Q--T- 
 
                  M                                                 
  4081 AAGCAAATTGTAGAGAAATATGCATGCACCACAAGGATATCTCCTAATACAAGCCAGCAG 
  3910 AAGCAAATTGTAGAGAAATATGCATGCACCACAAGGATATCTCCTAATACAAGCCAGCAG 
  1304 -K--Q--I--V--E--K--Y--A--C--T--T--R--I--S--P--N--T--S--Q--Q- 
 
                              R                                     
  4141 AATTTTGTCACGCAACGTAGTAAGAGAGCTTTGAAACAATTCAGACTCCCACTAGAAGAA 
  3970 AATTTTGTCACGCAACGTAGTAAGAGAGCTTTGAAACAATTCAGACTCCCACTAGAAGAA 
  1324 -N--F--V--T--Q--R--S--K--R--A--L--K--Q--F--R--L--P--L--E--E- 
 
                                                                   
                                 14EF   
  4201 ACAGAACTTGAAAAAAGGATAATTGTGGATGACACCTCAACCCAGTGGTCCAAAAACATG 
  4030 ACAGAACTTGAAAAAAGGATAATTGTGGATGACACCTCAACCCAGTGGTCCAAAAACATG 
  1344 -T--E--L--E--K--R--I--I--V--D--D--T--S--T--Q--W--S--K--N--M- 
 
                                                                    
  4261 AAACATTTGACCCCGAGCACCCTCACACAGATAGACTACAATGAGAAGGAGAAAGGGGCC 
  4090 AAACATTTGACCCCGAGCACCCTCACACAGATAGACTACAATGAGAAGGAGAAAGGGGCC 
  1364 -K--H--L--T--P--S--T--L--T--Q--I--D--Y--N--E--K--E--K--G--A- 
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             14DR                                                       
  4321 ATTACTCAGTCTCCCTTATCAGATTGCCTTACGAGGAGTCATAGCATCCCTCAAGCAAAT 
  4150 ATTACTCAGTCTCCCTTATCAGATTGCCTTACGAGGAGTCATAGCATCCCTCAAGCAAAT 
  1384 -I--T--Q--S--P--L--S--D--C--L--T--R--S--H--S--I--P--Q--A--N- 
 
                                                                    
  4381 AGATCTCCATTACCCATTGCAAAGGTATCATCATTTCCATCTATTAGACCTATATATCTG 
  4210 AGATCTCCATTACCCATTGCAAAGGTATCATCATTTCCATCTATTAGACCTATATATCTG 
  1404 -R--S--P--L--P--I--A--K--V--S--S--F--P--S--I--R--P--I--Y--L- 
 
                                                                    
  4441 ACCAGGGTCCTATTCCAAGACAACTCTTCTCATCTTCCAGCAGCATCTTATAGAAAGAAA 
  4270 ACCAGGGTCCTATTCCAAGACAACTCTTCTCATCTTCCAGCAGCATCTTATAGAAAGAAA 
  1424 -T--R--V--L--F--Q--D--N--S--S--H--L--P--A--A--S--Y--R--K--K- 
 
                                                                    
  4501 GATTCTGGGGTCCAAGAAAGCAGTCATTTCTTACAAGGAGCCAAAAAAAATAACCTTTCT 
  4330 GATTCTGGGGTCCAAGAAAGCAGTCATTTCTTACAAGGAGCCAAAAAAAATAACCTTTCT 
  1444 -D--S--G--V--Q--E--S--S--H--F--L--Q--G--A--K--K--N--N--L--S- 
 
                                                           Y        
  4561 TTAGCCATTCTAACCTTGGAGATGACTGGTGATCAAAGAGAGGTTGGCTCCCTGGGGACA 
  4390 TTAGCCATTCTAACCTTGGAGATGACTGGTGATCAAAGAGAGGTTGGCTCCCTGGGGACA 
  1464 -L--A--I--L--T--L--E--M--T--G--D--Q--R--E--V--G--S-=L=-G--T- 
 
 
                        S                                R          
  4621 AGTGCCACAAATTCAGTCACATACAAGAAAGTTGAGAACACTGTTCTCCCGAAACCAGAC 
  4450 AGTGCCACAAATTCAGTCACATACAAGAAAGTTGAGAACACTGTTCTCCCGAAACCAGAC 
  1484 -S--A--T--N--S--V--T--Y--K--K--V--E--N--T--V--L--P--K--P--D- 
 
                  M                                                 
  4681 TTGCCCAAAACATCTGGCAAAGTTGAATTGCTTCCAAAAGTTCACATTTATCAGAAGGAC 
  4510 TTGCCCAAAACATCTGGCAAAGTTGAATTGCTTCCAAAAGTTCACATTTATCAGAAGGAC 
  1504 -L--P--K--T--S--G--K--V--E--L--L--P--K--V--H--I--Y--Q--K--D- 
 
           14FF                                               14ER Y 
  4741 CTATTCCCTACGGAAACTAGCAATGGGTCTCCTGGCCATCTGGATCTCGTGGAAGGGAGC 
  4570 CTATTCCCTACGGAAACTAGCAATGGGTCTCCTGGCCATCTGGATCTCGTGGAAGGGAGC 
  1524 -L--F--P--T--E--T--S--N--G--S--P--G--H--L--D--L--V--E--G--S- 
 
                                                                    
  4801 CTTCTTCAGGGAACAGAGGGAGCGATTAAGTGGAATGAAGCAAACAGACCTGGAAAAGTT 
  4630 CTTCTTCAGGGAACAGAGGGAGCGATTAAGTGGAATGAAGCAAACAGACCTGGAAAAGTT 
  1544 -L--L--Q--G--T--E--G--A--I--K--W--N--E--A--N--R--P--G--K--V- 
 
                                                                    
  4861 CCCTTTCTGAGAGTAGCAACAGAAAGCTCTGCAAAGACTCCCTCCAAGCTATTGGATCCT 
  4690 CCCTTTCTGAGAGTAGCAACAGAAAGCTCTGCAAAGACTCCCTCCAAGCTATTGGATCCT 
  1564 -P--F--L--R--V--A--T--E--S--S--A--K--T--P--S--K--L--L--D--P- 
 
                                                                    
  4921 CTTGCTTGGGATAACCACTATGGTACTCAGATACCAAAAGAAGAGTGGAAATCCCAAGAG 
  4750 CTTGCTTGGGATAACCACTATGGTACTCAGATACCAAAAGAAGAGTGGAAATCCCAAGAG 
  1584 -L--A--W--D--N--H--Y--G--T--Q--I--P--K--E--E--W--K--S--Q--E- 
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  4981 AAGTCACCAGAAAAAACAGCTTTTAAGAAAAAGGATACCATTTTGTCCCTGAACGCTTGT 
  4810 AAGTCACCAGAAAAAACAGCTTTTAAGAAAAAGGATACCATTTTGTCCCTGAACGCTTGT 
  1604 -K--S--P--E--K--T--A--F--K--K--K--D--T--I--L--S--L--N--A--C- 
 
                                                                    
  5041 GAAAGCAATCATGCAATAGCAGCAATAAATGAGGGACAAAATAAGCCCGAAATAGAAGTC 
  4870 GAAAGCAATCATGCAATAGCAGCAATAAATGAGGGACAAAATAAGCCCGAAATAGAAGTC 
  1624 -E--S--N--H--A--I--A--A--I--N--E--G--Q--N--K--P--E--I--E--V- 
 
                                                                    
  5101 ACCTGGGCAAAGCAAGGTAGGACTGAAAGGCTGTGCTCTCAAAACCCACCAGTCTTGAAA 
  4930 ACCTGGGCAAAGCAAGGTAGGACTGAAAGGCTGTGCTCTCAAAACCCACCAGTCTTGAAA 
  1644 -T--W--A--K--Q--G--R--T--E--R--L--C--S--Q--N--P--P--V--L--K- 
 
                                                                    
  5161 CGCCATCAACGGGAAATAACTCGTACTACTCTTCAGTCAGATCAAGAGGAAATTGACTAT 
  4990 CGCCATCAACGGGAAATAACTCGTACTACTCTTCAGTCAGATCAAGAGGAAATTGACTAT 
  1664 -R--H--Q--R--E--I--T--R--T--T--L--Q--S--D--Q--E--E--I--D--Y- 
 
 
 
                                                     W              
  5221 GATGATACCATATCAGTTGAAATGAAGAAGGAAGATTTTGACATTTATGATGAGGATGAA 
  5050 GATGATACCATATCAGTTGAAATGAAGAAGGAAGATTTTGACATTTATGATGAGGATGAA 
  1684 -D--D--T--I--S--V--E--M--K--K--E--D--F--D--I-=Y=-D--E--D--E- 
 
                                                                    
  5281 AATCAGAGCCCCCGCAGCTTTCAAAAGAAAACACGACACTATTTTATTGCTGCAGTGGAG 
  5110 AATCAGAGCCCCCGCAGCTTTCAAAAGAAAACACGACACTATTTTATTGCTGCAGTGGAG 
  1704 -N--Q--S--P--R--S--F--Q--K--K--T--R--H--Y--F--I--A--A--V--E- 
 
                                                                    
  5341 AGGCTCTGGGATTATGGGATGAGTAGCTCCCCACATGTTCTAAGAAACAGGGCTCAGAGT 
  5170 AGGCTCTGGGATTATGGGATGAGTAGCTCCCCACATGTTCTAAGAAACAGGGCTCAGAGT 
  1724 -R--L--W--D--Y--G--M--S--S--S--P--H--V--L--R--N--R--A--Q--S- 
 
                                                                    
  5401 GGCAGTGTCCCTCAGTTCAAGAAAGTTGTTTTCCAGGAATTTACTGATGGCTCCTTTACT 
  5230 GGCAGTGTCCCTCAGTTCAAGAAAGTTGTTTTCCAGGAATTTACTGATGGCTCCTTTACT 
  1744 -G--S--V--P--Q--F--K--K--V--V--F--Q--E--F--T--D--G--S--F--T- 
 
         R         14DF                 K S          R              
  5461 CAGCCCTTATACCGTGGAGAACTAAATGAACATTTGGGACTCCTGGGGCCATATATAAGA 
  5290 CAGCCCTTATACCGTGGAGAACTAAATGAACATTTGGGACTCCTGGGGCCATATATAAGA 
  1764 -Q--P--L--Y--R--G--E--L--N--E--H-=L=-G--L--L-=G=-P--Y--I--R- 
 
                                                       BR        M  
  5521 GCAGAAGTTGAAGATAATATCATGGTAACTTTCAGAAATCAGGCCTCTCGTCCCTATTCC 
  5350 GCAGAAGTTGAAGATAATATCATGGTAACTTTCAGAAATCAGGCCTCTCGTCCCTATTCC 
  1784 -A--E--V--E--D--N--I--M--V--T--F--R--N--Q--A--S-=R=-P--Y-=S= 
 
                   Y                                                
  5581 TTCTATTCTAGCCTTATTTCTTATGAGGAAGATCAGAGGCAAGGAGCAGAACCTAGAAAA 
  5410 TTCTATTCTAGCCTTATTTCTTATGAGGAAGATCAGAGGCAAGGAGCAGAACCTAGAAAA 
  1804 -F--Y--S--S-=L=-I--S--Y--E--E--D--Q--R--Q--G--A--E--P--R--K- 
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               R    
  5641 AACTTTGTCAAGCCTAATGAAACCAAAACTTACTTTTGGAAAGTGCAACATCATATGGCA 
  5470 AACTTTGTCAAGCCTAATGAAACCAAAACTTACTTTTGGAAAGTGCAACATCATATGGCA 
  1824 -N--F--V--K--P--N--E--T--K--T--Y--F--W--K--V--Q--H--H-=M=-A- 
 
       Y  M                        Y                                
  5701 CCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTTGACCTGGAA 
  5530 CCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTTGACCTGGAA 
  1844 =P==T=-K--D--E--F--D--C--K-=A=-W--A--Y--F--S--D--V--D--L--E- 
 
          D      R                 S                                
  5761 AAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAACACACTGAAC 
  5590 AAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAACACACTGAAC 
  1864 -K-=D=-V-=H=-S--G--L--I--G-=P=-L--L--V--C--H--T--N--T--L--N- 
 
 
                                                                    
  5821 CCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACCATCTTTGAT 
  5650 CCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACCATCTTTGAT 
  1884 -P--A--H--G--R--Q--V--T--V--Q--E--F--A--L--F--F--T--I--F--D- 
 
       R                                                      SS    
  5881 GAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCTCCCTGCAAT 
  5710 GAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCTCCCTGCAAT 
  1904 =E=-T--K--S--W--Y--F--T--E--N--M--E--R--N--C--R--A--P-=C=-N- 
 
                                                           R        
  5941 ATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATCAATGGCTAC 
  5770 ATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATCAATGGCTAC 
  1924 -I--Q--M--E--D--P--T--F--K--E--N--Y--R--F--H--A--I-=N=-G--Y- 
 
 
 
                                                        D           
  6001 ATAATGGATACACTACCTGGCTTAGTAATGGCTCAGGATCAAAGGATTCGATGGTATCTG 
  5830 ATAATGGATACACTACCTGGCTTAGTAATGGCTCAGGATCAAAGGATTCGATGGTATCTG 
  1944 -I--M--D--T--L--P--G--L--V--M--A--Q--D--Q--R--I-=R=-W--Y--L- 
 
                 R                                   K Y            
  6061 CTCAGCATGGGCAGCAATGAAAACATCCATTCTATTCATTTCAGTGGACATGTGTTCACT 
  5890 CTCAGCATGGGCAGCAATGAAAACATCCATTCTATTCATTTCAGTGGACATGTGTTCACT 
  1964 -L--S--M-=G=-S--N--E--N--I--H--S--I--H--F--S-=G==H=-V--F--T- 
 
                                                                    
  6121 GTACGAAAAAAAGAGGAGTATAAAATGGCACTGTACAATCTCTATCCAGGTGTTTTTGAG 
  5950 GTACGAAAAAAAGAGGAGTATAAAATGGCACTGTACAATCTCTATCCAGGTGTTTTTGAG 
  1984 -V--R--K--K--E--E--Y--K--M--A--L--Y--N--L--Y--P--G--V--F--E- 
 
                                           Y                        
  6181 ACAGTGGAAATGTTACCATCCAAAGCTGGAATTTGGCGGGTGGAATGCCTTATTGGCGAG 
  6010 ACAGTGGAAATGTTACCATCCAAAGCTGGAATTTGGCGGGTGGAATGCCTTATTGGCGAG 
  2004 -T--V--E--M--L--P--S--K--A--G--I--W-=R=-V--E--C--L--I--G--E- 
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  6241 CATCTACATGCTGGGATGAGCACACTTTTTCTGGTGTACAGCAATAAGTGTCAGACTCCC 
  6070 CATCTACATGCTGGGATGAGCACACTTTTTCTGGTGTACAGCAATAAGTGTCAGACTCCC 
  2024 -H--L--H--A--G--M--S--T--L--F--L--V--Y--S--N--K--C--Q--T--P- 
 
                                                                    
  6301 CTGGGAATGGCTTCTGGACACATTAGAGATTTTCAGATTACAGCTTCAGGACAATATGGA 
  6130 CTGGGAATGGCTTCTGGACACATTAGAGATTTTCAGATTACAGCTTCAGGACAATATGGA 
  2044 -L--G--M--A--S--G--H--I--R--D--F--Q--I--T--A--S--G--Q--Y--G- 
 
          Y                                                         
  6361 CAGTGGGCCCCAAAGCTGGCCAGACTTCATTATTCCGGATCAATCAATGCCTGGAGCACC 
  6190 CAGTGGGCCCCAAAGCTGGCCAGACTTCATTATTCCGGATCAATCAATGCCTGGAGCACC 
  2064 -Q-=W=-A--P--K--L--A--R--L--H--Y--S--G--S--I--N--A--W--S--T- 
 
 
 
                    Y              R                                
  6421 AAGGAGCCCTTTTCTTGGATCAAGGTGGATCTGTTGGCACCAATGATTATTCACGGCATC 
  6250 AAGGAGCCCTTTTCTTGGATCAAGGTGGATCTGTTGGCACCAATGATTATTCACGGCATC 
  2084 -K--E--P--F-=S=-W--I--K--V-=D=-L--L--A--P--M--I--I--H--G--I- 
 
                                                                    
  6481 AAGACCCAGGGTGCCCGTCAGAAGTTCTCCAGCCTCTACATCTCTCAGTTTATCATCATG 
  6310 AAGACCCAGGGTGCCCGTCAGAAGTTCTCCAGCCTCTACATCTCTCAGTTTATCATCATG 
  2104 -K--T--Q--G--A--R--Q--K--F--S--S--L--Y--I--S--Q--F--I--I--M- 
 
                                                                    
  6541 TATAGTCTTGATGGGAAGAAGTGGCAGACTTATCGAGGAAATTCCACTGGAACCTTAATG 
  6370 TATAGTCTTGATGGGAAGAAGTGGCAGACTTATCGAGGAAATTCCACTGGAACCTTAATG 
  2124 -Y--S--L--D--G--K--K--W--Q--T--Y--R--G--N--S--T--G--T--L--M- 
 
                                                                    
  6601 GTCTTCTTTGGCAATGTGGATTCATCTGGGATAAAACACAATATTTTTAACCCTCCAATT 
  6430 GTCTTCTTTGGCAATGTGGATTCATCTGGGATAAAACACAATATTTTTAACCCTCCAATT 
  2144 -V--F--F--G--N--V--D--S--S--G--I--K--H--N--I--F--N--P--P--I- 
 
                                                 YD          YR     
  6661 ATTGCTCGATACATCCGTTTGCACCCAACTCATTATAGCATTCGCAGCACTCTTCGCATG 
  6490 ATTGCTCGATACATCCGTTTGCACCCAACTCATTATAGCATTCGCAGCACTCTTCGCATG 
  2164 -I--A--R--Y--I--R--L--H--P--T--H--Y--S--I-=R=-S--T--L-=R=-M- 
 
                                                                    
  6721 GAGTTGATGGGCTGTGATTTAAATAGTTGCAGCATGCCATTGGGAATGGAGAGTAAAGCA 
  6550 GAGTTGATGGGCTGTGATTTAAATAGTTGCAGCATGCCATTGGGAATGGAGAGTAAAGCA 
  2184 -E--L--M--G--C--D--L--N--S--C--S--M--P--L--G--M--E--S--K--A- 
 
                            S          Y                            
  6781 ATATCAGATGCACAGATTACTGCTTCATCCTACTTTACCAATATGTTTGCCACCTGGTCT 
  6610 ATATCAGATGCACAGATTACTGCTTCATCCTACTTTACCAATATGTTTGCCACCTGGTCT 
  2204 -I--S--D--A--Q--I--T-=A=-S--S--Y--F--T--N--M--F--A--T--W--S- 
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                   SD                                               
  6841 CCTTCAAAAGCTCGACTTCACCTCCAAGGGAGGAGTAATGCCTGGAGACCTCAGGTGAAT 
  6670 CCTTCAAAAGCTCGACTTCACCTCCAAGGGAGGAGTAATGCCTGGAGACCTCAGGTGAAT 
  2224 -P--S--K--A-=R=-L--H--L--Q--G--R--S--N--A--W--R--P--Q--V--N- 
 
                     K                        R                     
  6901 AATCCAAAAGAGTGGCTGCAAGTGGACTTCCAGAAGACAATGAAAGTCACAGGAGTAACT 
  6730 AATCCAAAAGAGTGGCTGCAAGTGGACTTCCAGAAGACAATGAAAGTCACAGGAGTAACT 
  2244 -N--P--K--E-=W=-L--Q--V--D--F--Q--K--T-=M=-K--V--T--G--V--T- 
 
           R                                                        
  6961 ACTCAGGGAGTAAAATCTCTGCTTACCAGCATGTATGTGAAGGAGTTCCTCATCTCCAGC 
  6790 ACTCAGGGAGTAAAATCTCTGCTTACCAGCATGTATGTGAAGGAGTTCCTCATCTCCAGC 
  2264 -T-=Q=-G--V--K--S--L--L--T--S--M--Y--V--K--E--F--L--I--S--S- 
 
 
 
                                                                    
  7021 AGTCAAGATGGCCATCAGTGGACTCTCTTTTTTCAGAATGGCAAAGTAAAGGTTTTTCAG 
  6850 AGTCAAGATGGCCATCAGTGGACTCTCTTTTTTCAGAATGGCAAAGTAAAGGTTTTTCAG 
  2284 -S--Q--D--G--H--Q--W--T--L--F--F--Q--N--G--K--V--K--V--F--Q- 
 
                                                                    
  7081 GGAAATCAAGACTCCTTCACACCTGTGGTGAACTCTCTAGACCCACCGTTACTGACTCGC 
  6910 GGAAATCAAGACTCCTTCACACCTGTGGTGAACTCTCTAGACCCACCGTTACTGACTCGC 
  2304 -G--N--Q--D--S--F--T--P--V--V--N--S--L--D--P--P--L--L--T--R- 
 
                                                                    
  7141 TACCTTCGAATTCACCCCCAGAGTTGGGTGCACCAGATTGCCCTGAGGATGGAGGTTCTG 
  6970 TACCTTCGAATTCACCCCCAGAGTTGGGTGCACCAGATTGCCCTGAGGATGGAGGTTCTG 
  2324 -Y--L--R--I--H--P--Q--S--W--V--H--Q--I--A--L--R--M--E--V--L- 
 
                                                               
  7201 GGCTGCGAGGCACAGGACCTCTACTGAGGG 
  7030 GGCTGCGAGGCACAGGACCTCTACTGA 
  2344 -G--C--E--A--Q--D--L--Y--*- 
                                                                    
                                   Y                                   
7231 TGGCCACTGCAGCACCTGCCACTGCCGTCACCTCTCCCTCCTCAGCTCCAGGGCAGTGTC 
     ............................................................ 
     ............................................................ 
 
                                                                    
7321 CCTCCCTGGCTTGCCTTCTACCTTTGTGCTAAATCCTAGCAGACACTGCCTTGAAGCCTC 
     ............................................................ 
 
                                                                    
7381 CTGAATTAACTATCATCAGTCCTGCATTTCTTTGGTGGGGGGCCAGGAGGGTGCATCCAA 
     ............................................................ 
     ............................................................ 
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7441 TTTAACTTAACTCTTACCTATTTTCTGCAGCTGCTCCCAGATTACTCCTTCCTTCCAATA 
     ............................................................ 
     ............................................................ 
 
                          26BF                                          
7501 TAACTAGGCAAAAAGAAGTGAGGAGAAACCTGCATGAAAGCATTCTTCCCTGAAAAGTTA 
     ............................................................ 
     ............................................................ 
 
                                       26AR                             
 7561 GGCCTCTCAGAGTCACCACTTCCTCTGTTGTAGAAAAACTATGTGATGAAACTTTGAAAA 
     ............................................................ 
     ............................................................ 
 
                                                                    
7621 AGATATTTATGATGTTAACATTTCAGGTTAAGCCTCATACGTTTAAAATAAAACTCTCAG 
     ............................................................ 
     ............................................................ 
 
                                                                    
7681 TTGTTTATTATCCTGATCAAGCATGGAACAAAGCATGTTTCAGGATCAGATCAATACAAT 
     ............................................................ 
     ............................................................ 
 
                                                                    
7741 CTTGGAGTCAAAAGGCAAATCATTTGGACAATCTGCAAAATGGAGAGAATACAATAACTA 
     ............................................................ 
     ............................................................ 
 
                                                                    
 7801 CTACAGTAAAGTCTGTTTCTGCTTCCTTACACATAGATATAATTATGTTATTTAGTCATT 
     ............................................................ 
     ............................................................ 
 
                                                                    
7861 ATGAGGGGCACATTCTTATCTCCAAAACTAGCATTCTTAAACTGAGAATTATAGATGGGG 
     ............................................................ 
 
                                  R       *                      
 7921 TTCAAGAATCCCTAAGTCCCCTGAAATTATATAAGGCATTCTGTATAAATGCAAATGTGC 
       ............................................................ 
       ............................................................ 
 
                                                                    
 7981 ATTTTTCTGACGAGTGTCCATAGATATAAAGCCATTTGGTCTTAATTCTGACCAATAAAA 
     ............................................................ 
     ............................................................ 
 
                                                                    
 8041 AAATAAGTCAGGAGGATGCAATTGTTGAAAGCTTTGAAATAAAATAACAATGTCTTCTTG 
     ............................................................ 
     ............................................................ 
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                      26BR                                               
8101 AAATTTGTGATGGCCAAGAAAGAAAATGATGATGACATTAGGCTTCTAAAGGACATACAT 
     ............................................................ 
     ............................................................ 
 
                                                                    
8161 TTAATATTTCTGTGGAAATATGAGGAAAATCCATGGTTATCTGAGATAGGAGATACAAAC 
     ............................................................ 
     ............................................................ 
 
                                                                    
 8221 TTTGTAATTCTAATAATGCACTCAGTTTACTCTCTCCCTCTACTAATTTCCTGCTGAAAA 
     ............................................................ 
     ............................................................ 
 
                         
        **                                       
 8281 TAACACAACAAAAATGTAACAGGGGAAATTATATACCGTGACTGAAAACTAGAGTCCTAC 
     ............................................................ 
     ............................................................ 
 
                                                                    
8341 TTACATAGTTGAAATATCAAGGAGGTCAGAAGAAAATTGGACTGGTGAAAACAGAAAAAA 
     ............................................................ 
     ............................................................ 
 
                                              Y    26CF               
8401 CACTCCAGTCTGCCATATCACCACACAATAGGATCCCCCTTCTTGCCCTCCACCCCCATA 
     ............................................................ 
     ............................................................ 
 
              26DR R                                                  
8461 AGATTGTGAAGGGTTTACTGCTCCTTCCATCTGCCTGACCCCTTCACTATGACTACACAG 
     ............................................................ 
     ........................................................... 
                                R                                
 8521 AATCTCCTGATAGTAAAGGGGGCTGGAGACAAGGATAAGTTATAGAGCAGTTGGAGGAAG 
     ............................................................ 
     ............................................................ 
 
                                                            R      
8581 CATCCAAAGATTGCAACCCAGGGCAAATGGAAAACAGGAGATCCTAATATGAAAGAAAAA 
     ............................................................ 
     ............................................................ 
 
                                                                    
8641 TGGATCCCAATCTGAGAAAAGGCAAAAGAATGGCTACTTTTTTCTATGCTGGAGTATTTT 
     ............................................................ 
     ............................................................ 
 
                                   Y                             
 8701 CTAATAATCCTGCTTGACCCTTATCTGACCTCTTTGGAAACTATAACATAGCTGTCACAG 
     ............................................................ 
     ............................................................ 
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                            M                                    
 8761 TATAGTCACAATCCACAAATGATGCAGGTGCAAATGGTTTATAGCCCTGTGAAGTTCTTA 
    ............................................................ 
    ............................................................ 
 
                                                                     
8821 AAGTTTAGAGGCTAACTTACAGAAATGAATAAGTTGTTTTGTTTTATAGCCCGGTAGAGG 
       ............................................................ 
     ............................................................ 
 
          26EF                                      R  26DR           
 8881 AGTTAACCCCAAAGGTGATATGGTTTTATTTCCTGTTATGTTTAACTTGATAATCTTATT 
    ............................................................ 
    ............................................................ 
 
 
                                                                    
 8941 TTGGCATTCTTTTCCCATTGACTATATACATCTCTATTTCTCAAATGTTCATGGAACTAG 
    ............................................................ 
    ............................................................ 
 
                                                                   
 9001 CTCTTTTATTTTCCTGCTGGTTTCTTCAGTAATGAGTTAAATAAAACATTGACACATAC 
     ........................................................... 
     ........................................................... 
 
       26ER 
Aaacaaatgcctttgagaattgtgtttttacactggaaataaaaatgtgaacactgattt 
ttaaaacaaataggggcactgaatagcaagatggacactctagaaaaccaaattagtgag 
ttagaaaaccagattaaattgaactcagagtaaaaatgatataattcatgagagtctgaa 
taaaataaatcagaaatggagcctcaatccaggagaacagcttatatggagagagagaga 
ctgagagagaaatgggagtttctgttcaatgggcataaagtttcagctatgctgctgggc 
acagtggctcatgcctgtaatcctggcactttgggaggccaaggcgggcggatcacctga 
ggtcgggagttcaagaccagcctagccaacatggcgaaatcccgtcgctaataaaaatat 
aaaaattagttgggcatggtggcacatgcctgtagtcccagctacttgggaggttgaggc 
acaagaatcgcttgaacccgggaggcgggtggaggttgcagtgagccaagatcgtgccgt 
tgcattccatcagcctgggcaacagagtgagactccatctcaaaaaaaaaaaagtttcag 
ttatgcaagatgaattaagttctacagatctaatgtacaacattgtgcatatagctaacg 
ataccatactgggcacttaaaaatttgttaagagagcagataccacgttgtgttcttact 
acagttttacaacaatgcaaaaatgcattgtaaacactatgtgcaaatagaatagcaaag 
aatgtatacagtgcccatgagcataacattctagtggacccacaatgcatcagagttcag 
tgagactcaaagggagaagaatgttggcaaagtcagtggggaggagaaaatgagtgtgat 
gaaataggcggtctcattaaacttcccttacaaaacacaagatcaaagataaaattatta 
agaatttcgagacagtgacatcagagcaaacgaaacatag 
. 
 
  
